sv1za

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. o

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. o

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission acting pursuant to said Section 8(a) may determine.

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

This is Nanosys, Inc.’s initial public offering. Nanosys is selling all of the shares.

We expect the initial public offering price per share to be between $15.00 and $17.00 per share. Currently, no public market exists for the shares. We have applied to have our common stock quoted on the Nasdaq National Market under the symbol “NNSY.”

Investing in the common stock involves risks that are described in the “Risk Factors” section beginning on page 6 of this prospectus.

The underwriters may also purchase up to an additional 937,500 shares from Nanosys at the initial public offering price, less the underwriting discount, within 30 days from the date of this prospectus to cover overallotments.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

You should rely only on the information contained in this prospectus. We have not, and the underwriters have not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.

We currently have two applications pending to register Nanosys and the Nanosys logo as our trademarks. Other service marks, trademarks and trade names referred to in this prospectus are the property of their respective owners.

You should read the following summary, together with the more detailed information regarding our company, especially the “Risk Factors” section, and our financial statements and notes to those statements appearing elsewhere in this prospectus, before deciding to invest in shares of our common stock.

We are in the early stages of investigative research to develop nanotechnology-enabled products based on our specialized expertise and intellectual property. We plan to sell our nanotechnology-enabled products to our partners and directly to end user customers. We are developing products based on our core technology, which includes patents, know how and other intellectual property. We use our core technology to create nano-sized structures, or nanostructures, composed of inorganic materials, such as silicon. Unlike traditional materials which are used to fabricate devices, our nanostructures can themselves act as devices. We are utilizing our technology to develop potential products for multiple industries such as energy, defense, electronics, life sciences and information technology. We have not yet developed any of these products and may not be able to do so for several years, if at all.

We have established and intend to continue to establish collaborations with partners and government agencies that we believe could benefit significantly from the incorporation of nanotechnology-enabled products into their end user products. Our current collaborators include E.I. DuPont de Nemours and Company, In-Q-Tel, Inc., Intel Corporation, Matsushita Electric Works, Ltd., Science Applications International Corporation and various United States government agencies. Our product development activities and collaborations typically contemplate several phases, including an investigation phase, a development phase and a commercialization phase. We are currently in the investigation phase of all of our potential products, including pursuant to our collaborations with our partners. As part of our strategy, we intend to enter into additional collaborations to enter multiple markets and expand our core technology across additional multiple industries and applications. We may also generate revenue from research feasibility studies in the early stages of collaborative arrangements. We intend to continue to pursue and to enter into new collaborations and government contracts and grants that will enable us to further our core technology, provide additional funding and allow us to develop dual use products and technology that may be sold in both government and commercial markets.

Some of our nanotechnology-enabled product development efforts include disposable test plates for use with tools for life sciences research, solar cells, electronic circuits on flexible film and semiconductor memory devices that retain data in the absence of power. We have assembled an experienced business and technical team, with development and product commercialization expertise, which is supported by the members of our scientific advisory board who are recognized experts in the field of nanotechnology. We have over 250 patents and patent applications which we have licensed from educational institutions and research centers or developed internally. Our granted patents and patent applications derive from over 79 different patent families, each of which represents what we or our licensors believe is a distinct technological development, or in some cases, a collection of distinct technological developments. In addition, some of our patents or patent applications represent foreign patents or patent applications that relate to similar or identical technology to our United States patents and patent applications. We believe our strong team will enable us to deliver nanotechnology-enabled products for use in multiple industries.

Nanotechnology is the ability to control or manipulate materials on the atomic scale to create structures that have novel properties and functions because of their size, shape or composition. By organizing atoms into structures of various shapes and sizes on a nanoscale, important properties including electrical, optical and physical, can be controlled. At the nanoscale, these properties can be fundamentally different than the properties of the same materials at a larger, traditional scale. When nanostructures are engineered into end user products, these products benefit from the unique properties exhibited by the nanostructures. Multiple industries are approaching the point at which their ability to economically manufacture products with increasing levels of performance and functionality is being constrained by traditional technologies. Many companies are seeking to incorporate the potential benefits of

Nanotechnology and commercialization expertise. We have assembled an experienced business and technical team with development and commercialization expertise. This team has previously commercialized a number of products based on new technology. Our internal expertise is complemented by our scientific advisory board that includes prominent nanotechnology experts from a number of leading educational institutions and research centers.

Significant intellectual property position. We have a significant body of nanotechnology-related intellectual property, including patents and patent applications licensed to us on an exclusive basis, as well as our own patent applications and trade secrets. When combined with our technical expertise, we believe our intellectual property provides us with a strong competitive advantage in developing nanotechnology-enabled products.

Design and fabrication capabilities. Our proprietary computer modeling and development capabilities enable us to rapidly and efficiently design and fabricate nanostructures based on our knowledge of applicable principles in chemistry, physics and engineering. We are developing processes designed for the consistent and reliable manufacture of inorganic nanostructures with desired composition, size, shape and surface chemistry and their practical and rapid integration into products.

Leverage our core technology across multiple industries and applications. We seek to employ our core technology across multiple industries and applications through collaborations to accelerate the development of our products. We believe that our core technology can simultaneously address short, medium and long-term opportunities and will reduce our dependence on any particular industry, partner or application.

Support core technology development through commercial and government funding. We have been able to fund a significant amount of our technology development through agreements with commercial partners and United States government agencies. We intend to continue to leverage commercial and government funding to support the development of our core technology and products of interest to our partners, the government and us.

Build common manufacturing capabilities to achieve economies of scale. We believe our core technology enables us to utilize a common set of manufacturing capabilities to supply our partners and customers with a variety of nanotechnology-enabled products. By building proprietary manufacturing capabilities that can be applied to multiple products, we believe we can benefit from manufacturing economies of scale to provide cost effective, high quality products to our partners and customers.

Continue to expand and leverage our intellectual property position. We believe our significant intellectual property position provides us with a competitive advantage in developing nanotechnology-enabled products. We plan to continue to expand our intellectual property position through internally generated and licensed patent rights and other intellectual property and associations with leading experts in nanotechnology.

From our inception in July 2001 through March 31, 2004, we incurred net losses of approximately $20.9 million. Our technology and potential product applications are new and still in the early stages of development. To date, we have not successfully developed any commercially available products. We are currently in the investigation phase of all of our potential products. We do not anticipate that our first products will be commercially available for at least several years, if at all. Even if we raise additional capital from collaboration agreements, we may need additional funding for our operations and we cannot assure you that it will be available on commercially reasonable terms, if at all. Our ability to achieve profitability will depend upon many factors, including our ability to:


	•	further develop our technology to enable the development of our potential products;

	•	enter into investigation phase, development phase and commercialization phase agreements with appropriate partners;

	•	develop commercially viable products by designing and synthesizing nanostructures and determining how to manufacture them on a commercial scale;

	•	alone, or with our partners, convince customers of the benefits of our technology and products;

	•	establish a commercial scale manufacturing capability for our products;

	•	avoid infringing and successfully defend any allegations of infringing the intellectual property rights of others;

	•	enforce our intellectual property rights against others;

	•	comply with government and environmental regulations;

	•	address any legal restrictions due to ethical concerns or export regulations; and

	•	hire, train and retain qualified personnel.

We were incorporated in Delaware in July 2001. Our fiscal year ends on December 31. Our principal offices are located at 2625 Hanover Street, Palo Alto, California 94304. Our telephone number is (650) 331-2100. You can access our web site at www.nanosysinc.com. Information contained on our web site is not a part of this prospectus. In this prospectus, references to “Nanosys,” “we,” “us” and “our” refer to Nanosys, Inc., a Delaware corporation.

The number of shares of common stock to be outstanding upon completion of this offering is based on 15,620,313 shares outstanding as of June 30, 2004, which includes 12,693,952 shares of preferred stock that will convert to common stock immediately prior to the closing of this offering and excludes:



	•	533,854 shares of common stock issuable upon exercise of options outstanding at a weighted average exercise price of $1.86 per share as of June 30, 2004;



	•	279,778 shares of common stock issuable upon exercise of warrants outstanding at a weighted average exercise price of $0.50 per share as of June 30, 2004; and



	•	a total of 1,479,422 shares of common stock available for future issuance under our stock plans, excluding the annual increases in the number of shares authorized under our 2004 stock plan beginning January 1, 2005. See “Executive Compensation — Incentive Plans” for a description of how these annual increases are determined.


	•	assumes the completion of a reverse one for three split of our outstanding capital stock prior to the effective time of this offering;


	•	assumes the conversion of our preferred stock on a one for one basis into 12,693,952 shares of common stock immediately prior to the closing of this offering;


	•	assumes the filing of our amended and restated certificate of incorporation increasing the number of shares of our authorized common stock from 53,500,000 shares to 120,000,000 shares prior to the closing of this offering;

	•	assumes the filing of our amended and restated certificate of incorporation authorizing a class of 10,000,000 shares of undesignated preferred stock prior to the closing of this offering; and


	•	assumes no exercise by the underwriters of their option to purchase 937,500 additional shares of our common stock in this offering.

The following table sets forth a summary of our financial data for the periods presented. This summary financial information should be read in conjunction with “Selected Financial Data,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the financial statements and related notes contained elsewhere in this prospectus.


	•	on an actual basis; and

	•	on a pro forma basis to give effect to the automatic conversion of all outstanding shares of our preferred stock into common stock immediately prior to the closing of this offering; and


	•	on a pro forma as adjusted basis to reflect our receipt of the estimated net proceeds from the sale of 6,250,000 shares of common stock by us in this offering at an assumed initial public offering price of $16.00 per share, after deducting the underwriting discount and estimated offering expenses payable by us.

Any investment in our common stock involves a high degree of risk. You should consider the risks described below carefully and all of the information contained in this prospectus before deciding whether to purchase our common stock. If any of these risks actually occur, our business, financial condition and results of operations may suffer significantly. As a result, the trading price of our common stock could decline and you may lose all or part of your investment in our common stock.

We have a history of net losses, we expect to continue to incur net losses in the foreseeable future, and may never achieve profitability.

From our inception in July 2001 through March 31, 2004, we incurred net losses of approximately $20.9 million. Our losses have resulted principally from research and development and selling, general and administrative expenses associated with our operations. To date, we have not made any product sales and do not anticipate commercial product sales for the next several years. We expect our losses to continue for the foreseeable future. Our revenue to date has been generated from collaborative agreements with companies and governmental entities, as well as government grants. We cannot assure you that we will develop products or if developed, that these products will be commercially viable. We expect to incur substantial additional operating losses as a result of increases in expenses for research and product development, manufacturing and selling, general and administrative costs. In addition, upon the completion of this offering, we will incur substantial expenses to comply with our obligations as a public company. We may never achieve profitability. We may need additional funding for our operations and we cannot assure you that it will be available on commercially reasonable terms, if at all. Our ability to achieve profitability will depend upon many factors, including our ability to:


	•	further develop our technology to enable the development of our potential products;

	•	enter into investigation phase, development phase and commercialization phase agreements with appropriate partners;

	•	develop commercially viable products by designing and synthesizing nanostructures and determining how to manufacture them on a commercial scale;

	•	alone, or with our partners, convince our customers of the benefits of our technology and products;

	•	establish a commercial scale manufacturing capability for our products;

	•	avoid infringing and successfully defend any allegations of infringing the intellectual property rights of others;

	•	enforce our intellectual property rights against others;

	•	comply with government and environmental regulations;

	•	address any legal restrictions due to ethical concerns or export regulations; and

	•	hire, train and retain qualified personnel.

We may need to raise additional capital in the future and if we are unable to secure adequate funds on terms acceptable to us, we may be unable to support our business requirements or build our business.

We currently anticipate that the net proceeds of this offering, together with our current cash, cash equivalents and available-for-sale securities, will be sufficient to meet our anticipated operating and capital requirements for at least the next year. We anticipate that we will need to generate additional funding by entering into new collaboration agreements. Even if we receive funding from future collaboration agreements, we may need to raise additional capital in order to complete our development activities and to

build our commercial scale manufacturing facilities. We may raise additional capital through a variety of sources, including the public equity market, private financings and debt. If we raise additional capital through the issuance of equity or securities convertible into equity, our stockholders may experience dilution. Those securities may have rights, preferences or privileges senior to those of the holders of the common stock. Additional financing may not be available to us on favorable terms, if at all. If we are unable to obtain financing, or to obtain it on acceptable terms, we may be unable to successfully support our business requirements or build our business.

We are deploying new technology and, as a result, we may not be able to successfully develop our products.

Our technology is new and unproven and we are still in the early stages of investigating the feasibility of using our technology to develop our potential products. Our potential products require significant and lengthy product development efforts. To date, we have not developed any commercially available products. During our product development process, we may experience technological issues that we may be unable to overcome. For example, we must determine how to synthesize nanostructures for our potential products, how to design those potential products, whether we can use cost effective manufacturing processes, such as roll to roll manufacturing, to make our potential products, whether we can obtain collaborative partner or government support for the investigation and development of our products and whether there is likely to be a viable commercial market for our products. Because of these uncertainties, none of our potential products may be successfully developed. If we are not able to successfully develop nanotechnology-enabled products, we will be unable to generate product revenue or build a sustainable or profitable business.

In order to successfully develop our potential products, we believe that we have to design and synthesize our potential products to be composed of one or more inorganic materials, such as silicon, which can provide functional characteristics to the resulting device. We must determine which composition of the potential product will be cost effective, comply with environmental and human safety laws and provide the functionality we desire. Our potential products also depend on our ability to adequately determine the size of the appropriate nanostructure and our ability to recreate nanostructures of that size in large volume. For example, if we are unable to control the size of the nanostructure as intended, we may not be able to control the color of light emitted by the resulting product, which would impair our ability to participate in an end user product that requires a specific color, such as solid state lighting. Our ability to successfully design and synthesize our potential products also depends on our ability to select and control the shape of the nanostructures used in the potential product. If the shape of the nanostructure we select does not have the electromagnetic or mechanical characteristics we expect or does not conduct electricity as anticipated, we may not be able to commercialize our products in a cost effective manner. We must also be able to control the surface chemistry of the individual nanostructures incorporated in our potential products for those products to be commercially viable. If we cannot control surface chemistry, we will not be able to process the individual nanostructures into a form that is low cost and easy to manufacture. For example, if we cannot coat the nanostructures in our potential solar cell applications in a uniform manner, we may not be able to use the relatively low cost roll to roll manufacturing processes that we anticipate using.

We will need to achieve commercial acceptance of our products to obtain product revenue and achieve profitability.

Even if our products are technologically feasible, we may not successfully develop commercially viable products on a timely basis, if at all. It will be at least several years before our first products are commercially available and during this period, superior competitive technologies may be introduced or customer needs may change resulting in our products being unsuitable for commercialization. Our revenue growth and achievement of profitability will depend substantially on our ability to introduce new products into the marketplace that are widely accepted by customers. If we are unable to cost effectively achieve commercial acceptance of our products, our business will be materially and adversely affected.

We are developing nanotechnology-enabled products based on nanostructures that have integrated functional properties. To date, the markets we are targeting have generally not adopted nanotechnology-enabled products. We do not know when a market for these nanotechnology-enabled products will develop, if at all, and we cannot reasonably estimate the projected size of any market that may develop. In addition, nanotechnology-enabled products may achieve some degree of market acceptance in one industry but may not achieve market acceptance in other industries for which we are developing products. If the markets we are targeting fail to accept nanotechnology-enabled products or to determine that other products were superior, we may not be able to achieve commercial acceptance of our potential products. Even if our potential products achieve commercial acceptance, if the size of the potential markets for our products is not sufficient, we will be unable to generate significant revenue or achieve profitability.

We plan to concurrently develop a number of products and any one or all of them may fail to achieve commercial acceptance.

We plan to concurrently develop a number of potential products utilizing our technology and know how. We expect that one or more of our potential products will not be technologically feasible or will not achieve commercial acceptance, and we cannot predict which, if any, of our products will be successfully developed or commercialized.

We have limited resources and our focus on particular nanotechnology-enabled products may result in our failure to capitalize on other opportunities.

We have limited resources available to successfully develop and commercialize our nanotechnology-enabled products. As of June 30, 2004, we had 43 employees. There is a wide array of potential applications for nanotechnology-enabled products and our limited resources require us to focus on specific products and collaborations which may never result in commercially successful products and to forego other opportunities. We are also required, pursuant to our existing collaborations, to devote the efforts of a specified number of full-time employee equivalents toward those collaborations. If we are unable to adequately or appropriately manage our resources for existing collaborations, we may negatively impact our relationships with our partners. In addition, we are required to devote the efforts of certain of our employees to work on existing collaborations and, as a consequence, we may not have the resources to enter into additional collaborations with existing or new partners without the time and expense needed to identify, hire and train more personnel.

To develop products for certain target markets, we depend on entering into collaborations to offset cash used in operating activities and leverage our partners’ financial, research and development, manufacturing, marketing and sales capabilities. We may not be able to enter into new collaborations for our target markets, which would limit our access to important financial, research and development, marketing and sales resources. The collaborations we have entered into to date are limited to investigating the feasibility of developing products for certain applications. Our partners are not obligated to extend these agreements to the development or commercialization phases regardless of whether we demonstrate that our potential products are technologically feasible. One partner may also react negatively to the non-extension of our collaboration with another partner. We will need to convince our current and future partners of the feasibility and benefits of using our nanotechnology-enabled products as part of their end user products, which may be time consuming. If we are unable to persuade our partners to use our nanotechnology-enabled products, we may not be able to commercialize our products or to generate revenues from product sales.

Even if we successfully maintain or enter into new collaborations, we may have limited or no control over our partners’ development and commercialization schedule, their efforts to complete the end user products or their marketing of the end user products. Our partners may elect not to proceed with the development of our products for a variety of reasons, including their intention to develop a competing technology, changes in strategic focus or personnel, budgetary constraints, general economic conditions,

environmental concerns, changes in the marketplace, regulatory issues or other reasons. We cannot assure you that any of our partners will perform their development obligations in a timely manner or will devote sufficient resources to the collaborative effort. Even if our partners elect to proceed with the development of an end user product, they may not do so at the pace we would expect. Once end user products are commercially viable, our partners may not commit the time and resources to marketing and selling these products necessary to achieve widespread commercial acceptance. If our partners fail to provide sufficient resources to the development and commercialization of the end user products or elect not to proceed, our business will be harmed.

To use our nanotechnology-enabled products, our partners will be required to integrate these products into their final products and they may not do so successfully.

We anticipate that most of our products will be integrated into end user products by our partners. Although we intend to develop our products to be integrated with our partners’ existing manufacturing capabilities, our partners will be required to make modifications to or expand their manufacturing capabilities. Our current or future partners may not elect to integrate our products into their end user products or may not devote adequate resources to modifying their manufacturing capabilities so that our products can be successfully incorporated into their end user products.

In some cases, a partner may determine that in order to incorporate our nanotechnology-enabled products, it would be required to adopt a new manufacturing process or capability. The adoption of a new manufacturing process or capability is resource intensive and our current and future partners may not complete the adoption or devote adequate resources to the incorporation of our nanotechnology-enabled products into those new processes or capabilities.

We do not currently have the ability to manufacture nanotechnology-enabled products in volume and will not be able to sell products without developing volume manufacturing capabilities.

The manufacture of our potential nanotechnology-enabled products is unproven and will require long lead times to establish adequate facilities. We currently have one facility located in Palo Alto, California with limited manufacturing capabilities. Some of our potential products may require us to manufacture large volumes of materials that are substantially larger than our current capabilities in order to meet commercial demand. To date, we have not demonstrated the ability to manufacture nanotechnology-enabled products on a commercial scale. We may not be able to develop commercial scale manufacturing capabilities or produce products cost effectively. Unless we are able to economically manufacture or obtain our products in commercial quantities that meet acceptable performance and quality specifications, our business will be harmed.

Even if we develop commercially acceptable products, we cannot determine whether we can manufacture our products in a cost effective manner or achieve profitability.

Even if our technology and products gain commercial acceptance, we may not be able to manufacture our products at a cost that enables us to become and remain profitable. We believe that we can use modified commercially available equipment and commercially available raw materials to manufacture our products. However, we have not completed the design and set up of a commercial scale manufacturing facility. Even if we are able to manufacture our products on a commercial scale, the cost of manufacturing our products may be higher than we expect. If the costs associated with that manufacturing, together with our royalty obligations, are not significantly less than the prices at which we can sell our products, we will not be able to achieve profitability.

We do not have a sales force and must enter into distribution agreements and original equipment manufacturer agreements to sell our products.

We have not established, nor do we plan to establish, an end user product sales, marketing and support organization. We expect to enter into agreements with partners to incorporate our potential

products into their end user products or enter into distribution agreements with third parties to sell our internally developed end user products. We may be unable to enter into these agreements on commercially acceptable terms, if at all. To date we have not entered into any of these agreements and we have no assurance that we will receive an adequate economic return from the sales of our products by our partners or distributors. Our partners and distributors could also sell competitive products. If we do not enter into these agreements or our partners or distributors do not perform as expected, we may be required to establish our own end user product sales, marketing or support organization. We may not be able to accomplish this in a timely or a cost effective manner. Regardless of whether we establish an end user product sales, marketing or support organization, it is unlikely that we will have the access to the potential end user customers that our potential partners or distributors would have and our ability to generate revenue and become profitable may be significantly impaired.

We are also dependent on government grants and contracts to offset cash used in operating activities and we may not succeed if government funding priorities change or we are unable to renew our agreements.

Our strategy for developing certain aspects of our core technology and products depends in part on our ability to continue to receive government grants and enter into government contracts. We may not be awarded any future government grants or enter into future government contracts. To date, grants that we have been awarded or contracts we have entered into have been for the purpose of investigating the feasibility of nanotechnology for certain applications. The applicable government agencies are not obligated to extend these agreements and in certain cases, may terminate the funding prior to expiration, regardless of whether we have demonstrated technological feasibility or have met specified milestones. In addition, we may not be successful in securing future government contracts or grants. Government priorities regarding funding for nanotechnology may change and grant funding resources may no longer be available at previous levels. If we are unsuccessful in obtaining additional government grants and contracts or if government agencies decide to reduce or discontinue support of nanotechnology, we may be required to seek alternative sources of revenue or capital.

We may not be able to commercialize the technology we develop under government contracts.

If the applicable government agency determines that it controls the rights to the technology that we develop under government contracts, we may be unable to commercialize this technology. We may also be prohibited from commercially selling certain products that we develop under government contracts or related products based on the same core technology if the government determines that the commercial availability of those products could pose a risk to national security. Any of these determinations would limit our ability to generate product revenue.

The loss of key personnel or the inability to attract, train and retain additional personnel could have a negative effect on our business.

We believe our future success will depend upon our ability to retain highly skilled personnel, including Lawrence A. Bock, our executive chairman of the board of directors, Calvin Y. H. Chow, our chief executive officer, and J. Wallace Parce, Ph.D., our chief technical officer and vice president of research. Each of Messrs. Bock and Chow and Dr. Parce has extensive experience in assisting companies to develop and sell new products based on a technology platform. Mr. Bock has extensive expertise in the development of businesses based on new technologies. Mr. Chow has extensive experience in product development and operations. Dr. Parce has extensive experience in multidisciplinary technical product development. We do not have any key person life insurance for our employees. Our employees are at will and not subject to employment contracts.

As we seek to expand our operations, hiring of additional qualified technical and manufacturing personnel will be difficult due to the limited availability of qualified professionals. The number of people with experience in the field of nanotechnology is limited and we face intense competition for these types of employees. We may not be successful in attracting, training and retaining personnel in the future. Failure

We are dependent on the services of our scientific advisors for some of our development activities and our business could be harmed if we were unable to utilize their services or obtain the rights to the intellectual property they develop.

We depend on the services of members of our scientific advisory board to assist us with technical and business development activities. These individuals are generally employed by universities or research centers and act as consultants to us generally on an exclusive basis in a defined field relating to nanotechnology during the term of their agreements with us. However, we have permitted several of our scientific advisors to provide services to identified companies with whom they had pre-existing relationships. Some of these companies compete with us. Because they are not our employees, we do not have access to all of their time or work product and may have difficulty obtaining the amount of time and attention from these scientific advisors that we need. These scientific advisors may also have research interests that diverge from or conflict with ours or economic interests that are more closely aligned with our competitors to which they also provide services. In addition, we do not have any assurance that these scientific advisors will continue to provide services to us or, if not, that they will not provide services to our competitors. If we were unable to utilize the services of these individuals, our development efforts or our relationships with new or existing partners may be harmed. Because these individuals are employed by third parties, we also face the risk that their employers will attempt to assert that development efforts these scientific advisors have undertaken on our behalf belong to their employer. Any dispute over the ownership or rights to the intellectual property developed by these scientific advisors could disrupt our business, be costly to resolve and could prevent us from developing certain technology or applications.

We licensed a substantial portion of our core technology from educational institutions and research centers and our business could be harmed if these institutions develop important intellectual property to which we do not have rights.

We licensed a substantial portion of our core technology from educational institutions and research centers, including Columbia University, Ernest Orlando Lawrence Berkeley National Laboratory, Harvard University, the Massachusetts Institute of Technology and The Regents of the University of California. These licenses give us the right to use certain technology previously developed by researchers at these licensors. In certain cases we also have the right to practice improvements on the licensed technology to the extent they are encompassed by the licensed patents and within our field of use. Our licensors may currently own and may in the future obtain additional patents and patent applications that are necessary for the development, manufacture and commercial sale of our anticipated products. We may be unable to agree with one or more of these licensors that certain intellectual property developed by researchers at these licensors is covered by our existing licenses. In the event that the new intellectual property is not covered by our existing licenses, we would be required to negotiate a new license agreement. We may not be able to reach agreement with the licensors on the terms of the license and the terms may not permit us to sell our products at a profit after payment of royalties or on commercially reasonable terms, if at all, which could harm our business.

If we fail to meet our financial, technical or commercial diligence obligations under licenses granting us rights to our core technology, we may lose those rights.

Our licenses with the educational institutions and research centers require us to meet certain financial, technical or commercial diligence requirements in order to maintain our rights to a substantial portion of our technology. Our failure to meet those requirements could lead to various adverse consequences, including the loss of exclusive rights or loss of all rights to key aspects of our core technology. We depend substantially on our partners and scientific advisory board members for the development of our products and, therefore, to help to meet our diligence obligations. We cannot predict whether we will be able to meet all diligence requirements necessary to retain rights to our licensed

We may not be able to produce and sell our products on commercially reasonable terms if we are required to pay unanticipated royalties.

Our licenses with educational institutions and research centers include provisions intended to prevent us from having to pay multiple royalties at the full rate for the same product because the product utilizes more than one licensed patent. If these provisions do not operate as we anticipate and we are forced to pay royalties at the full rate on each patent we have licensed as it applies to a single product, we may not be able to sell our products for a profit. In addition, if our licensors were to conclude that the royalty limiting provisions did not apply to patents licensed from other licensors, we may be required to pay royalties at a higher rate to each licensor from which we have licensed technology. In either case, the cost of commercializing our products would increase.

We use hazardous materials in our business, and any claims relating to improper handling, storage or disposal of these materials could subject us to significant liabilities.

Our business involves the use of a broad range of hazardous chemicals and materials. Environmental laws impose stringent civil and criminal penalties for improper handling, disposal and storage of these materials. In addition, in the event of an improper or unauthorized release of or exposure of employees or others to hazardous materials, we could be subject to civil damages due to personal injury or property damage caused by the release or exposure. A failure to comply with environmental laws could result in fines and the revocation of environmental permits, which could prevent us from conducting our business. Accordingly, any violation of environmental laws, increase in the scope of environmental laws or failure to properly handle, store or dispose of hazardous materials could result in restrictions on our ability to operate our business and could require us to incur potentially significant costs for personal injuries, property damage and environmental cleanup and remediation.

We face competition from companies in multiple industries, as well as from the internal efforts of our current and potential partners and, if we fail to compete effectively, our business could suffer.

We compete in intensely competitive markets for end user products. The nanotechnology-enabled products we are currently developing will compete directly with products incorporating conventional materials and technologies, including traditional semiconductors manufactured on the nanoscale. We believe our potential products will face significant competition from existing manufacturers in our current target markets including:


	•	manufacturers of substrates for time of flight mass spectrometry equipment, such as Waters Corporation;

	•	manufacturers of solar cells, such as Sharp Electronics Corporation and BP plc;

	•	manufacturers of thin film electronics, such as Samsung Electronics Co., Ltd., NEC Corporation and Koninklijke Philips Electronics N.V.; and

	•	manufacturers of memory products, such as Advanced Micro Devices, Inc. and Samsung.

In addition, we may also face competition from focused nanotechnology companies, such as Evident Technologies, Inc., Konarka Technologies Inc., Nantero, Inc., NanoHorizons, Inc., Nanosolar, Inc., Quantum Dot Corporation, UltraDots, Inc. and ZettaCore, Inc. and other newly created nanotechnology companies.

We may also face significant competition from our current and future partners, such as E.I. DuPont de Nemours and Company, or DuPont, Intel and Matsushita Electric Works, which are assessing the feasibility of expanding their development and manufacturing capabilities and portfolio of intellectual

property to incorporate nanotechnology-enabled components into their end user products. If our current and future partners expand their product offerings to compete directly with our nanotechnology-enabled products or actively seek to participate as vendors in the nanotechnology-enabled product market, our revenue and operating results could be negatively affected.


	•	Size and resources. Our competitors, as well as our current and future partners, may have access to substantially greater financial, engineering, manufacturing and other resources than we do, which may enable them to react more effectively to new market opportunities.

	•	Name recognition. Many of our competitors and our current and future partners have greater name recognition and market presence than we do, which may allow them to market themselves more effectively to new customers or partners.

	•	Access to information. Our current and future partners may have better access to information regarding their own manufacturing processes, which may enable them to develop nanotechnology-enabled products that can be more easily incorporated into the partners’ products.

	•	Limits of product offerings. Although we intend to offer a broad range of nanotechnology-enabled products, a current or future partner may require nanotechnology-enabled products or functionalities that we do not offer. As a result, our competitors may exploit the areas in which we do not develop product offerings.

	•	Reliance on internal manufacturing. We intend to manufacture our products internally rather than license the manufacturing of those products to our current and future partners. Our partners may conclude that we will be unable to supply the volume or quality of products they need. In addition, those partners may want to control key steps in their manufacturing process and will therefore want to manufacture the nanotechnology-enabled products themselves. In order to successfully integrate our proposed products with theirs, we may be required to rely on our partners for access to their manufacturing process and capabilities. If this access is restricted or denied, our nanotechnology-enabled products may not be competitive with products internally developed by our partners or others.

	•	Scalability of development. A significant challenge in commercializing our nanotechnology-enabled products across multiple industries and end user products will be our ability to leverage our core technology and development efforts. Most nanotechnology-enabled products require custom development to meet application specific product requirements. To minimize custom development efforts, we will need to develop nanotechnology-enabled products that utilize our common set of our core technology and can benefit from our previous development efforts. If we are unable to achieve this, our development capabilities will be less competitive.

If we do not compete successfully, our ability to develop and sell our products could be harmed and our business could suffer.

Nanotechnology-enabled products are new and may be viewed as being harmful to human health or the environment.

We intend to develop and sell nanotechnology-enabled products composed of materials, such as silicon germanium, gallium arsenide, gallium nitride, cadmium selenide or indium phosphide, because of the functions and properties of nanostructures made with those materials. Nanotechnology-enabled products have no historical safety record. Because of the size or shape of the nanostructures or because they may contain harmful elements, such as arsenic and cadmium, our products could pose a safety risk to human health or the environment. In addition, some countries have adopted regulations prohibiting or limiting the use of certain products that contain certain chemicals, which may inhibit our ability to sell

Public perception of ethical and social issues may limit or discourage the use of nanotechnology-enabled products, which could reduce our revenue and harm our business.

The subject of nanotechnology has received negative publicity and has aroused public debate. Government authorities could, for social or other purposes, prohibit or regulate the use of nanotechnology. Ethical and other concerns about nanotechnology could adversely affect acceptance of our potential products or lead to government regulation of nanotechnology-enabled products.

We may be unable to export our proposed products or technology to other countries, convey information about our technology to citizens of other countries or sell certain products commercially, if the products or technology is subject to United States export or other regulations.

We are developing certain nanotechnology-enabled products that we believe the United States and other governments may be interested in using for military and information gathering or antiterrorism activities. United States government export regulations may restrict us from selling or exporting these products into other countries, exporting our technology to those countries, conveying information about our technology to citizens of other countries or selling these products to commercial customers. We may be unable to obtain export licenses for products or technology if necessary. We do not currently have the ability to assess whether national security concerns would affect nanotechnology-enabled products generally or our business in particular and, if so, what procedures and policies we would have to adopt to comply with any existing or future regulations that may apply to us.

If export controls affecting our products are expanded, our business will be adversely affected.

The United States government regulates the sale and shipment of numerous technologies by United States companies to foreign countries. If the United States government places expanded export controls on our technology or products, our business would be materially and adversely affected. If the United States government determines that we have not complied with the applicable export regulations, we may face penalties in the form of fines or other punishment.

Our inability to adequately protect our nanotechnology-related intellectual property could harm our business.

Our ability to achieve commercial success will depend in part on obtaining and maintaining our nanotechnology-related intellectual property as well as successfully defending our intellectual property against third party challenges. If we or our licensors are unable to obtain and maintain patent and trade secret protection of our technology and products, our business could be harmed. In addition, we will only be able to protect our technology from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover that use.

Patents and patent applications covering a substantial portion of our core technology are owned by third party licensors. While we have certain rights to participate in the prosecution, maintenance and enforcement of those patents and patent applications, in a majority of cases, the licensors have retained the right to prosecute, maintain and enforce the patents and patent applications. We cannot be certain that the licensors will do so in the best interests of our business. Any failure of the licensors to follow our advice or take certain actions with respect to the patents and patent applications, including prosecuting, maintaining, enforcing the patents and patent applications or in a timely manner converting provisional patent applications to regular utility applications, as well as our own failure to take such actions, could harm our business.

We are obligated to fund the prosecution and maintenance of the patents and applications we acquired under the license agreements that we have with various licensors. In addition, in some cases, we have also agreed to indemnify the licensors for any actions we take with respect to developing the technology we have licensed that becomes subject to a third party claim. Our obligations to indemnify these licensors may cause us to incur unanticipated expenses and divert our management’s attention from running our business.

Commercial application of nanotechnology is new and the scope and breadth of patent protection is uncertain. Consequently, the patent positions of nanotechnology companies have not been tested and complex legal and factual questions for which important legal principles will be developed or may remain unresolved. In addition, to date there has been relatively little litigation surrounding nanotechnology related patents, and, therefore, it is not clear whether such patents will be subject to interpretations or legal doctrines that differ from conventional patent law principles. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third party patents.

The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep a competitive advantage. For example:


	•	we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications or issued patents;

	•	we or our licensors might not have been the first to file patent applications for these inventions;

	•	it is possible that none of our pending patent applications or none of the pending patent applications of our licensors will result in issued patents;

	•	our issued patents and issued patents of our licensors may not provide a basis for commercially viable products, may not provide us with any competitive advantages or may be challenged and invalidated by third parties;

	•	our and our licensors’ patent applications or patents may be subject to interference, opposition or similar administrative proceedings, which could result in the patent applications failing to issue or the patents deemed invalid;

	•	we may not develop additional proprietary technology that is patentable; or

	•	the patents of others may have an adverse effect on our business.

We also rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. Trade secrets are difficult to protect. While we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, partners and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know how.

Our patents and patent applications may cover technologies that have few or no commercial applications.

The patents and patent applications that we have licensed from academic or government institutions are directed to technologies that were invented in the course of academic or government research activities, and may not have been invented with a view toward commercial applications. As a result, these licensed patents and patent applications may only cover technologies that have few or no

We may become involved in litigation or other proceedings to defend against claims of infringement of intellectual property rights of others or enforce our intellectual property rights, the outcome of which could have a material adverse impact on our business.

While we are not currently involved in any legal proceedings related to intellectual property, the defense and prosecution of intellectual property suits, interferences, oppositions and related legal and administrative proceedings in the United States and elsewhere are costly, time consuming to pursue and could result in the diversion of our limited financial and managerial resources. An adverse ruling, including an adverse decision as to the infringement of any third party intellectual property rights or the enforceability or validity of our intellectual property rights could subject us to significant damages or prevent us from using the intellectual property or selling our products. Even if we prevail, we could incur substantial costs and our management’s attention may be diverted.

The industries for which we are investigating products are characterized by the existence of a large number of patents and frequent litigation based upon allegations of patent infringement. As our potential products progress toward commercialization in these markets, the possibility of an infringement claim against us or our partners increases. We may not possess rights to use all of the intellectual property required to develop, manufacture or commercialize our anticipated products. While we attempt to ensure that our products and the methods we employ to develop and manufacture them do not infringe other parties’ patents and other proprietary rights, competitors or other parties may assert that we infringe their proprietary rights and bring lawsuits against us seeking to enforce those proprietary rights.

In recent years, several thousand patent applications have been filed with the United States Patent and Trademark office that refer to nanoscale materials or structures. Information contained in patent applications is generally not publicly available. Consequently, we are unable to evaluate the underlying intellectual property until these patent applications become issued or published. The process to issue patents is long and certain innovations that have not yet resulted in issued patents could have been developed prior to our intellectual property. These patents, when issued, may predate our patents and may have superior rights and superior claims or otherwise be in conflict with our technology or business processes.

If a patent infringement suit were brought against us or our partners, we or they could be forced to stop or delay research, development, manufacturing or sales of the end user product or potential product that is the subject of the suit. We or our partners therefore may choose to seek, or be required to seek, a license from the third party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our partners were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or forced to cease some aspect of our business operations, as a result of patent infringement claims. Alternatively, we could encounter delays in product introductions while we attempt to design around the patents. Our redesigned products may be inferior to our original designs or we may be unable to continue product development in the particular field.

We may become involved in litigation or other enforcement action not only as a result of alleged infringement of a third party’s intellectual property rights, but also to protect our own intellectual property rights. Under our licenses with educational institutions and research centers, we have certain rights to enforce our intellectual property rights covered by those licenses. We cannot guarantee that our licensors or their other licensees will assist us in enforcing these rights. The patent protection strategies of our licensors or their other licensees may conflict with ours. Additionally, by seeking to enforce our rights we may expose our patents to challenges, which could result in not only loss of any enforcement action or litigation proceeding, but invalidation of our patents or those of our licensors that are subject to dispute, which could have a material adverse impact on our business.

We may be subject to damages resulting from claims that we have wrongfully used the alleged trade secrets of our employees’ former employers.

Many of our employees were previously employed at universities or other companies, including our competitors or potential competitors. Although we have no current or pending claims against us, we may be subject to claims that we have relied on information that these employees have inadvertently or otherwise disclosed that represent the trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper or prevent our ability to commercialize certain potential products, which could severely harm our business. Even if we are successful, litigation could result in substantial costs and be a distraction to management.

A substantial portion of our technology is subject to government rights and retained rights of our licensors and we may not be able to prevent the loss of those rights or the grant of similar rights to third parties.

A substantial portion of our technology was licensed from educational institutions and research centers funded by various government agencies. Under these funding arrangements, a government agency may obtain rights over the technology including the right to require that a compulsory license be granted to one or more third parties selected by the government agency. The grant of a license for our core technology to a third party could have a material and adverse effect on our business. In addition, our licensors retained certain rights under the licenses including the right to grant additional licenses to a substantial portion of our core technology to third parties for noncommercial academic and research use. It is difficult to monitor and enforce these uses and we cannot predict whether the third party licensors would comply with the use restrictions of their licenses. We could incur substantial expenses to enforce our rights against them.

After the offering there will be few objective metrics by which our progress will be measured. Consequently, we expect that the market price of our common stock may fluctuate significantly. We do not expect to generate substantial revenue from the sale of our nanotechnology-enabled products for several years, if at all. In the absence of product revenue as a measure of our operating performance, we anticipate that investors and market analysts will assess our performance by considering factors such as:


	•	our ability to enter into or extend investigation phase, development phase, commercialization phase and other agreements with new and existing partners;

	•	announcements regarding the status of any or all of our collaborations or products;

	•	general and industry specific economic conditions, which may affect our partners’ development expenditures and commercialization of new products;

	•	the success or failure of our competitors’ efforts to develop competitive products;

	•	announcements regarding developments in the nanotechnology field in general;

	•	the issuance of competitive patents or disallowance or loss of our patent rights; and

	•	announcements regarding government funding and initiatives related to the development of nanotechnology.

We will not have control over many of these factors but expect that our stock price may be influenced by them. As a result, our stock price may be volatile and you may lose all or part of your investment.

If securities or industry analysts do not publish research reports about our business, of if they make adverse recommendations regarding an investment in our stock, our stock price and trading volume may decline.

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about our business. We do not currently have and may never obtain research coverage by industry or securities analysts. If no industry or securities analysts commence coverage of our company, the trading price of our stock could be negatively impacted. In the event we obtain industry or security analyst coverage, if one or more of the analysts downgrade our stock or comment negatively on our prospects, our stock price would likely decline. If one of more of these analysts cease to cover us or our industry or fails to publish reports about our company regularly, our common stock could lose visibility in the financial markets, which could also cause our stock price or trading volume to decline.

Some of our existing stockholders can exert control over us and may not make decisions that are in the best interests of all stockholders.

After this offering, our officers, directors and holders of more than 5% of our common stock will together control approximately 36.8% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may also have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock, even when such a change may be in the best interests of all stockholders.

Prior to this offering, there has been no public market for our common stock. We and the representatives of the underwriters will determine the initial public offering price of our common stock through negotiation. This price will not necessarily reflect the price at which investors in the market will be willing to buy and sell our shares following this offering. An active trading market for our common stock may not develop following this offering. You may not be able to sell your shares quickly or at prices acceptable to you if trading in our stock is not active.

We may be the subject of securities class action litigation due to future stock price volatility.

In the past, when the market price of a stock has been volatile, holders of that stock have often initiated securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management.

We will have broad discretion in how we use the proceeds of this offering and we may not use these proceeds effectively, which may cause our stock price to decline.

Our management will have significant flexibility in using the proceeds we receive in this offering. Because substantially all of the proceeds are not required to be allocated to any specific investment or transaction, you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used in ways that will improve our business or market value.

We will incur increased costs as a result of complying with the laws and regulations affecting public companies.

Complying with existing, recently enacted and proposed changes in the laws and regulations affecting public companies, including the provisions of the Sarbanes Oxley Act of 2002 and recently adopted rules of the Securities and Exchange Commission and the Nasdaq National Market, will result in significant costs to us. In addition to the significantly higher legal, accounting and internal costs, we will incur significant costs to obtain director and officer liability insurance. The impact of these laws and

regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on our board committees or as executive officers. We are presently reviewing existing and new laws and are evaluating and monitoring developments with respect to new and proposed rules and cannot predict or estimate the amount of additional costs we may incur to comply with these rules or the timing of such costs. If we are unable to successfully comply with the new laws, regulations and rules, we could be subject to enforcement proceedings by the Securities and Exchange Commission or our common stock might be delisted from the Nasdaq National Market, either of which would cause the market price for our common stock to decline.

Provisions of our charter documents may have anti-takeover effects that could prevent a change in our control, even if this would be beneficial to stockholders.

Provisions of our amended and restated certificate of incorporation, bylaws and Delaware law could make it more difficult for a third party to acquire us, even if doing so would be beneficial to our stockholders. These provisions include:


	•	a classified board of directors, in which our board is divided into three classes with three year terms with only one class elected at each annual meeting of stockholders, which means that a holder of a majority of our common stock will need two annual meetings of stockholders to gain control of the board;

	•	a provision that prohibits our stockholders from acting by written consent without a meeting;

	•	a provision that permits only the board of directors, the chief executive officer, president or the chairman to call special meetings of stockholders; and

	•	a provision that requires advance notice of items of business to be brought before stockholders meetings.

These provisions can be amended only with the vote of the holders of 66 2/3% of our outstanding capital stock.

If you purchase common stock in this offering, you will pay more for your shares than the amounts paid by existing stockholders for their shares. As a result, you will experience immediate and substantial dilution of approximately $9.77 per share, representing the difference between our pro forma net tangible book value per share as of March 31, 2004, after giving effect to this offering and an assumed initial public offering price of $16.00 per share. In addition, you may experience further dilution to the extent that shares of our common stock are issued upon the exercise of stock options or warrants. As of March 31, 2004, we had outstanding options to purchase 330,527 shares of our common stock at a weighted average exercise price of $0.48 per share and warrants to purchase 279,778 shares of our redeemable convertible preferred stock at a weighted average exercise price of $0.50 per share. In addition, as of March 31, 2004, 1,688,418 shares (inclusive of our 2004 stock plan adopted in April 2004) were reserved for future issuance under our stock plans, excluding annual increases commencing on January 1, 2005. Substantially all of the shares issuable upon the exercise of currently outstanding stock options will be issued at a purchase price less than the public offering price per share in this offering.

Substantially all of our outstanding shares, other than the 6,250,000 shares sold in this offering, will be restricted from immediate resale but may be sold into the market beginning 180 days after this offering. These future sales could cause the market price of our common stock to drop significantly.

Our current stock, option and warrant holders hold a substantial number of shares or rights to acquire shares, which they will be able to sell in the public market in the near future. If our existing securityholders sell, or are perceived to be prepared to sell, a substantial number of shares of our common stock in the public market following this offering, the market price of our common stock could fall. In addition, the sale of these shares could impair our ability to raise capital through the sale of additional shares of stock.

After this offering, we will have outstanding 21,870,313 shares of common stock. These shares will become eligible for resale in the public market as shown in the table below.

After the offering, the current holders of our preferred stock will have rights, subject to specified conditions, to require us to file registration statements covering our shares owned by them or to include shares owned by them in registration statements that we may file.

In addition, as of June 30, 2004, we had outstanding options to purchase 533,854 shares of our common stock and 279,778 shares of redeemable convertible preferred stock that could be purchased upon the exercise of outstanding warrants. Our available but unissued options were 1,479,422 as of June 30, 2004. If these options or warrants are granted, exercised and sold, you may experience additional dilution.

This prospectus, including the sections entitled “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business,” contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, our partners’ or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. These risks and other factors include those listed under “Risk Factors” and elsewhere in this prospectus. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risks outlined under “Risk Factors.” These factors may cause our actual results to differ materially from any forward-looking statement.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. We are under no duty to update any of the forward-looking statements after the date of this prospectus to conform our prior statements to actual results.

We estimate that the net proceeds from the sale of 6,250,000 shares of common stock by us in this offering will be approximately $91,100,000 based on an assumed initial public offering price of $16.00 per share and after deducting the underwriting discount and estimated offering expenses payable by us. If the underwriters exercise their over-allotment option in full, we estimate that our net proceeds will be approximately $105,050,000.

The primary purpose of this offering is to raise capital to fund the development of our core technology and potential nanotechnology-enabled products. We also expect to use the proceeds of this offering for general corporate purposes, including working capital, capital expenditures and potential acquisitions of complementary businesses, products and technologies. We have no present commitments or agreements with respect to any acquisitions. The amounts that we actually expend for working capital purposes will vary significantly depending on a number of factors, including future growth in revenue, if any, and the amount of cash we generate from operations. Pending these uses, we intend to invest the net proceeds in interest bearing, investment grade securities.

We have never declared or paid any dividends on our capital stock. We currently expect to retain future earnings, if any, to support the development of our business and do not anticipate paying any cash dividends in the foreseeable future. Subject to limited exceptions, we are restricted in our ability to pay dividends on or making distributions with respect to our capital stock by the covenants contained in our equipment line of credit with Silicon Valley Bank.

The following table sets forth our unaudited capitalization as of March 31, 2004. Our capitalization is presented:


	•	on an actual basis; and

	•	on a pro forma basis, to reflect the automatic conversion of all outstanding shares of our preferred stock into common stock immediately prior to the closing of this offering; and


	•	on a pro forma as adjusted basis to reflect our receipt of the estimated net proceeds from the sale of 6,250,000 shares of common stock by us in this offering at an assumed initial public offering price of $16.00 per share, after deducting the underwriting discount and estimated offering expenses payable by us.

We also consider as outstanding 1,069,154 shares of common stock, which are subject to our liability of $589,000 for early exercise of stock options and restricted stock purchase awards as of March 31, 2004, but these shares are not reflected in stockholders’ equity in the table above because they were subject to our right of repurchase. In addition to the 20,750,934 shares of common stock to be outstanding after the offering, we may issue additional shares of common stock under the following plans and arrangements:


	•	330,527 shares of common stock issuable upon exercise of options and restricted stock purchase awards outstanding at a weighted average exercise price of $0.48 per share as of March 31, 2004;


	•	279,778 shares of common stock issuable upon exercise of warrants outstanding at a weighted average exercise price of $0.50 per share as of March 31, 2004;

	•	a total of 1,688,418 shares of common stock available for future issuance under our stock plans, including our 2004 stock plan which was adopted by our board of directors in April 2004, excluding the annual increases in the number of shares authorized under our 2004 stock plan beginning January 1, 2005. For a description of how these annual increases are determined see “Executive Compensation — Incentive Plans.”

You should read this table together with the sections of this prospectus entitled “Selected Financial Data” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and with the financial statements and related notes beginning on page F-1.

If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the initial public offering price per share and the pro forma net tangible book value per share. Our historical net tangible book value as of March 31, 2004 was approximately $(18.6) million, or approximately $(10.04) per share. Historical net tangible book value per share represents our total tangible assets less total liabilities divided by the total number of shares of common stock outstanding on that date. Our pro forma net tangible book value as of March 31, 2004 was approximately $38.2 million, or approximately $2.63 per share. Pro forma net tangible book value per share represents the amount of our total tangible assets reduced by the amount of our total liabilities and divided by the total number of shares of common stock outstanding including the automatic conversion of all outstanding shares of our preferred stock. Dilution in pro forma net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the pro forma net tangible book value per share of common stock immediately after the completion of this offering. After giving effect to the sale of the 6,250,000 shares of common stock offered by us at an assumed initial public offering price of $16.00 per share, and after deducting the underwriting discount and estimated offering expenses payable by us, our pro forma net tangible book value as of March 31, 2004 would have been approximately $129.3 million, or $6.23 per share of common stock. This represents an immediate increase in pro forma net tangible book value of $3.60 per share to existing stockholders and an immediate dilution of $9.77 per share to new investors of common stock. The following table illustrates this dilution on a per share basis:

If the underwriters exercise their over-allotment option in full, the pro forma net tangible book value as of March 31, 2004 would have been $6.60 per share, representing an immediate increase to existing stockholders of $3.97 per share and an immediate dilution of $9.40 per share to new investors.

The following table summarizes after giving effect to the offering, based on an assumed initial public offering price of $16.00 per share, as of March 31, 2004, the differences between the existing stockholders and new investors with respect to the number of shares of common stock purchased from us, the total consideration paid to us and the average price per share paid.

The foregoing discussion and tables are based upon the number of shares issued and outstanding on March 31, 2004, assumes the automatic conversion of all shares of our preferred stock and assumes no exercise of options outstanding as of March 31, 2004. As of that date, there were 330,527 shares of our common stock issuable upon exercise of options outstanding and restricted stock awards at a weighted average exercise price of $0.48 per share. In addition, as of March 31, 2004, we had warrants outstanding to purchase 279,778 shares of our redeemable convertible preferred stock at a weighted average exercise

Assuming the exercise in full of all our outstanding options and warrants as of March 31, 2004, the average price per share paid by our existing stockholders would be reduced to $2.55 per share, representing an immediate dilution of $9.93 per share to new investors. Assuming the exercise in full of all our outstanding options and warrants as of March 31, 2004, the percentage of shares held by existing stockholders will increase to approximately 72% of the total number of shares outstanding after this offering, and the percentage of shares of common stock held by new investors will decrease to approximately 28%.

The selected financial data set forth below should be read together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” our financial statements and related notes, and the other information contained elsewhere in this prospectus. We have derived our selected statement of operations data for the period from July 12, 2001 (inception) to December 31, 2001, and the years ended December 31, 2002 and December 31, 2003 and the selected balance sheet data as of December 31, 2002 and 2003 from the audited financial statements included elsewhere in this prospectus. We have derived our selected statement of operations data for the three months ended March 31, 2003 and 2004 and our selected balance sheet data as of March 31, 2004 from the unaudited condensed financial statements included elsewhere in this prospectus. The selected balance sheet data as of December 31, 2001 were derived from the unaudited financial statements not included in this prospectus. Historical results are not necessarily indicative of results to be expected for future periods.


(2)	The unaudited pro forma basic and diluted net loss per share calculation assumes the conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock using the as-if-converted method as of the date of issuance.

The following information should be read together with the audited financial statements and the notes thereto and other information included elsewhere in this prospectus.

We are in the early stages of investigative research to develop nanotechnology-enabled products based on our specialized expertise and intellectual property. We are applying this investigative research to develop potential products for multiple industries such as energy, defense, electronics, life sciences and information technology. Our technology and potential product applications are new and still in the early stages of development. To date, we have not successfully developed any commercially available products. Since our inception in July 2001 we have licensed patents from educational institutions and research centers and developed our technology internally. We are currently in the investigation phase of all of our potential products. We do not anticipate that our first products will be commercially available for at least several years, if at all.

To date, our revenue has resulted from collaborations with partners and government agencies to explore the feasibility of developing nanotechnology-enabled products. As part of our business strategy, we intend to enter into additional collaborations to enter multiple markets and expand our core technology across multiple industries and applications. We expect that we will continue to enter into investigative stage research under new collaborations, while other potential products and related collaboration arrangements proceed to development and commercialization phases. We may also generate revenue from research feasibility studies in the early stages of collaborative arrangements. Our product development activities and collaborations typically contemplate several phases, including an investigation phase, a development phase and a commercialization phase. We are currently generating revenue from the investigation phase of our collaborations with partners. We have also entered into arrangements with United States government agencies. Our strategy for pursuing government contracts and grants is to focus on opportunities that will enable us to further our core technology development. We intend to continue to pursue government contracts and grants that enable us to develop dual use products and technologies that may be sold in both the governmental and commercial markets. Our strategy for developing products and future product revenue depends on entering into collaborations to leverage our partners’ financial, research and development, manufacturing, marketing and sales capabilities. We are obligated to perform the objectives defined in our statement of work with our partners or government agencies on a reasonable efforts basis. If we are successful in completing an investigation phase agreement, our partner typically has the right to negotiate with us for a limited period of time to extend these agreements to the development or commercialization phases. In the near term, we will have a limited number of development or commercialization agreements, if any. Even if we receive additional funding from collaboration agreements, we may need additional capital for our operations and we cannot be assured it will be available on favorable terms if at all. We cannot predict how these agreements will be structured, how we will be able to recognize revenue under these agreements or the timing of any revenue recognition. As a result, our operating results could fluctuate significantly from period to period due to the timing of our revenue recognition.

In order to generate product sales, we will need to develop commercially viable products and the ability to manufacture those products in commercial quantities. The development and manufacture of nanotechnology-enabled products is unproven and we will need to devote substantial capital resources to establish our development and manufacturing capabilities including building of facilities, purchase and modification of equipment and hiring and training of additional personnel. In addition, we will need to avoid infringing the intellectual property rights of third parties.

Our research and development expense consists primarily of personnel salary costs, license and patent fees, facility costs, supplies and professional services. We expense all research and development costs as they are incurred including up front licensing fees. We expect that total expenses related to

research and development will increase in future periods as we continue to expand our headcount and facilities to address expansion of our existing and new product development activities. In addition, total research and development expenses are expected to increase in future periods as a result of the amortization of deferred compensation for employees and stock-based compensation expense related to awards to nonemployees.

Our selling, general and administrative expenses include personnel costs for finance, human resources, business development, legal and general management, as well as professional services, such as legal and accounting. We expect our selling, general and administrative expenses to increase in future periods as we continue to expand our business development headcount in an effort to generate additional collaborative partnerships. We also expect an increase in general and administrative headcount necessary to support regulatory compliance, investor relations and other costs associated with being a public company. In addition, total selling, general and administrative expenses are expected to increase in future periods as a result of our facilities expansion and the amortization of deferred compensation for employees and stock-based compensation expense related to awards to nonemployees.

From our inception on July 12, 2001 through March 31, 2004, we incurred net losses of approximately $20.9 million. We expect these losses to continue for the foreseeable future. In the next few years, we expect to incur substantial additional operating losses as a result of increases in expenses for research and development, manufacturing and selling, general and administrative costs.

In order to prepare financial statements in accordance with accounting principles generally accepted in the United States, we make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We have identified the following critical accounting estimates that involve a higher degree of subjectivity and judgment, are susceptible to change, and materially impact our financial condition or operating performance.

We have granted stock options and restricted stock purchase awards to employees and others. Given the absence of an active market for our common stock, we are required to estimate the fair value of our common stock based on a variety of company- and industry-specific factors for the purpose of measuring the cost of the transaction and properly reflecting it in our financial statements. The significant factors considered in the estimation of the fair value of our common stock are the anticipated initial public offering price, the price paid by third parties in cash for our redeemable convertible preferred stock in April 2003, the rights and privileges of the redeemable convertible preferred stock in comparison to our common stock, the risks and uncertainties involved with ownership of our common stock and, more recently, the anticipated initial public offering price.

We had no employee stock compensation expense reflected in our reported net loss in any period prior to 2003, as all options granted had an exercise price equal to the fair value of the underlying common stock on the date of the grant. In connection with the preparation of the financial statements necessary for the filing of our initial public offering, we have reassessed the fair value of our common stock and determined that some of the stock options and restricted stock purchase awards granted during 2003 were granted at exercise prices that were below the deemed fair value of the common stock on the date of grant. Accordingly, we recorded deferred compensation of approximately $1.1 million during 2003. The deferred compensation will be amortized on a straight-line basis over the vesting period of the related awards, generally five years. In 2003, we recorded expense for the amortization of deferred compensation of approximately $74,000 and we recorded stock-based compensation expense for nonemployees of approximately $964,000. In the three months ended March 31, 2004, additional stock options and restricted stock purchase awards were granted at exercise prices that were below the deemed fair value on the date of grant and we recorded additional deferred compensation of approximately $11.4 million. Subsequent to March 31, 2004, we granted additional stock options at exercise prices below the deemed

Our results of operations for future periods will include the amortization of deferred compensation and stock-based compensation expense for nonemployees. The amount of expense expected to be recorded in future periods related to the amortization of deferred stock-based compensation for employees is as follows (in millions):

Please note that the amount of expense recorded in future periods related to stock-based compensation expense for nonemployees will be dependent upon the valuation of our common stock at the date of vesting of the nonemployee award. As of June 30, 2004, we had approximately 461,000 unvested shares related to awards of stock options or restricted stock to nonemployees, at exercise or issuance prices ranging from $0.003 to $4.50 per share, which remained subject to remeasurement at fair value and may result in future nonemployee stock-based compensation expense.

We receive payments under research and development contracts and government grants. These payments are non-refundable but are reported as deferred revenue until they are recognizable as revenue. We follow the following principles in recognizing revenue:


	•	Fixed-fee research and development contracts generally provide us with an up-front fee and a contractually defined period of service. Fees for services we perform under fixed-fee research and development contracts are recognized ratably over the period we perform these services.

	•	Variable-fee research and development contracts generally provide us with fees based upon an agreed-upon rate for time incurred by full time equivalent research staff. Fees for services we perform under variable-fee research and development contracts are recognized based upon the full time equivalent time incurred.

	•	Government grants generally provide us with fixed payments and a contractually defined period of research. Payments received under grants are recognized as revenues ratably over the period we perform the research. We retain ownership and exclusive rights to all our inventions under these arrangements except for nonexclusive, nontransferable, irrevocable, paid-up licenses granted to the United States government to practice directly or indirectly the subject invention throughout the world.

Under all arrangements, we do not recognize revenue unless there is persuasive evidence of an arrangement, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and the collection of the related receivable is probable. Upon the completion of each of our research and development contracts and government grants and submission of any final written reports, no further obligations exist under these arrangements. We retain the rights to commercialize the technology we developed under collaborative arrangements and government grants without any royalty obligations.

In order to meet our customer’s needs, we have entered into revenue arrangements with multiple deliverables. For example, the arrangements with the United States government may include a

combination of research and development services and limited license rights. We evaluate multiple element revenue agreements entered into on or after July 1, 2003 under Emerging Issues Task Force No. 00-21, “Revenue Arrangements with Multiple Deliverables,” to determine whether the delivered item has value to the customer on a stand-alone basis and whether we have objective and reliable evidence of the fair value of the undelivered item. Deliverables in an arrangement that do not meet the separation criteria in Issue 00-21 must be treated as one unit of accounting for purposes of revenue recognition. Generally, we treat our revenue arrangements with multiple deliverables as a combined unit of accounting and recognize revenue when we deliver the services.

In September 2003, in connection with a revenue arrangement with a customer, we issued warrants for the purchase of Series C redeemable convertible preferred stock. In accordance with Emerging Issues Task Force Issue No. 01-9, Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor’s Products), we estimated the portion of the consideration received from the customer that related to the issuance of the warrants and the portion that related to revenue for the performance of research and development services. The warrants become exercisable by the customer as the customer makes milestone payments to us. Until the warrants are fully exercisable, they are subject to remeasurement at fair value. In 2003, we received $1.0 million in cash proceeds which were attributed entirely to the value of the warrants. Because the value of the warrant exceeded the estimated total cash proceeds under the arrangement, we did not recognize any revenue under the arrangement and therefore recorded $370,000 of research and development expense in 2003. As of March 31, 2004, the warrants remained unvested and were remeasured at fair value. Because the estimated fair value of our stock increased during the three months ended March 31, 2004, additional expense was recorded related to the warrants. Accordingly, we recorded $723,000 of research and development expense during the three months ended March 31, 2004. Subsequent to March 31, 2004, the remaining cash proceeds of $2 million were received and the warrants became fully exercisable. As a result, the remeasurement of the warrants to fair market value ceased. We expect to record approximately $200,000 of research and development expense related to the warrants in the three months ending June 30, 2004.

Our total revenue increased from $597,000 for the three months ended March 31, 2003 to $1.2 million for the three months ended March 31, 2004. This increase was primarily due to the addition of new research collaborations with commercial partners and United States government agencies. We generated a portion of our revenue from research feasibility studies we performed under our collaboration arrangements.

Revenue for the three months ended March 31, 2003 consisted primarily of $400,000, or 67% of revenue, from Matsushita Electric Works, which represented all of our non-United States revenue during the period, and $139,000, or 23% of revenue, from SAIC. Revenue recognized in the three months ended March 31, 2004 consisted primarily of $315,000, or 27% of revenue, from Matsushita Electric Works, which represented all of our non-United States revenue, $310,000, or 26% of revenue, from Intel, and $218,000, or 19% of revenue, from SAIC, and $149,000, or 13% of revenue, from DuPont. The remainder of revenue in each period was derived from grants from United States government agencies.

We receive revenue from contracts with commercial collaborators and contracts and grants with United States government agencies. We are currently in the investigation phase of all of our potential products, including pursuant to our collaborations with partners. Our ability to generate revenue in future periods will be dependent upon our ability to extend current collaborations or enter into new collaborations.

Research and development expenses increased from $2.0 million in the three months ended March 31, 2003 to $3.9 million in the three months ended March 31, 2004. The $1.9 million increase reflected the recruitment and hiring of additional research personnel which increased from 19 persons at March 31, 2003 to 23 persons at March 31, 2004, as well as an increase in stock-based compensation expense of approximately $1.2 million. We expect our research and development costs to increase in the future as we pursue our research and expand our staff to support these efforts.

Our research and development efforts span multiple industries and technology we develop for one industry can in many cases also be utilized in other industries. Our current development projects include disposable test plates, known as consumable substrates, for life sciences research, solar cells, electronic circuits on flexible film known as flexible electronics, and semiconductor memory devices that retain data in the absence of power, known as non-volatile memory. We have not tracked our historical research and development costs by project. Our technology and potential product applications are new and still in the early stages of investigative research. We are unable to predict the costs to complete any of our individual research and development projects or the anticipated completion date of any of our individual research and development projects.

General and administrative expenses increased from $643,000 in the three months ended March 31, 2003 to $1.3 million in the three months ended March 31, 2004. The $639,000 increase reflects the recruitment and hiring of additional administrative personnel which increased from eight persons at March 31, 2003 to 11 persons at March 31, 2004, as well as an increase in stock-based compensation expense of $346,000 and a $72,000 increase in professional fees.

Interest income (expense) and other income, net includes interest and other income offset by interest expense, if any. Interest income includes income earned on our cash and cash equivalents. Interest expense represents interest paid on our equipment line of credit. Our interest income (expense) and other income, net, increased from $0 in the three months ended March 31, 2003 to $105,000 in the three months ended March 31, 2004, due largely to an increase in interest income related to an increase in average investment balances resulting from our sale of redeemable convertible preferred stock in 2003.

Period from Inception (July 12, 2001) to December 31, 2001 and Years Ended December 31, 2002 and December 31, 2003

We did not have any revenue from inception to December 31, 2001. Our revenue for 2002 was $283,000 and revenue for 2003 was $3.0 million.

We recognized revenue from Matsushita Electric Works, a Japanese company, of $200,000, or 71% of revenue, in 2002, which represented all of our non-United States revenue in 2002. Revenue recognized in 2003 consisted primarily of $1.6 million, or 53% of revenue, from Matsushita Electric Works, which represented all of our non-United States revenue, $586,000, or 19% of revenue, from SAIC, and $340,000, or 11% of revenue, from Sciperio, Inc., for which we are a subcontractor under a United States government contract. The remainder of revenue in each year was derived from contracts with other corporate collaborators and United States government agencies.

Our research and development expenses increased from $237,000 in the period from inception to December 31, 2001 to $5.2 million in 2002. The research and development expenses in the period of inception to December 31, 2001 related to the establishment of our operations and initial licensing activities. In 2002, research and development expenses increased by $5.0 million to $5.2 million primarily due to an increase in research personnel from one person at the beginning of 2002 to 17 persons as of December 31, 2002 as we began development of our technology. Our 2002 expenses increased due to a $1.3 million increase in laboratory and facility costs incurred to initially establish our scientific laboratories, $1.2 million of personnel-related costs, $830,000 in fees to outside service providers and $702,000 for the licensing and patenting of our technology.

Our research and development expenses increased from $5.2 million in 2002 to $9.9 million in 2003. This increase of $4.8 million in 2003 was due primarily to an increase in our research and development headcount from 17 persons to 22 persons during 2003. Our 2003 expense increases included a $1.8 million increase in personnel related costs, $1.4 million of stock-based compensation expense, $613,000 in laboratory and facility related costs and $677,000 for the licensing and patenting of our technology.

Our selling, general and administrative expenses increased from $562,000 in the period from inception to December 31, 2001 to $2.3 million in 2002. Our selling, general and administrative expenses in the period of inception to December 31, 2001 related to the initial establishment of our operations. In 2002, selling, general and administrative expenses increased by $1.8 million to $2.3 million, primarily due to an $896,000 increase in personnel-related costs, a $224,000 increase in professional services, such as legal and accounting, and a $436,000 increase in facilities expenses.

Our selling, general and administrative expenses increased from $2.3 million in 2002 to $2.6 million in 2003. This increase of $228,000 in 2003 was primarily due to a $143,000 increase in personnel related costs.

Our interest income (expense) and other income, net, increased from $7,000 in the period from inception to December 31, 2001, to $126,000 in 2002. Our interest income (expense)and other income, net increased from $126,000 in 2002 to $294,000 in 2003. The increases were primarily due to interest income resulting from higher average investment balances as a result of receipt of proceeds from the sales of our redeemable convertible preferred stock that were partially offset by interest expense related to our equipment line of credit.

In the period from inception to March 31, 2004, we did not have any income tax expense, as we had net operating losses for all periods presented.

At December 31, 2003, we had approximately $13.9 million of net operating loss carryforwards and approximately $295,000 in federal research and development tax credit carryforwards available to offset any future taxable income we may generate. These net operating losses and tax credit carryforwards will expire beginning in 2013. Our deferred tax assets have been offset by a full valuation allowance, as the realization of such assets is uncertain. The Internal Revenue Code of 1986, as amended, places certain limitations on the annual amount of net operating loss and tax credit carryforwards that can be utilized in any particular year if certain changes in our ownership occur.

From inception through March 31, 2004, we raised $54.4 million in private equity financings, net of issuance costs. In addition to equity financings, our sources of cash include non-refundable payments received from collaborative partners and government agencies, as well as borrowings under an equipment line of credit. As of March 31, 2004, our cash, cash equivalents and available-for-sale investments totaled $37.7 million.

We believe that the net proceeds from this offering, together with our current cash, cash equivalents and available-for-sale securities will be sufficient to meet our anticipated operating and capital requirements for at least the next year. We have no current plans, nor are we currently negotiating, to obtain additional financing following the closing of this offering. Since we anticipate incurring substantial losses for the foreseeable future, we may need to raise additional capital in order to complete our development activities and to build our commercial scale manufacturing facilities. We may raise additional capital through a variety of sources, including the public equity market, private financings, collaborative arrangements and debt. If we raise additional capital through the issuance of equity or securities convertible into equity, our stockholders may experience dilution. Those securities may have rights, preferences or privileges senior to those of the holders of the common stock. Additional financing may not be available to us on favorable terms, if at all. If we are unable to obtain financing, or to obtain it on acceptable terms, we may be unable to successfully support our business requirements.

The cash used in operating activities increased in each of the periods presented. The increase in operating expenditures was primarily a result of continued increases in our research and development activities, including the additions to headcount, fees to outside service providers and costs for the licensing and patenting of our technology. For example, our total number of employees increased from 24, as of December 31, 2002 to 34 as of March 31, 2004. We expect our cash used in operating activities to increase in future periods to support continued increases in personnel and related costs. Cash used in operating activities varies from our total operating expenses recorded in the statement of operations primarily as a result of non-cash charges for stock-based compensation, depreciation and amortization.

Cash used in operating activities was partially offset by non-refundable payments received from customers. To date, we have entered into a limited number of collaborations with commercial partners and government agencies. Our collaborations typically contemplate several phases, including an investigation phase, a development phase and a commercialization phase. Under these investigation phase agreements, we are responsible for performing investigative research and development at specified levels. We are obligated to perform the objectives defined in our statement of work with our partners or government agencies on a reasonable efforts basis. We typically receive research and development payments at specified periods and amounts per full time employee equivalent working on the project, payments on the achievement of specified milestones, or both. The payments received under these collaborations have been subject to significant volatility. For example, cash payments received from customers were approximately $2.1 million, $1.1 million, and $1.8 million in 2002, 2003, and the three months ended March 31, 2004, respectively. Cash payments received from customers are frequently in the form of up-front payments and may differ greatly from the amount of revenue recognized in the statement of operations. In addition, because of the short-term nature of our product development collaborations, our cash payments from our commercial partners, government grants and government contracts are subject to significant variability. Accordingly, our past performance may not be indicative of our future performance. In order to finance future operations, we may need to raise additional funding.

Net cash used in investing activities was $528,000 for the three months ended March 31, 2003 and $315,000 for the three months ended March 31, 2004. Net cash used in investing activities was $117,000 from the period from inception to December 31, 2001, and $2.5 million in 2002, and

$35.7 million in 2003. From inception to December 31, 2002, investing activities were primarily for the purchase of equipment to support our expanding operations. In 2003, we also made an investment in marketable securities, net of maturities, of $33.2 million, which represented a portion of the proceeds of our series C redeemable preferred stock financing in addition to the purchase of equipment and leasehold improvements. In the three months ended March 31, 2003, we had purchases of equipment of $528,000. In the three months ended March 31, 2004, we had net maturities of investments of $125,000, offset by purchases of equipment of $440,000. We expect to continue to make significant additions to equipment and leasehold improvements when we begin the development of our manufacturing capabilities as we continue to support our research and development activities. However, we do not anticipate that a substantial portion of those investments will occur during 2004. In order to finance anticipated investments in manufacturing facilities, we may need to raise additional capital. Because our technology is in the early stages of development, we are unable to accurately estimate the amount of capital required to establish these manufacturing capabilities.

Financing activities provided cash of $1.6 million for the period from inception to December 31, 2001, $16.6 million in 2002 and $38.1 million in 2003. Financing activities provided cash of $601,000 for the three months ended March 31, 2003 and $440,000 during the three months ended March 31, 2004. These amounts were primarily the proceeds we received from the sale of convertible redeemable preferred stock, equipment line of credit and proceeds from the sale of common stock and exercise of stock options.

In 2002, we entered into an equipment line of credit, which provided for up to a maximum of $2.5 million to finance the purchases of equipment. We borrowed up to the maximum permitted under the equipment line of credit during the commitment period, which expired on March 1, 2003. Once we borrowed up to the maximum amount, no further borrowings were available. Borrowings under the equipment line of credit converted to notes payable that are repayable ratably over 36 months, bear interest at 5%, and are secured by our financed equipment. As of December 31, 2003 and March 31, 2004, there were $1.5 million and $1.3 million of outstanding notes payable under the equipment line of credit, respectively. We cannot borrow additional amounts under the line of credit. During the term of the outstanding notes, we are prohibited from making cash dividends or distributions with respect to our capital stock.

Our contractual obligations as of December 31, 2003 were as follows (in thousands):


*	Operating lease commitments exclude approximately $96,000 of rental income under a non-cancelable sublease that terminated in April 2004.

We have entered into several license agreements with educational institutions that provide us with the right to exploit technology developed by researchers at those institutions. In connection with those licenses, we will be obligated to pay specified royalties to our licensors from sales on applicable products if they are commercialized. If we do not have any sales from commercial products, we are obligated to pay minimum royalties under the agreements. In addition, in connection with the execution of a patent license agreement with the Ernest Orlando Berkeley National Laboratory, we are obligated to pay a license milestone payment in cash. The dollar amount of the milestone payment will be 23,333 (subject to

adjustments for splits, dividends and the like in our common stock) multiplied by the initial public offering price per share, which will be payable at various times over 26 months after the closing of our initial public offering. We expect to expense this license milestone when and if the milestone is achieved. The minimum royalty obligations are waived in certain license agreements through 2004 if our expenditures in selected areas of research and development exceed specified amounts. Assuming we are unable to obtain waivers of any minimum royalty obligations, the following table reflects our future minimum royalty obligations as of December 31, 2003 (in thousands):

On March 31, 2004, the Financial Accounting Standards Board issued its Exposure Draft, Share-Based Payment, which is a proposed amendment to FASB Statement No. 123, Accounting for Stock-Based Compensation. Generally, the approach in the Exposure Draft is similar to the approach described in Statement 123. However, the Exposure Draft would require all share based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. The Financial Accounting Standards Board expects to issue a final standard late in 2004 that would be effective for 2005. The pro forma impact of the adoption of Statement 123 on our historical financial statements is included in the footnotes to the financial statements. We expect to continue to grant stock-based compensation to employees and the impact of the adoption of the new standard, when and if issued, may have a material impact on our future results of operations.

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. We do not hold or issue financial instruments for trading purposes or have any derivative financial instruments. To date, all of our agreements with partners and government agencies have payments denominated in United States dollars. Our exposure to market risk is limited to interest rate fluctuations due to changes in the general level of United States interest rates, particularly because the majority of our investments are in short-term debt securities. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. To minimize risk, we maintain our portfolio of available-for-sale investments in a variety of interest-bearing instruments, including United States government and agency securities, high-grade United States corporate bonds, auction-rate securities issued by states of the United States, commercial paper and money market funds. The investment portfolio is subject to interest rate fluctuations and will fall in value in the event market interest rates increase. As of December 31, 2002, our cash reserves were maintained in money market investment accounts and were not exposed to material market risks. As of December 31, 2003 and March 31, 2004, a hypothetical 1% increase in interest rates would result in an adverse change of approximately $200,000 in the fair value of our available-for-sale investments.

We are in the early stages of investigative research to develop nanotechnology-enabled products based on our specialized expertise and intellectual property. We plan to sell our nanotechnology-enabled products to our partners and directly to end user customers. We are developing products based on our core technology that incorporate proprietary, inorganic nanostructures with integrated functionality. We are utilizing our technology to develop potential products for multiple industries such as energy, defense, electronics, life sciences and information technology. We have not yet developed any of these products and may not be able to do so for several years, if at all.

We expect that we will continue to enter into investigative stage research under new collaborations, while other potential products and related collaboration arrangements proceed to development and commercialization phases. We have also entered into arrangements with United States government agencies. We believe our strategy for pursuing government contracts and grants to focus on additional product opportunities will enable us to further our core technology development. We intend to continue to pursue government contracts and grants that enable us to develop dual use products and technologies that may be sold in both government and commercial markets. Upon the completion of each of our current research and development contracts and government grants and the submission of any final reports, we have no further obligations under these arrangements. We retain the rights to commercialize the technology we developed under collaborative arrangements and government grants without any royalty obligations.

Some of our nanotechnology-enabled product development efforts include consumables for life sciences research, solar cells, flexible electronics and non-volatile memory. We have assembled an experienced business and technical team, with development and commercialization expertise, which is supported by the members of our scientific advisory board who are recognized experts in the field of nanotechnology. We have over 250 patents and patent applications which we have licensed from educational institutions and research centers or developed internally. Our granted patents and patent applications derive from over 79 different patent families, each of which represents what we or our licensors believe is a distinct technological development, or in some cases, a collection of distinct technological developments. In addition, some of our patents or patent applications represent foreign patents or patent applications that relate to similar or identical technology to our United States patents and patent applications. We believe our strong team will enable us to deliver nanotechnology-enabled products for use in multiple industries.

Nanotechnology is the ability to control or manipulate materials on the atomic scale to create structures that have novel properties and functions because of their size, shape or composition. These structures are typically less than 100 nanometers in size. A nanometer is one billionth of a meter, which is approximately 100,000 times smaller than the width of a human hair and is up to 100 times smaller than geometries typically used in commercial semiconductor manufacturing today. By organizing atoms into

structures of different shapes and sizes on a nanoscale, important properties including electrical, optical and physical, can be controlled. At the nanoscale, these properties can be fundamentally different than the properties of the same materials at a larger, traditional scale. When nanostructures are engineered into end user products, these products benefit from the unique properties exhibited by the nanostructures. We believe that the application of nanotechnology to multiple industries will significantly improve the performance, cost and functionality of existing products and allow the development of products previously not possible. As an example, with certain traditional materials, color is varied by using different chemicals. At the nanoscale, variations in color can be achieved by varying the size of a nanostructure, rather than its chemical composition. This could improve performance and color flexibility in products, such as displays, solid state lighting and solar cells, while reducing their cost and manufacturing complexity.

Many of the unique properties of nanostructures arise at sizes for which traditional fabrication processes, such as those used in semiconductor manufacturing, are either impractical or not possible using today’s technologies. Scientists have therefore developed methods for forming these nanostructures from the bottom up, building them atom by atom with precise control. Innovative and novel technologies are required for the design and synthesis of nanostructures, their assembly into products and their interface into end user products.

Common materials used to create nanostructures can be organic, such as carbon, or inorganic, such as silicon. We believe that inorganic nanostructures can be created with consistent, desired characteristics in commercially required quantities in a cost effective manner. Inorganic materials are appealing for fabrication of nanostructures for several reasons:


	•	there is a broad range of inorganic materials, such as silicon, silicon germanium, gallium arsenide, gallium nitride, cadmium selenide and indium phosphide, from which to create nanostructures, enabling different product properties;

	•	inorganic materials can form structures in a consistent manner and allow the use of similar fabrication methods to create a wide variety of nanostructures with reproducible physical and functional characteristics;

	•	significant information and expertise exists in traditional industries regarding the techniques to manipulate and interface with inorganic materials; this provides a strong foundation on which to design and build products based on nanostructures formed from these same materials; and

	•	inorganic nanostructures can be synthesized atom by atom leveraging commercially available equipment, creating billions of precisely defined functional nanostructures per batch and potentially lowering the total cost of the end user product.

While the concept of nanotechnology started in the research community several decades ago, to date nanotechnology products have had limited applications in commercial products. Nanoscale materials, however, are being utilized in a variety of basic applications, such as sunscreens, water repellant fabrics, carbon fiber tennis rackets and antistatic mats. Recently, a number of factors have converged to act as catalysts for the development of more advanced and complex nanotechnology products. Analytical instruments, such as scanning probe and electron microscopes, have been significantly improved in recent years, allowing researchers to better understand electrical, chemical and physical properties at the nanoscale. At the same time, governments have made research and development of nanotechnology a priority. For example, in December 2003 the United States adopted the 21st Century Nanotechnology Research and Development Act, which allocated approximately $3.7 billion dollars to nanotechnology development over the next four years. Governments of other major industrialized countries have also committed to advance the progress of nanotechnology by providing substantial research and development funding. In addition, multiple industries are approaching the point at which their ability to economically manufacture products with increasing levels of performance and functionality is being constrained by traditional technologies. Nanotechnology provides the potential to address these challenges.

Many companies are seeking to incorporate the potential benefits of nanotechnology into their end user products on a timely and cost effective basis. We believe that these companies will be motivated to work with focused nanotechnology suppliers that have the expertise, infrastructure and intellectual property needed to allow them to incorporate nanotechnology cost effectively into their end user products. The development of nanotechnology-enabled products requires specialized expertise in chemistry, physics, engineering, materials science, quantum mechanics and advanced manufacturing, as well as access to intellectual property.

We are developing nanotechnology-enabled products for partners and customers in multiple industries based on our specialized expertise and intellectual property. We believe our strong team of technical and business experts and related development and commercialization capabilities will enable us to provide our partners and customers with nanotechnology-enabled products. We are utilizing our technology to develop potential products for multiple industries such as energy, defense, electronics, life sciences and information technology. The key elements of our solution include:

Broadly applicable technology. We intend to apply our core technology to develop and manufacture nanotechnology-enabled products for direct sale or incorporation into end user products across multiple industries or applications. Technology we develop for one product can in many cases also be utilized for other applications or products. For example, we are using technology that we initially developed for potential use in DNA microarrays, a DNA detection technology, in our consumable substrates that are intended for use with time of flight mass spectrometry testing. We believe this approach will enable our partners and customers to leverage the advantages of nanotechnology without requiring them to heavily invest in the resources necessary to develop in-house nanotechnology expertise and infrastructure.

Nanotechnology and commercialization expertise. We have assembled an experienced business and technical team with development and commercialization expertise. This team has previously commercialized a number of products based on new core technology. Our internal expertise is complemented by our scientific advisory board that includes prominent nanotechnology experts from a number of leading educational institutions and research centers.

Significant intellectual property position. We have a significant body of nanotechnology-related intellectual property, including patents and patent applications licensed to us on an exclusive basis, as well as our own patent applications and trade secrets. This intellectual property covers a variety of technologies applicable to nanostructure compositions and devices, as well as their design, manufacture and use. When combined with our technical expertise, we believe our intellectual property provides us with a strong competitive advantage in developing nanotechnology-enabled products.

Design and fabrication capabilities. Our proprietary computer modeling and synthesis capabilities enable us to rapidly and efficiently design and fabricate nanostructures based on our knowledge of applicable principles in chemistry, physics and engineering. We are developing processes designed for the consistent and reliable manufacture of inorganic nanostructures with desired composition, size, shape and surface chemistry and their practical and rapid integration into products.

Our objective is to become an industry leading nanotechnology company developing and manufacturing products that incorporate proprietary, inorganic nanostructures with integrated functionality for multiple industries. To facilitate the commercial adoption of our products, we have established and intend to continue to establish collaborations with partners and government agencies that we believe will benefit significantly from the incorporation of nanotechnology-enabled products into their end user products. In addition, there may be certain opportunities, such as the use of nanostructures in medical devices, that we do not have the resources, financial or otherwise, to pursue without a partner or government agency. In these instances, we may pursue other arrangements, which could include

Utilize collaborations to enter multiple markets. We plan to collaborate with partners to sell and, in many cases, co-develop products. We intend to sell to our partners nanotechnology-enabled products that they can integrate into their end user products. By leveraging our partners development, manufacturing, sales and market expertise and customer relationships, we believe the time to market of our products will be reduced. We intend to select partners who value nanotechnology solutions and have a development, manufacturing and sales and marketing capability to maximize the commercial potential of our nanotechnology-enabled products. Through this strategy, we can remain focused on our core expertise of developing and manufacturing products based on inorganic nanostructure technology.

Leverage our core technology across multiple industries and applications. We seek to employ our core technology across multiple industries and applications through collaborations in order to accelerate the development of our products. We believe that our core technology can simultaneously address short, medium and long-term opportunities and will reduce our dependence on any particular industry, partner or application. Each of our product development efforts is intended to leverage our technology, know how and manufacturing capabilities.

Support core technology development through commercial and government funding. We have been able to fund a significant amount of our technology development through agreements with commercial partners and government agencies. Through these collaborations, we have gained valuable knowledge about the markets for our potential products. We intend to continue to leverage commercial and government funding to support the development of our core technology and products of interest to our partners, the government and us.

Build common manufacturing capabilities to achieve economies of scale. We believe our core technology enables us to utilize a common set of manufacturing capabilities to supply our partners with a variety of nanotechnology-enabled products. By building proprietary manufacturing capabilities that can be applied to multiple products, we believe that we can benefit from manufacturing economies of scale to provide cost effective, high quality products to our partners and customers.

Continue to expand and leverage our intellectual property position. We believe our significant intellectual property position provides us with a competitive advantage in developing nanotechnology-enabled products. We believe our intellectual property position is a reason why our partners seek to collaborate with us. We plan to continue to expand our intellectual property position through internally generated and licensed patent rights and other intellectual property and associations with leading experts in nanotechnology.

All of our product development efforts are in the early stage, or in what we term the investigation phase. During this phase, we intend to assess the primary areas of technological risk of the potential product and the performance characteristics of our technology in the given application, as well as whether there is a viable commercial market for the potential product. The investigation phase allows us to evaluate whether or not there are any suitable commercial product opportunities that could take advantage of the performance characteristics of our technology. Until we complete the investigation phase, we will not identify the specific products we intend to develop or the specifications for those products. After the successful completion of an investigation phase that leads to the identification of a specific product opportunity and the required product specifications, we anticipate that each product, subject to mutually agreed terms with our collaborating partner, if any, will enter a development phase, followed by a commercial production phase. We anticipate that the investigation phase for each product may last from six months to two years. The length of each phase will be dependent upon the complexity of each product we anticipate developing. We cannot predict when or if we will complete development and commercialize any potential products identified in the investigation phase. In order to diversify our development risk, we

Consumable Substrates for Life Sciences Research. We are developing nanostructure coatings that have a wide variety of potential applications in life sciences research. We are developing a disposable plate, or substrate, coated with nanostructures for use in existing time of flight mass spectrometry instruments. We are using technology that we initially developed for microarrays, or biochips, for use in the detection of DNA to develop our consumable substrates that are intended for use with time of flight mass spectrometry testing. At this time, we are not actively pursuing the development of microarrays used for DNA detection but we may elect to pursue the development of microarrays used for DNA detection in the future if we determine that the potential product is technologically feasible and we believe that a viable commercial market for the potential product exists. Time of flight mass spectrometry is widely used in the pharmaceutical and biotechnology industries to analyze large molecules. Our substrates enable time of flight mass spectrometry to also potentially be used for the rapid and accurate analysis of small molecules for high throughput screening of potential drug candidates and synthetic chemistry. We plan to develop and manufacture this product and enter into a product marketing agreement with one or more distributors or mass spectrometry instrument manufacturers. This product is in the investigation phase and we have developed a technological evaluation prototype of this product. This technological evaluation prototype is a research material, not a product or product prototype that reflects a near to final form of our potential product. The criteria upon which we intend to evaluate the results of our investigation phase activities include sensitivity, repeatability and compatibility with a broad range of sample types.

Solar Cells. We are developing solar cells for use in building materials, aerospace applications and portable power generation to meet various performance requirements and simplify manufacturing processes to lower costs. We believe that because of the flexible and light weight nature of our solar cells and our ability to customize their optical properties, our solar cells could be used in a variety of products, such as architectural glass, roofing tiles, aerospace and portable power supplies. To develop nanotechnology-enabled solar cells, we are collaborating with Matsushita Electric Works and United States government agencies. We anticipate that we would manufacture the products resulting from these development efforts and would sell them to our partners or other customers for integration into their end user products. This product is in the investigation phase and we have developed a technological evaluation prototype of this product. This technological evaluation prototype is a research material, not a product or product prototype that reflects a near to final form of our potential product. The criteria upon which we intend to evaluate the results of our investigation phase activities include efficiency, cost per watt of power generated and manufacturability.

Flexible Electronics. We are developing high performance, flexible electronics to be used in a variety of application areas including large area and portable displays, low cost radio frequency identification tags and electronically steerable antenna arrays for wireless communications. Our thin film electronics technology may allow us to achieve the electronic performance of silicon wafers, over large areas on a light weight, flexible substrate. We expect this technology to be compatible with traditional thin film manufacturing equipment, as well as advanced printable electronics technologies. To develop our nanotechnology-enabled thin film electronics products, we are collaborating with DuPont and a United States government agency. We anticipate that we would manufacture the products resulting from these development efforts and would sell them to our partners or other customers for integration into their end user products. This product is in the investigation phase and we have developed a technological evaluation prototype of this product. This technological evaluation prototype is a research material, not a product or product prototype that reflects a near to final form of our potential product. The criteria upon which we intend to evaluate the results of our investigation phase activities include transistor performance, substrate compatibility and manufacturability.

Non-Volatile Memory. We are developing nanostructures for non-volatile memory products for anticipated use in applications such as digital cameras, MP3 players and mobile phones. To develop non-volatile memory products, we are collaborating with Intel. We anticipate that we would manufacture the

products resulting from these development efforts and would sell them to our collaborators or other customers for integration into a non-volatile memory device. This product is in the investigation phase and we have developed a technological evaluation prototype of this product. This technological evaluation prototype is a research material, not a product or product prototype that reflects a near to final form of our potential product. The criteria upon which we intend to evaluate the results of our investigation phase activities include storage density, speed and compatibility with existing manufacturing processes.

We seek to partner with leading companies across various industries to develop, manufacture and commercialize products based on our proprietary nanotechnology platform. We intend to leverage the development, manufacturing, sales and marketing capabilities of our partners. Initially, we intend to enter into product development agreements with commercial entities to explore the technical and market feasibility of developing products in specific areas of interest while at the same time expanding the underlying capability of our technology. Our collaborations typically contemplate several phases, including an investigation phase, a development phase and a commercialization phase, which may be covered in one or more agreements. We intend to enter into agreements in multiple industries simultaneously to accelerate the development of our technology across numerous product areas.

To date we have entered into several product development collaborations to evaluate the technical and market feasibility of potential products in specified fields of interest. Under these investigation phase agreements, we are responsible for performing investigative research and development at specified levels. We typically receive research and development funding at specified periods and amounts per full time employee equivalent working on the project, payments on the achievement of specified milestones, or both. We typically retain the exclusive rights to specified categories of nanotechnology inventions made by either party as a result of the investigation phase. Upon completion of an investigation phase, we and our partner typically have a given period in which to negotiate a related development, commercialization or supply agreement in a defined field. We have not yet entered into any of these agreements and we cannot be certain that we will be able to enter into such agreements in the future. In addition to relying upon partners to fund a portion of our research and development expenses for certain of our potential products, we also plan to fund development of potential products internally and with government funding.

We intend to expand existing collaborations and enter into new collaborations. Following successful product development either pursuant to a product development collaboration or our internal research programs, we intend to enter into original equipment manufacturer or distribution partnerships. These partnerships may be in the form of original equipment manufacturer agreements for products manufactured by us for integration by our partner into their end user products. We may also enter into distribution agreements for our partner to distribute end user products manufactured by us, in order to access the marketing expertise, customer relationships, distribution capabilities and sales force of our partner. To date, we have not entered into any original equipment manufacturer or distribution partnerships and we cannot be certain that we will be able to enter into any in the future.

In November 2002, we entered into a development agreement with Matsushita Electric Works to develop a proof of concept solar cell meeting certain specifications and incorporate nanotechnology-enabled solar cells into building materials pursuant to which Matsushita Electric Works paid us $2.0 million at the beginning of the investigation period. We also granted Matsushita an option to renegotiate the terms of additional investigational work by paying us an additional $500,000. In addition, Matsushita Electric Works agreed to spend at least $2.0 million internally on the project. In February 2004, we and Matsushita Electric Works amended the agreement to extend the investigation period until August 2004 and renegotiate certain terms of the agreement and Matsushita Electric Works paid us an additional $500,000.

Our agreement provides that during the investigation period, we and Matsushita Electric Works will exclusively work together on investigating these products for sale in certain Asian countries. Matsushita Electric Works also has the exclusive right to negotiate with us for a certain period following completion of the collaboration to enter into an agreement to develop and commercialize solar cells containing inorganic nanostructures for use in building materials in those countries.

In December 2003, we entered into a cooperative development agreement with Intel to investigate the feasibility of using our nanostructures in non-volatile memory devices pursuant to which Intel is obligated to pay us at least $1.9 million in exchange for performing research services unless the agreement is terminated by Intel. We granted Intel the right to exclusively negotiate with us for a specified period to enter into a development and commercialization agreement for the development of non-volatile memory devices using certain of our nanostructures, during which period we have agreed not to enter into any discussions regarding that type of product with any third party. Upon the payment of additional amounts, Intel may extend its exclusive negotiation period for additional three-month periods up to March 31, 2006.

In January 2004, we entered into a cooperative development agreement with DuPont to investigate the commercial feasibility of using nanostructures for thin film electronics applications pursuant to which DuPont paid us $325,000 in exchange for performing research services during the first three months of the agreement. The agreement was scheduled to terminate on May 17, 2004 unless the parties agreed to continue the collaboration. In May 2004, the parties agreed to continue the collaboration for the remainder of the one year term of the agreement and to negotiate mutually acceptable statements of work based on the results of the collaboration to date.

We have also entered into arrangements with United States government agencies. Our strategy for pursuing government contracts and grants is to focus on opportunities that will enable us to further our core technology development. We intend to pursue government contracts and grants that enable us to develop dual use products and technologies that may be sold in both government and commercial markets.

In September 2003, we entered into a development agreement with In-Q-Tel to investigate the application of our nanostructures to flexible, high performance electronics pursuant to which In-Q-Tel is obligated to pay us up to $3.0 million in exchange for performing research services. The project with In-Q-Tel is divided into two phases: a six month feasibility phase followed by a 12 month technical development and optimization phase. In-Q-Tel paid us $1.0 million at the commencement of the first phase. In April 2004, we received a notice from In-Q-Tel to proceed to the second phase and an additional payment of $1.0 million based on the achievement of specific milestones. In June 2004, we received the remaining cash payment of $1.0 million. In connection with the agreement, we issued In-Q-Tel warrants for 241,028 shares of our series C preferred stock at a price of $0.003 per share. The warrants are now fully exercisable and will expire if not exercised prior to the closing of this offering.

Master Marketing and Business Development Agreement with Science Applications International Corporation, or SAIC

In July 2003, we entered into a 24 month master marketing and business development agreement with SAIC to identify and jointly pursue United States government contracts or grant opportunities relating to nanoscience and nanotechnology. Our obligations to each other under the agreement are generally nonexclusive, provided that in certain circumstances we and SAIC have a right of first offer to pursue certain government contract or grant opportunities along with the other party. Under the agreement, SAIC is

obligated to pay us $1.6 million in exchange for performing research services. In addition, SAIC agreed to spend at least $600,000 internally on the project by dedicating the services of its employees. SAIC is entitled to receive the first $2.2 million in profit, after reimbursement of our actual expenses, not including any fees or profits, and SAIC’s costs, that we or SAIC receive under any United States government contract or grant arising out of work performed under our agreement. We and SAIC are not obligated to pursue any government contract or grant on a joint basis until such time as we and SAIC mutually agree to pursue the particular opportunity. To date, we have not entered into any agreement to pursue a government contract or grant with SAIC. We or SAIC may terminate the agreement beginning on September 30, 2004 by giving the other party 90 days prior notice. We currently do not intend to terminate the SAIC agreement and we have not received any request for termination and are not aware of any plans by SAIC to terminate the agreement.

Since August 2002, we have been awarded an aggregate of more than $1.7 million in grants from or contracts with United States government agencies to fund research relating to the development of our core technology and applications in the areas of biological detection, solar power, thin-film electronics and light emitting structures. We received these grants from and entered into contracts with several government agencies, including the Defense Advanced Research Projects Agency, the National Institute of Health and the National Aeronautics and Space Administration. We retain the rights to commercialize nanotechnology-enabled products developed using the research funded under these grants or contracts.

In June 2004, we entered into a one year agreement with DARPA to investigate and develop a solar cell that meets given efficiency, weight and cost specifications and incorporates nanotechnology-enabled devices for the potential use by the United States Air Force. DARPA has agreed to pay us up to $1.5 million during the first 12 months of the agreement and to pay our sub-contractors up to an additional $700,000 during that period. DARPA at its option may extend the agreement by paying us additional amounts.

We are developing our core technology, which is based on a proprietary class of inorganic nanostructures, to engineer and integrate the physical, functional and performance characteristics of nanostructures for the purpose of creating products. Unlike traditional materials which are used to fabricate devices, each nanostructure can incorporate device functionality. These nanostructures, which can be made with features as small as a few nanometers, are synthesized atom by atom in a controlled chemical environment, creating precisely defined functional nanostructures. To design products for different application areas, our nanostructure fabrication process enables us to define and control many of the important chemical and physical parameters of our nanostructures, such as composition, shape, size and surface chemistry.


	•	Composition: Our core technology allows us to fabricate nanostructures from one or more inorganic materials, including silicon, silicon germanium, gallium arsenide, gallium nitride, cadmium selenide and indium phosphide. Different inorganic materials can manifest different properties or perform different functions. For example, traditional integrated circuits are made from silicon, while light emitting diodes, or LEDs, are often made from gallium nitride. We can also incorporate two or more materials into each individual nanostructure, forming functional interfaces between the different materials that can provide unique electrical, optical or physical properties. Whether we are developing a solar cell, an LED or a memory device, the composition of the nanostructures can be selected to suit the application.

	•	Size: Our core technology allows us to control the size of the nanostructures. While the composition of a nanostructure largely defines its overall function, we can adjust the desired


		functional properties by controlling the size of the nanostructure. This feature allows us to further change the performance characteristics of our products in a way that is not possible using traditional technology. For example, when using a nanostructure to form an LED, we can tailor the size of the nanostructure to select the precise color of the emitted light.

	•	Shape: We can form nanostructures in a variety of shapes, including spheres, rods and wires, as well as more complex shapes. By controlling the shape, we can create additional functionality in our individual nanostructures and increase their performance, as well as, we believe, reduce the manufacturing complexity and cost of the products in which they are used.

	•	Surface chemistry: While functionality results from the nanostructures’ composition, size and shape, processability arises from the material filling the space between individual nanostructures. The interface between the nanostructures and the filling materials is formed through a surface chemistry that acts as a physical and functional connection between the nanostructures and the other components in the end user product. By controlling the surface chemistry independent of the composition, size and shape of the nanostructures, we potentially can separately define and optimize functional and manufacturing characteristics.

We have several core competencies that act as fundamental building blocks for developing applications from concept to product. Our core competencies include: synthesis, assembly, nano to macro interfaces, application specific formats and computer modeling and simulation. Developing our nanotechnology-enabled products requires the consistent synthesis, characterization and control of the nanostructures, which we then assemble in a directed fashion to achieve a desired function. The nano to macro interface allows us to integrate our nanostructures and their functionality into the rest of the system. Finally, the nanostructures must be incorporated into an application specific format that is compatible with the end user product. To direct nanostructure and product development throughout this process, we use computer modeling and simulation for multiple levels of the design, from the individual nanostructures to the end user application. As we develop products, we expect the resulting advances will expand and enhance our core technology, which in turn, can provide us with more application and collaboration opportunities.

We are currently applying our core competencies to develop potential products for various applications in multiple industries. One potential product is a new type of solar cell that performs like a traditional solar cell, but can be configured like a light weight, flexible plastic. In particular, this technology has the potential to provide low cost solar power through currently available, high volume and inexpensive manufacturing techniques based on roll to roll manufacturing. Roll to roll manufacturing is a well established technique used in the photographic film, plastics, printing and paper industries. Roll to roll manufacturing has been used for decades and it is a relatively inexpensive process as compared to traditional semiconductor manufacturing.

As an illustration of our development process, using the following steps, we have created a functioning solar cell:


	•	Synthesis: We developed tetrapod nanostructures for this application that are capable of light absorption, charge generation and charge conduction when incorporated into a polymer and thus act as a solar cell. We selected the composition and size and then constructed the nanostructure to absorb the sun’s light in an optimal manner and to separate resulting electrical charges.

	•	Assembly: To enable high volume, inexpensive manufacturing, it is desirable to process the nanostructures while suspended in a liquid and then harden the liquid into a film. We selected a plastic matrix from which a film is made. We also designed the specific surface chemistry on the nanostructures to allow their uniform mixing into the plastic matrix. To achieve good solar efficiency, it is also desirable to have each nanostructure closely positioned to the top and bottom of the film where the electricity from each nanostructure


		sized solar cell will be collected. We selected the shape of the nanostructure to orient itself naturally to provide a high conductivity electrical path across the film.


	•	Nano to macro interface: Each individual nanostructure generates electrical charges when it absorbs the sun’s rays. We designed the nanostructure’s surface chemistry to facilitate the transfer of electrical charges out of the nanostructure. We apply traditional electrodes to the top and bottom of the film, which is composed of trillions of nanostructure sized solar cells, to transfer electrical charges out of the film into an electrical system, such as a storage battery or electrical device.

	•	Application specific format: For a solar cell, there are several application specific requirements: the device must operate at an equal or higher level of efficiency and at a lower cost than current products, light must enter the device, the cell must be connected to a circuit to remove the electrical charges and the device must tolerate long-term environmental exposure. We plan to select electrodes and encapsulating films for our nanostructures to achieve the application specific requirements. For example, the layer on top of the film must be a clear conducting layer to allow light to enter the film while also conducting electricity away.

	•	Computer modeling and simulation: Throughout the development process, we use computer modeling and simulation. We calculate the necessary physical and functional properties of the individual nanostructures to guide synthesis. We model the solar spectrum to determine the optimum absorption characteristics of the nanostructures. We calculate the necessary physical and functional properties of the nanostructures so that they can act as solar cells. We model the surface chemistry to optimize electrical charge transfer from the nanostructure to the electrodes and model the electrodes for optimal electrical charge transport. By modeling and simulating throughout the process, we expect to minimize the number of design iterations, thereby accelerating the entire development cycle.

We use similar building blocks to develop and construct our other potential products as outlined above. In addition, we use similar methods to evaluate the applicability of our nanotechnology to prospective products.

Since our inception, we have devoted significant resources to the development of our products and technology. We conduct our research and development operations in Palo Alto, California. As of June 30, 2004, our research and development team consisted of 28 people.

We had research and development expenses of $237,000 in the period from inception to December 31, 2001, $5.2 million in 2002, $9.9 million in 2003, and $3.9 million in the three months ended March 31, 2004. Our partners funded none of our research and development activities from inception to December 31, 2001, $283,000 of our research and development activities in 2002, $3.0 million of our research and development activities in 2003 and $1.2 million in the three months ended March 31, 2004. We pursue our product development objectives by developing potential nanotechnology-enabled products internally and with those development partners identified above, but may from time to time acquire products, technologies and businesses complementary to ours or form alliances with other companies.

Our strategy is to seek patents on new and improvement inventions relating to our technology that we consider important to the development of our business. Our patents and patent applications are generally directed to nanomaterial compositions, processes for making nanomaterial compositions, processes, treatments and structures that allow incorporation of these nanomaterial compositions into useful forms and the application of these useful forms of nanomaterial compositions in what we believe are potentially useful commercial applications. We believe that the patents and patent applications that we own or have licensed will provide us with a competitive advantage in these areas by providing us with the

exclusive rights to the inventions that are claimed in these patents and patent applications. As of June 30, 2004, we owned or had exclusive rights to 38 issued United States patents, five issued or granted foreign patents and 219 additional pending United States and foreign patent applications. Some of these patents and patent applications derive from a common parent patent application or are foreign counterpart patent applications to United States patents or patent applications, and relate to a similar or identical technology. Our granted patents and patent applications derive from over 79 different patent families, each of which represents what we or our licensors believe is a distinct technological development, or in some cases, a collection of distinct technological developments, that were sufficiently related to warrant being grouped within a common patent family and are one or more patentably distinct inventions. In many cases, each patent family is or may be divided, either by the responsible patent office, or by us or our licensors, into separate patent applications that are intended to pursue claims to these patentably distinct inventions. Our owned or licensed issued or granted patents expire at various times between 2011 and 2021. Included in the patents and applications enumerated above are the 38 issued U.S. patents, the five issued or granted foreign patents and 150 pending patent applications that are licensed to us from research and educational institutions including:


	•	Columbia University;

	•	Ernest Orlando Lawrence Berkeley National Laboratory;

	•	Harvard University;

	•	The Massachusetts Institute of Technology; and

	•	The Regents of the University of California.

We acquired the exclusive rights to use specific patents of these educational institutions in fields that are relevant to our business. The Regents of the University of California act as the contract operator of the Ernest Orlando Lawrence Berkeley National Laboratory. Some of the patent and patent applications under our license from the Massachusetts Institute of Technology are jointly owned by Lumileds Lighting, U.S. LLC. One family of patent applications under our licenses with Harvard is a co-exclusively licensed to Nantero and Nantero also has patent rights from certain other Harvard licenses as necessary to protect its rights under the co-exclusive license. Our agreements with these parties expire upon the expiration of the related patents.

Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our technology and products as well as successfully defending these patents against third party challenges. If we or our licensors are unable to obtain and maintain patent and trade secret protection of our technology and products, our business could be harmed. In addition, we will only be able to protect our technology from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover that use. Some of our patent applications, as well as the patent applications that we have licensed, are provisional patent applications. For any inventions described in these provisional patent applications to undergo examination before the United States Patent and Trademark Office, a prerequisite to issuance of any patent, they must be converted from a provisional patent application to a regular utility patent application. This conversion must take place within one year of the filing date of the provisional patent application. While we expect to convert these provisional patent applications to regular utility patent applications, failure by us or our licensors to convert any of these provisional patent applications to regular utility patent applications in a timely fashion could result in the loss of our ability to obtain patent protection to some or all of the inventions described in these provisional patent applications.

Patents and patent applications covering a substantial portion of our core technology are owned by our third party licensors. While we have certain rights to participate in prosecution, maintenance and enforcement of those patents and patent applications, in the majority of cases these licensors have retained the right to prosecute, maintain and enforce those patents and patent applications. We cannot be certain they will do so in the best interests of our business. Any failure on the part of the licensors to follow our

Our licensors may currently own and may in the future obtain additional patents and patent applications that are necessary for the development, manufacture and commercial sale of our anticipated products. These additional patents and patent applications may not be licensed to us under our existing licenses and we may be unable to obtain licenses to these patents or patent applications on commercially reasonable terms, if at all, which could harm our business.

Commercial application of nanotechnology is new and the scope and breadth of patent protection is uncertain. Consequently, the patent positions of nanotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles may remain unresolved. In addition, to date there has been relatively little litigation surrounding nanotechnology related patents, and, therefore, it is not clear whether such patents will be subject to interpretations or legal doctrines that differ from conventional patent law principles. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third party patents.


	•	we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications or issued patents;

	•	we or our licensors might not have been the first to file patent applications for these inventions;

	•	it is possible that none of our pending patent applications or none of the pending patent applications of our licensors will result in issued patents;

	•	our issued patents and issued patents of our licensors may not provide a basis for commercially viable products, may not provide us with any competitive advantages or may be challenged and invalidated by third parties;

	•	our and our licensors’ patent applications or patents may be subject to interference, opposition or similar administrative proceedings, which could result in those patent applications failing to issue as patents or those patents being held invalid;

	•	we may not develop additional proprietary technologies that are patentable; or

	•	the patents of others may have an adverse effect on our business.

We also rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. Trade secrets are difficult to protect. While we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, partners or other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know how.

While we are not currently involved in any legal proceedings related to our intellectual property, the defense and prosecution of intellectual property suits, interferences, oppositions and related legal and administrative proceedings in the United States and elsewhere are costly, time consuming to pursue and could result in the diversion of our limited financial and managerial resources. The outcome of these proceedings is uncertain and could significantly harm our business. The industries for which we are investigating products are characterized by the existence of a large number of patents and frequent litigation based upon allegations of patent infringement. As our potential products progress toward commercialization in these markets, the possibility of an infringement claim against us or our collaborators increases. While we attempt to ensure that our products and the methods we employ to develop and manufacture them do not infringe other parties’ patents and other proprietary rights, competitors or other parties may assert that we infringe their proprietary rights.

In recent years, several thousand patent applications have been filed with the United States Patent and Trademark office that refer to nanoscale materials or structures. Information contained in patent applications is generally not publicly available. Consequently, we are unable to evaluate the underlying intellectual property until these patent applications become issued or published. The process to issue patents is long and certain innovations that have not yet resulted in issued patents could have been developed prior to our intellectual property. These patents, when issued, may predate our patents and may have superior claims or superior rights or otherwise be in conflict with our technology or business processes.

If a patent infringement suit were brought against us or our partners, we or they could be forced to stop or delay research, development, manufacturing or sales of the end user product or potential product that is the subject of the suit. We or our partners therefore may choose to seek, or be required to seek, a license from the third party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our partners were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or forced to cease some aspect of our business operations, as a result of patent infringement claims, which could have a material adverse impact on our business. Alternatively, we could encounter delays in product introductions while we attempt to design around the patents. Our redesigned products may be inferior to our original designs or we may be unable to continue product development in the particular field.

We compete in intensely competitive markets for end user products. The nanotechnology-enabled products we are currently developing will compete directly with products incorporating conventional materials and technologies, including traditional semiconductors manufactured on the nanoscale. We believe our nanotechnology-enabled products will face significant competition from existing manufacturers in our target markets including:


	•	manufacturers of substrates for time of flight mass spectrometry equipment, such as Waters;

	•	manufacturers of solar cells, such as Sharp and BP;

	•	manufacturers of thin film electronics, such as Samsung, NEC and Philips; and


	•	manufacturers of memory products, such as Advanced Micro Devices and Samsung.

In addition, we may also face competition from focused nanotechnology companies, such as Evident Technologies, Konarka, Nantero, NanoHorizons, Nanosolar, Quantum Dot, UltraDots, ZettaCore and other newly created nanotechnology companies.

We may also face significant competition from our current and future partners, such as DuPont, Intel and Matsushita Electric Works, which are assessing the feasibility of expanding their development and manufacturing capabilities and portfolio of intellectual property to incorporate nanotechnology-enabled components into their end user products. Nanotechnology-enabled products developed by our current and future partners are designed to utilize the qualities of the partner’s own manufacturing process and may benefit from certain capacity, informational, cost and technical advantages. If our current and future partners expand their product offerings to compete directly with our nanotechnology-enabled products or actively seek to participate as vendors in the nanotechnology-enabled product market, our revenue and operating results could be negatively affected.


	•	Size and resources. Our competitors, as well as our current and future partners, may have access to substantially greater financial, engineering, manufacturing and other resources than we do, which may enable them to react more effectively to new market opportunities.

	•	Name recognition. Many of our competitors and our current and future partners have greater name recognition and market presence than we do, which may allow them to market themselves more effectively to new customers or partners.

	•	Access to information. Our current and future partners may have better access to information regarding their own manufacturing processes, which may enable them to develop nanotechnology-enabled products that can be more easily incorporated into the customers’ or partners’ products.

	•	Limits of product offerings. Although we intend to offer a broad range of nanotechnology-enabled products, a current or future partner may require nanotechnology-enabled products or functionalities that we do not offer. As a result, our competitors may exploit the areas in which we do not develop product offerings.

	•	Reliance on internal manufacturing. We intend to manufacture our products internally rather than license the manufacturing of those products to our current and future partners. Our partners may conclude that we will be unable to supply the volume or quality of products they need. In addition, those partners may want to control key steps in their manufacturing process capabilities and will therefore want to manufacture the nanotechnology-enabled products themselves. In order to successfully integrate our proposed products with theirs, we may be required to rely on our partners for access to their manufacturing process and capabilities. If this access is restricted or denied, our nanotechnology-enabled products may not be competitive with products internally developed by our partners or others.

	•	Scalability of development. A significant challenge in commercializing our nanotechnology-enabled products across multiple industries and end user products will be our ability to leverage our core technology and development efforts. Most nanotechnology-enabled products require custom development to meet application specific product requirements. To minimize custom development efforts, we will need to develop nanotechnology-enabled products that utilize our common set of our core technology and can benefit from our previous development efforts. If we are unable to achieve this, our development capabilities will be less competitive.

If we do not compete successfully, our ability to develop and sell our products could be harmed and our business could suffer.

As of June 30, 2004, we had 43 employees, including 28 in research and development and 15 in selling, general and administrative functions. None of our employees are represented by a labor union or are the subject of a collective bargaining agreement. We have never experienced a work stoppage and believe that our employee relations are good. We believe our future success will depend in large part upon our ability to attract and retain highly skilled managerial, research and development, sales and marketing personnel.

Our principal offices are located in Palo Alto, California. Our facility is occupied under a lease that expires in 2005. At June 30, 2004, our leased space approximated 21,000 square feet.

We believe that our facilities are adequate for our current needs and that suitable additional or substitute space will be available as needed to accommodate expansion of our operations.

We are not currently a party to any material legal proceedings. From time to time, we may become subject to legal proceedings, including those requiring us to defend the parties which have licensed intellectual property to us.

We recruited a number of leading researchers in nanoscience to serve as members of our scientific advisory board. These advisors have entered into agreements with us to serve for fixed terms ranging from one to five years. In general, they serve on an exclusive basis within a defined field of collaboration. These advisors have received option grants and restricted stock purchase awards to purchase our common stock. In addition, some may receive cash compensation in connection with services rendered, and they receive reimbursement for expenses.

Members of our scientific advisory board provide research and/or advice to us in their area of specialization including:


	•	nanostructure design and fabrication;

	•	nanostructure surface chemistry and processing;

	•	nanostructure integration and interface technology;

	•	theoretical modeling and simulation of nanostructures and systems into which they are integrated;

	•	concepts for nanotechnology-based products and applications; and

	•	identifying emerging technologies related to research and development programs.

The following persons served on our scientific advisory board and their primary affiliations were as follows as of July 14, 2004:


(1)	The term may be renewed for successive one year terms by the written agreement of both parties, and may be terminated at any time by the written agreement of both parties or upon 30 days notice by the advisory board member and may be terminated by us for intentional misconduct or gross negligence upon 30 days written notice.

(2)	The term may be renewed for successive one year terms and may be terminated at any time upon written notice by either party.

Our directors and executive officers and certain information about them as of June 30, 2004 are as follows:


(1)	Member of the Audit Committee.

(2)	Member of the Compensation Committee.

(3)	Member of the Grant Committee.

(4)	Member of the Nominating and Governance Committee.

Mr. Bock has served as executive chairman of our board of directors since October 2003. Mr. Bock acted as our chief executive officer, president and a director from July 2001 to October 2003. Mr. Bock also acted as our chief financial officer from July 2001 to September 2001. Mr. Bock was a managing general partner of CW Group, a life sciences venture capital fund from June 1998 to April 2004 and from June 1998 to present has served as a general partner. From 1988 to June 1998, Mr. Bock was general partner of Avalon Ventures, a seed stage venture capital firm. Mr. Bock was the founder and initial chief executive officer of Metro Biosystems, Inc., Neurocrine Biosciences, Inc., Pharmacopeia, Inc., Argonaut Technologies, Inc. and Caliper Technologies Corp. Mr. Bock was also a co-founder of ARIAD Pharmaceuticals, Inc., Athena Neurosciences, Inc., GenPharm International, Vertex Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc. and Illumina, Inc. Mr. Bock holds a B.A. in Liberal Arts from Bowdoin College and an M.B.A. from the Anderson School at the University of California, Los Angeles.

Mr. Chow has served as our chief executive officer since October 2003 and as a director since February 2002. From November 2001 to October 2003, Mr. Chow served as our chief operating officer and, from November 2001 to June 2002, he served as our acting vice president of development. From October 1995 to September 2001, Mr. Chow, co-founded Caliper and served in various capacities, including most recently as its chief operating officer. From October 1985 to September 1995, Mr. Chow was a co-founder of and last served as vice president of engineering and operations at Molecular Devices Corporation. Mr. Chow holds a B.S.E.E. from the Illinois Institute of Technology and an M.S. in Electrical Engineering from Stanford University.

Dr. Parce has served as our chief technical officer and vice president of research since June 2002. Dr. Parce served on our Scientific Advisory Board from January 2002 to June 2002. From September 1995 to December 2002, Dr. Parce was a co-founder of and served as vice president of research at Caliper. Prior to joining Caliper, Dr. Parce spent 12 years with Molecular Devices Corporation as a co-founder,

Mr. Murphy has served as our vice president of intellectual property since April 2002. From March 1997 to March 2002, Mr. Murphy served in various capacities at Caliper, the most recent of which was vice president of intellectual property. From August 1994 to March 1997, Mr. Murphy was an associate at the law firm of Townsend and Townsend and Crew LLP. Mr. Murphy holds a B.S. in Microbiology from the University of California, Davis and a Juris Doctorate from the University of San Francisco.

Ms. Vergura has served as our vice president of finance since December 2001. From September 2001 to December 2001, Ms. Vergura provided services to us as a consultant. From August 1998 to April 2001 she served as the corporate controller and from January 2001 to April 2001 as director of financial planning at Convergent Networks, Inc., a broadband infrastructure company. From July 1997 to August 1998, Ms. Vergura served as the corporate controller at New Oak Communications, an extranet switching company that was acquired by Bay Networks. Ms. Vergura holds a B.S. in Business Administration from the University of Vermont.

Mr. Bybee has served as a member of our board of directors since October 2001. Since December 1996, Mr. Bybee has served as a managing director of ARCH Venture Partners, a venture capital company, and as a general partner of its related funds. From January 1994 to November 1996, he served as a vice president of ARCH Venture Partners. Mr. Bybee holds a B.S. in Engineering from Texas A&M University and an M.B.A. from the University of Chicago.

Mr. McKenna has served as a member of our board of directors since April 2002. Mr. McKenna has served as a marketing consultant to technology companies since 1970. He is chairman of Regis McKenna, Inc., a private firm specializing in the development of marketing information and network-based business strategies. Mr. McKenna has served as a general partner of McKenna Ventures, L.P., an investment partnership specialized in investments in early stage companies, since November 1998. Mr. McKenna holds a B.A. in Liberal Arts from Duquesne University.

Dr. Roberts has served as a member of our board of directors since May 2003. He joined Venrock Associates, a venture capital firm, in October 1997 and is now a general partner. Dr. Roberts worked at the investment banking firm Kidder Peabody & Co., Inc. in corporate finance from 1989 to 1992. Dr. Roberts also serves as a member of the Board of Directors of Sirna Therapeutics, Inc. Dr. Roberts holds a B.A. from Dartmouth College and a Ph.D. in Chemistry and Chemical Biology from Harvard University.

Dr. Somekh has served as a member of our board of directors since December 2003. Dr. Somekh has served as the president of Novellus, a manufacturer of semiconductor fabrication equipment, since February 2004. Dr. Somekh served in various capacities at Applied Materials, Inc. from 1980 to February 2004, the most recent of which was executive vice president, to which he was appointed in December 2000 and chairman, global executive committee, which took the place of the office of the president, to which he was appointed in October 2002. Dr. Somekh also serves as a member of the board of directors of Synopsys, Inc., an electronic design automation company. Dr. Somekh holds a B.S. in Physics from Tel Aviv University, an M.S. in Electrical Engineering from the California Institute of Technology and a Ph.D. in Electrical Engineering from the California Institute of Technology.

Mr. Young has served as a member of our board of directors since March 2004. Mr. Young is retired. He served as president and chief executive officer of Hewlett-Packard Company from 1978 to 1992 and served in other capacities at Hewlett-Packard from 1958 to 1978. Mr. Young currently serves as the chairman of the board of Ciphergen Biosystems, Inc. He also serves on the boards of directors of Affymetrix Inc., Perlegen Sciences, Inc., Fluidigm Corporation and Lucent Technologies, Inc. Mr. Young holds a B.S.E.E. from Oregon State University and an M.B.A. from the Stanford Graduate School of Business.

Dr. Yurek has served as a member of our board of directors since February 2004. Since 1988, Dr. Yurek has served in various capacities at American Superconductor Corporation, an electricity solutions company that he founded in 1987, and currently serves as its chief executive officer and chairman of the board of directors. From 1976 to 1988, Dr. Yurek was professor of materials science and engineering at the Massachusetts Institute of Technology. Dr. Yurek holds a B.S. and an M.S. in Metallurgy from Pennsylvania State University and a Ph.D. in Metallurgical Engineering from Ohio State University.

Our board of directors currently consists of eight members. Prior to the closing of this offering, our board of directors will be divided into three classes, with each director serving a three year term and one class being elected at each year’s annual meeting of stockholders. Dr. Yurek, Mr. Bybee and Dr. Roberts will be in the class of directors whose initial term expires at the 2005 annual meeting of stockholders. Mr. McKenna, Dr. Somekh and Mr. Chow will be in the class of directors whose initial term expires at the 2006 annual meeting of the stockholders. Mr. Bock and Mr. Young will be in the class of directors whose initial term expires at the 2007 annual meeting of stockholders. Mr. Chow, Mr. Bybee, Dr. Roberts and Dr. Yurek were appointed to our board of directors pursuant to an agreement among our current investors and us that will terminate upon completion of this offering.

Our board of directors currently has an audit committee, a compensation committee, a nominating and governance committee and a grant committee. Dr. Yurek, Mr. Young and Dr. Roberts are currently members of the audit committee. The audit committee reviews our internal accounting procedures and consults with and reviews the services provided by our independent accountants. Mr. Bybee, Mr. McKenna and Dr. Somekh are currently members of the compensation committee. The compensation committee reviews and recommends to the board of directors the compensation and benefits for all of our officers and establishes and reviews general policies relating to compensation and benefits for our other employees. Mr. Bybee, Mr. McKenna and Dr. Yurek are currently members of the nominating and governance committee. The nominating and governance committee assists our board of directors in the areas of membership selection, evaluation of overall effectiveness of the board of directors and the review of developments in corporate governance practices. Mr. Chow is the sole member of the grant committee. The grant committee approves option grants and other equity awards to our non-officer employees pursuant to guidelines set forth by the board of directors.

We reimburse our directors for reasonable travel expenses in connection with attendance at board and committee meetings. Under our 2001 stock plan, nonemployee directors are eligible to receive stock option grants at the discretion of the board of directors. In addition, in 2004, we granted restricted stock purchase rights to purchase our common stock to two of our nonemployee directors. For a description of these options, see “Our Relationships and Arrangements with Our Stockholders, Our Officers and Our Directors.” After this offering is completed, nonemployee directors will receive stock options pursuant to the 2004 stock plan. Each nonemployee director appointed to the board after the completion of this offering will receive an initial option to purchase 15,000 shares upon such appointment. Beginning in 2005, nonemployee directors who have been directors for at least six months will receive a subsequent option to purchase 3,000 shares following each annual meeting of our stockholders. Also, beginning in 2005, nonemployee directors who are members of the audit committee or compensation committee who have been members of such committee for at least six months will receive a subsequent option to purchase 1,000 shares following each annual meeting of our stockholders for each such committee upon which they serve, provided that the chairman of the audit committee and the chairman of the compensation committee will instead receive a subsequent option to purchase 1,500 shares. All such options shall have an exercise price equal to fair market value on the date of grant. Each initial option becomes exercisable as to one-third of the shares on each anniversary of the date of the grant, provided the nonemployee director remains a service provider on such dates. Each subsequent option becomes exercisable as to all of

the shares subject to the subsequent option on the one year anniversary of the date of grant, provided the nonemployee director remains a service provider on such date. In addition, upon the effective date of this offering, each nonemployee director will receive options for a number of shares equal to the number of shares granted to directors and audit and compensation committee members, with respect to the committees upon which the nonemployee director is then serving, at each annual meeting of stockholders, provided that the exercise price per share for each grant shall be equal to the price of our common stock in this offering. These options will also become exercisable as to all of the shares subject to the options on the one year anniversary of the date of grant. The term of such option is 10 years. Our board may also grant additional options to our directors under our 2004 stock plan, which became effective upon its adoption by our board of directors in April 2004.

Our board of directors established its compensation committee in October 2001. Prior to establishing the compensation committee, our board of directors as a whole performed the functions delegated to the compensation committee. No interlocking relationship exists between any member of our compensation committee and any member of any other company’s board of directors or compensation committee.

The following table sets forth all compensation awarded, earned or paid for services rendered in all capacities to us during 2003, to each person who acted as chief executive officer during 2003 and our next most highly compensated executive officers, to whom we refer to collectively as the named executive officers in this prospectus, each of whose compensation exceeded $100,000 in 2003.

The following table sets forth certain information concerning grants of stock options to each of our named executive officers during 2003.

The stock option granted to the named executive officer in 2003 vests as to 1/60 of the total number of shares subject to the option one month from the vesting commencement date and as to 1/60 of the total number of shares subject to the option each full month thereafter. Under the 2001 stock plan, our board retains discretion to modify the terms of outstanding options. The percentage of total options granted was based on an aggregate of options to purchase 58,331 shares of common stock granted to our employees and executive officers in 2003.

Options were granted at an exercise price equal to the fair market value of our common stock on the grant date, as determined by our board of directors. As there was no public market for our stock prior to this offering, the board of directors determined the fair market value of our common stock by considering a number of factors, including, but not limited to, our current financial performance and prospects for future growth and profitability, the status of product releases and product integration, the absence of a resale market for our common stock and comparisons of certain of our key valuation metrics with similar metrics for comparable publicly traded companies, including measures of market capitalization based on revenue multiples, price to earning ratios and operating margins.

The table sets forth the hypothetical gains or “option spreads” that would exist for the option at the end of their respective ten year terms based on assumed annualized rates of compound stock price appreciation of 5% and 10% from the dates the options were granted until the expiration of the ten year option term, assuming a fair value of our common stock of $16.00 at the time of issuance. The 5% and 10% assumed rates are promulgated by the Securities and Exchange Commission and do not represent our estimate or projection of future common stock prices or stock price growth.

Aggregated Option Exercises in Last Fiscal Year and Fiscal Year End Option Values

The following table sets forth certain information regarding the exercise of stock options in 2003 by the named executive officers and the value of options held by these individuals at December 31, 2003.

The value received is calculated as the market value of our common stock at the exercise date minus the exercise price. The value of unexercisable in the money options is deemed to be the market value of our common stock at fiscal year end minus the exercise price. The fair market value of our common stock on December 31, 2003, as determined by our board of directors, was $0.57 per share. However, we have used the estimated initial public offering price of $16.00 per share for purposes of this computation.

Employment Contracts, Change of Control Arrangements and Separation Agreements

We do not have any employment contracts, change of control arrangements or separation agreements with our officers.

Our board of directors adopted and our stockholders initially approved the 2001 stock plan in September and October of 2001, respectively. Our board of directors has decided not to grant any additional awards under the plan following the effective date of this offering. However, the plan will continue to govern the terms and conditions of the outstanding options and stock purchase rights previously granted under the plan.

A total of 3,045,667 shares of our common stock are authorized for issuance under the 2001 stock plan. As of June 30, 2004, options to acquire a total of 526,521 shares of our common stock were issued and outstanding under our 2001 stock plan, and a total of 2,039,724 shares of our common stock had been issued upon the exercise of options or stock purchase rights granted under the plan.

The plan provides for the grant of nonstatutory stock options and stock purchase rights to our employees, directors and consultants, and for the grant of incentive stock options within the meaning of Section 422 of the Internal Revenue Code to our employees. Our board of directors administers the 2001 stock plan. The administrator has the authority to determine the terms and conditions of the options and stock purchase rights granted under the plan.

The term of the options granted under the 2001 stock plan is set forth in the option agreement The exercise price for options granted under the 2001 stock plan is determined in the option agreement. However, in the case of options granted to an optionee who owns stock representing more than 10% of the voting power of all classes of voting stock of our company, parent or subsidiaries, the exercise price may be no less than 110% of the fair market value of a share of our common stock at the time of the grant. For all other optionees, the exercise price may not be less than fair market value of our common stock on the date of grant for an incentive stock option and may not be less than 85% of the fair market value on the date of grant for a non-incentive stock option. Generally, options granted under the 2001 stock plan to new service providers vest as to 20% of the shares subject to the option on the first anniversary of the vesting commencement date and as to 1/60 of the shares subject to the option per month thereafter.

To the extent incentive stock options granted to an optionee become exercisable in any calendar year for more than an aggregate fair market value in excess of $100,000 (determined on the date any such option was granted), such options will not be treated as incentive stock options for the amounts in excess of $100,000.

The administrator determines the exercise price of stock purchase rights granted under our 2001 stock plan. However, in the case of stock purchase rights granted to an optionee who owns stock representing more than 10% of the voting power of all classes of voting stock of our company, parent or subsidiaries, the purchase price may be no less than 100% of the fair market value of a share of our common stock at the time of the grant. For all other employees, the exercise price may not be less than 85% of the fair market value of our common stock on the date of grant. Unless the administrator determines otherwise, the restricted stock purchase agreement will grant us a repurchase option that we may exercise upon the voluntary or involuntary termination of the purchaser’s service with us for any reason (including death or disability). The purchase price for shares we repurchase will generally be the original price paid by the purchaser and may be paid by cancellation of any indebtedness of the purchaser to us. The administrator determines the rate at which our repurchase option will lapse, provided that for stock purchase rights granted to service providers other than officers, directors and consultants, the repurchase right must lapse as to 20% of the shares subject to the award each year from the date of grant.

Our 2001 stock plan provides that in the event of our merger with or into another corporation or our change of control, the successor corporation will assume or substitute each outstanding award. If the outstanding awards are not assumed or substituted, the administrator will provide notice to the optionee that he or she has the right to exercise the award as to all of the shares subject to the award, including shares that would not otherwise be exercisable, for a period of 15 days from the date of notice. The award will terminate upon the expiration of the 15-day period.

Our board of directors adopted our 2004 stock plan in April 2004 and we expect our stockholders to approve it on or before the effective time of this offering. Our 2004 stock plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to our employees and our parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, stock purchase rights, restricted stock, stock appreciation rights, performance units and performance shares to our employees, directors and consultants and our parent and subsidiary corporations’ employees and consultants.

On June 30, 2004, a total of 1,000,000 shares of our common stock were reserved for issuance pursuant to the 2004 stock plan, of which no awards were issued and outstanding as of June 30, 2004. The 2004 stock plan became effective on the date our board of directors adopted it. In addition, the shares reserved for issuance under our 2004 stock plan will be increased by the number of shares reserved but unissued under our 2001 stock plan as of the effective date of this offering, any shares returned to the 2001 stock plan as the result of termination of options or the repurchase of shares issued under such plan. As of June 30, 2004, 479,422 shares of our common stock were reserved for issuance under our 2001 stock plan that could be rolled into the 2004 stock plan. In addition, the 2004 stock plan provides for annual increases in the number of shares available for issuance on the first day of each fiscal year beginning with January 1, 2005, equal to the lesser of:


	•	5% of the outstanding shares of common stock on the first day of our fiscal year,

	•	2,000,000 shares, or

	•	an amount our board may determine.

Our board of directors or a committee of our board administers our 2004 stock plan. In the case of options intended to qualify as performance-based compensation within the meaning of Section 162(m) of the Internal Revenue Code, the committee will consist of two or more outside directors within the meaning of Section 162(m) of the Internal Revenue Code. The administrator has the power to determine the terms of the awards, including the exercise price, the number of shares subject to each such award, the exercisability of the awards and the form of consideration, if any, payable upon exercise. The administrator also has the authority to institute an exchange program by which outstanding awards may be surrendered in exchange for awards with a lower exercise price.

The administrator determines the exercise price of options granted under our 2004 stock plan, but with respect to nonstatutory stock options intended to qualify as performance-based compensation within the meaning of Section 162(m) of the Internal Revenue Code and all incentive stock options, the exercise price must at least be equal to the fair market value of our common stock on the date of grant. The term of an incentive stock option may not exceed ten years, except that with respect to any participant who owns 10% of the voting power of all classes of our outstanding stock, the term must not exceed five years and the exercise price must equal at least 110% of the fair market value on the grant date. The administrator determines the term of all other options.

No optionee may be granted an option to purchase more than 750,000 shares in any fiscal year. However, in connection with his or her initial service, an optionee may be granted an additional option to purchase up to 1,500,000 shares.

After termination of an employee, director or consultant, he or she may exercise his or her option for the period of time stated in the option agreement. Generally, if termination is due to death or disability, the option will remain exercisable for 12 months. In all other cases, the option will generally remain exercisable for three months. However, an option generally may not be exercised later than the expiration of its term.

Stock purchase rights, which represent the right to purchase our common stock, may be issued under our 2004 stock plan. The administrator determines the purchase price of stock purchase rights. Unless the administrator determines otherwise, we will retain a repurchase option that we may exercise

Stock appreciation rights may be granted under our 2004 stock plan. Stock appreciation rights allow the recipient to receive the appreciation in the fair market value of our common stock between the exercise date and the date of grant. The administrator determines the terms of stock appreciation rights, including when such rights become exercisable and whether to pay the increased appreciation in cash or with shares of our common stock, or a combination thereof.

Restricted stock may be granted under our 2004 stock plan. Restricted stock awards are shares of our common stock that vest in accordance with terms and conditions established by the administrator. The administrator will determine the number of shares of restricted stock granted to any employee. The administrator may impose whatever conditions to vesting it determines to be appropriate. For example, the administrator may set restrictions based on the achievement of specific performance goals. Shares of restricted stock that do not vest are subject to our right of repurchase or forfeiture.

Performance units and performance shares may be granted under our 2004 stock plan. Performance units and performance shares are awards that will result in a payment to a participant only if performance goals established by the administrator are achieved or the awards otherwise vest. The administrator will establish organizational or individual performance goals in its discretion, which, depending on the extent to which they are met, will determine the number and/or the value of performance units and performance shares to be paid out to participants. Performance units shall have an initial dollar value established by the administrator prior to the grant date. Performance shares shall have an initial value equal to the fair market value of our common stock on the grant date.

Our 2004 stock plan also provides for the automatic grant of options to our non-employee directors. Each non-employee director appointed to the board after the completion of this offering will receive an initial option to purchase 15,000 shares upon such appointment. Beginning in 2005, non-employee directors who have been directors for at least six months will receive a subsequent option to purchase 3,000 shares following each annual meeting of our stockholders. Also, beginning in 2005, non-employee directors who are members of the audit committee or compensation committee who have been members of such committee for at least six months will receive a subsequent option to purchase 1,000 shares following each annual meeting of our stockholders for each such committee upon which they serve, provided that the chairman of the audit committee and the chairman of the compensation committee will instead receive a subsequent option to purchase 1,500 shares. All such options shall have an exercise price equal to fair market value on the date of grant. Each initial option becomes exercisable as to one-third of the shares on each anniversary of the date of the grant, provided the non-employee director remains a service provider on such dates. Each subsequent option becomes exercisable as to all of the shares subject to the subsequent option on the one-year anniversary of the date of grant, provided the non-employee director remains a service provider on such date. In addition, upon the effective date of this offering, each nonemployee director will receive options for a number of shares equal to the number of shares granted to directors and audit and compensation committee members, with respect to the committees upon which the nonemployee director is then serving, at each annual meeting of stockholders, provided that the exercise price per share for each grant shall be equal to the price of our common stock in this offering. These options will also become exercisable as to all of the shares subject to the options on the one year anniversary of the date of grant.

Our 2004 stock plan generally does not allow for the transfer of awards and only the recipient of an award may exercise an award during his or her lifetime.

Our 2004 stock plan provides that in the event of our change of control, the successor corporation will assume or substitute an equivalent award for each outstanding award. If there is no assumption or substitution of outstanding awards, the administrator will provide notice to the recipient that he or she has the right to exercise his or her awards as to all of the shares subject to the awards, including shares which would not otherwise be exercisable, for a period of time as the administrator may determine from the date of the notice. The awards will terminate upon the expiration of such period. In addition, all restrictions and

rights of repurchase on restricted stock will lapse and, with respect to performance awards all performance goals will be deemed achieved at target levels, and all other terms and conditions met in the event of a change of control and these awards are not assumed. In the event an outside director is terminated on or following a change in control, other than pursuant to a voluntary resignation, his or her awards will fully vest and become immediately exercisable and, with respect to such director’s performance awards, all performance goals will be deemed achieved at target levels, and all other terms and conditions met.

Our 2004 stock plan will automatically terminate in 2014, unless we terminate it sooner. In addition, our board of directors has the authority to amend, suspend or terminate the 2004 stock plan provided such action does not impair the rights of any participant.

In 2001, we adopted the Nanosys 401(k) plan, which covers all of our eligible employees who have attained the age of 21 and have completed one month of service with us. The 401(k) plan is intended to qualify under Sections 401(a), 401(m) and 401(k) of the Internal Revenue Code and the 401(k) plan trust is intended to qualify under Section 501(a) of the Internal Revenue Code. All contributions to the 401(k) plan by eligible employees, and the investment earnings thereon, are not taxable to these employees until withdrawn and are 100% vested immediately. Our eligible employees may elect to reduce their current compensation up to the maximum statutorily prescribed annual limit, and to have these salary reductions contributed on their behalf to the 401(k) plan. We have not made any matching contributions to our 401(k) plan.

We have adopted provisions in our certificate of incorporation that will limit the liability of our directors and executive officers for monetary damages for breach of their fiduciary duties to the maximum extent permitted by Delaware law. Under Delaware laws a certificate of incorporation may provide that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except liability for:


	•	any breach of their duty of loyalty to our company or our stockholders;

	•	acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;

	•	unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or

	•	any transaction from which the director derived an improper personal benefit.

The limits on a director or officer’s liability in our certificate of incorporation will not apply to liabilities arising under the federal securities laws and will not affect the availability of equitable remedies such as injunctive relief or rescission.

Our certificate of incorporation together with our bylaws will provide that we must indemnify our directors and executive officers and may indemnify our other officers and employees and other agents to the fullest extent permitted by law. We believe that indemnification under our bylaws covers at least negligence and gross negligence on the part of indemnified parties. Our bylaws will also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity, regardless of whether our bylaws would otherwise permit indemnification. We believe that the indemnification provisions of our certificate of incorporation and bylaws are necessary to attract and retain qualified persons as directors and officers. We also maintain directors’ and officers’ liability insurance.

We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by the board of directors. These agreements provide for indemnification for related expenses including attorneys’ fees, judgments, fines and settlement amounts

At present we are not aware of any pending litigation or proceeding involving any director, officer, employee or agent of our company in such person’s capacity with our company where indemnification will be required or permitted. We are also not aware of any threatened litigation or proceedings that might result in a claim for indemnification.

The following table sets forth information known to us with respect to the beneficial ownership of our common stock as of June 30, 2004 and as adjusted to reflect the sale of 6,250,000 shares of common stock by us in this offering, by the following:


	•	each stockholder known by us to own beneficially more than 5% of our common stock;

	•	each of our executive officers named in the compensation table above;

	•	each of our directors; and

	•	all directors and executive officers as a group.

Except as otherwise noted below, the address is c/o Nanosys, Inc., 2625 Hanover Street, Palo Alto, California 94304.

We have determined beneficial ownership in accordance with the rules of the Securities and Exchange Commission. Except as otherwise indicated, we believe that the beneficial owners of the common stock listed below, based on the information furnished by these owners, have sole voting power and investment power with respect to these shares, subject to applicable community property laws. We have calculated the percentage of beneficial ownership based on 21,870,313 shares of common stock outstanding upon completion of this offering, which includes 15,620,313 shares of common stock outstanding as of June 30, 2004, after giving effect to the conversion of our outstanding preferred stock.

In computing the number of shares of common stock beneficially owned by a person and the percent ownership of that person, we deemed outstanding shares of common stock subject to options held by that person that are currently exercisable within 60 days of June 30, 2004. We did not deem these shares outstanding for purposes of computing the percent ownership of any other person.


	(1)	Represents: (a) 2,100,809 shares held by ARCH Venture Fund V, L.P., (b) 178,539 shares held by Healthcare Focus Fund, L.P. and (c) 12,780 shares held by ARCH V Entrepreneurs Fund, L.P. The people who have investment control of the ARCH Venture Fund V, L.P., ARCH V Entrepreneurs Fund, L.P., and the Healthcare Focus Fund, L.P. shares are Robert T. Nelsen, Steven Lazarus, Mr. Bybee, Patrick Ennis, Karen Kerr and Keith Crandell, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.

	(2)	Represents: (a) 1,573,608 shares held by CW Ventures III, L.P., (b) 275,009 shares held by CW Ventures III — A Co-Investment Fund, L.P. and (c) 264,973 shares held by JP Morgan/ CW Ventures III (Nanosys), L.P. The people who have investment control of the CW Ventures III, L.P., CW Ventures III — A Co-Investment Fund, L.P. and J.P. Morgan/ CW Ventures III (Nanosys), L.P. shares are Mr. Bock, Walter Channing, Charles Hartman and Barry Weinberg, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.

	(3)	Represents: (a) 2,028,932 shares held by Polaris Venture Partners III, L.P., (b) 52,680 shares held by Polaris Venture Partners Entrepreneurs Fund III, L.P., and (c) 31,978 shares held by Polaris Venture Partners Founders’ Fund III, L.P. The people who have investment control of the Polaris Venture Partners III, L.P., Polaris Venture Partners Entrepreneurs Fund III, L.P. and Polaris Venture Partners Founders’ Fund III, L.P. shares are Steve Arnold, John Flint, Terry McGuire and Alan Spoon, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.

	(4)	Represents: (a) 1,690,873 shares held by Venrock Associates III, L.P., (b) 380,446 shares held by Venrock Associates and (c) 42,271 shares held by Venrock Entrepreneurs Fund III, L.P. The people who have investment control of the Venrock Associates, Venrock Associates III, L.P. and Venrock Entrepreneurs Fund III, L.P. shares are Michael Brooks, Eric Copeland, Anthony Evnin, Linda Hanauer (Venrock Associates III, L.P. only), Dr. Roberts, Anthony Sun and Michael Tyrrell, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.


	(5)	Represents: (a) 316,666 shares held by The Bock Family Trust and in trust for the benefit of Mr. Bock’s children, of which 295,555 shares are subject to our right of repurchase upon Mr. Bock’s termination as our service provider, (b) 47,916 shares held by the Bock Family Trust, of which 22,361 of the shares remain subject to a repurchase right upon Mr. Bock and CW Group affiliates no longer remaining available to provide services to us, (c) 1,573,608 shares held by CW Ventures III, L.P., (d) 275,009 shares held by CW Ventures III — A Co-Investment Fund, L.P. and (e) 264,973 shares held by J.P. Morgan/ CW Ventures III (Nanosys), L.P. Mr. Bock is a general partner of CW Ventures IV, LLC which is the general partner of CW Ventures III, L.P., CW Ventures III — A Co-Investment Fund, L.P. and J.P. Morgan/ CW Ventures III (Nanosys), L.P. The people who have investment control of the CW Ventures III, L.P., CW Ventures III — A Co-Investment Fund, L.P. and J.P. Morgan/ CW Ventures III (Nanosys), L.P. shares are Walter Channing, Charles Hartman, Mr. Bock and Barry Weinberg, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.



	(6)	Represents 578,332 shares held by Mr. Chow, of which 351,415 shares are subject to our right of repurchase upon termination of Mr. Chow as a service provider.



	(7)	Represents: (a) 243,333 shares held by Dr. Parce, of which 147,769 shares are subject to our right of repurchase upon termination of Dr. Parce as a service provider and (b) the right to acquire 13,611 shares exercisable within 60 days of June 30, 2004.



	(8)	Represents: (a) 37,443 shares held by Mr. Murphy, of which 4,584 are subject to our right of repurchase upon termination of Mr. Murphy as a service provider, and (b) 5,473 shares underlying options held by Mr. Murphy that are exercisable within 60 days of June 30, 2004.



	(9)	Represents 95,831 shares held by Ms. Vergura, of which 43,792 shares are subject to our right of repurchase upon termination of Ms. Vergura as a service provider.


(10)	Represents: (a) 2,100,809 shares held by ARCH Venture Fund V, L.P., (b) 178,539 shares held by Healthcare Focus Fund, L.P. and (c) 12,780 shares held by ARCH V Entrepreneurs Fund, L.P. Mr. Bybee is a managing director of ARCH Venture Partners V, LLC, which is the general partner of ARCH Venture Partners V, L.P. ARCH Venture Partners V, L.P. is the general partner of ARCH Venture Fund V, L.P., ARCH V Entrepreneurs Fund, L.P., and Healthcare Focus Fund, L.P. The people who have investment control of the ARCH Venture Fund V, L.P., ARCH V Entrepreneurs Fund, L.P., and the Healthcare Focus Fund, L.P. shares are Robert T. Nelsen, Steven Lazarus, Mr. Bybee, Patrick Ennis, Karen Kerr and Keith Crandell, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.


(11)	Represents: (a) 41,666 shares held by Mr. McKenna, of which 25,000 shares are subject to our right of repurchase upon termination of Mr. McKenna as a service provider and (b) 45,699 shares held by McKenna Ventures L.P. Mr. McKenna disclaims beneficial ownership of the shares held by McKenna Ventures L.P. except to the extent of his proportionate interest.


(12)	Represents: (a) 1,690,873 shares held by Venrock Associates III, L.P., (b) 380,446 shares held by Venrock Associates and (c) 42,271 shares held by Venrock Entrepreneurs Fund III, L.P. Dr. Roberts is a general partner of Venrock Associates. Dr. Roberts is also a member of Venrock Management III LLC, the general partner of Venrock Associates III, L.P. and a member of VEF Management III LLC, the general partner of Venrock Entrepreneurs Fund III, L.P. The people who have investment control of the Venrock Associates, Venrock Associates III, L.P. and Venrock Entrepreneurs Fund III, L.P. shares are Michael Brooks, Eric Copeland, Anthony Evnin, Linda Hanauer (Venrock Associates III, L.P. only), Dr. Roberts, Anthony Sun and Michael Tyrrell, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.


(13)	Represents: 77,968 shares held by Dr. Somekh, 33,333 shares of which are subject to our right of repurchase upon his termination as a service provider.


(14)	Represents: 33,332 shares held by Dr. Yurek, all of which are subject to our right of repurchase upon his termination as a service provider.

(15)	See notes 5 through 14.

In October 2001, we sold 1,833,329 shares of our series A preferred stock at $0.90 per share. In January and February 2002, we sold 4,166,661 shares of our series B preferred stock at $3.60 per share. In April and May 2003 and April 2004, we sold 6,693,962 shares of our series C preferred stock at $5.601 per share. Our series A, series B and series C preferred stock is convertible into shares of our common stock on a one for one basis.

Upon the closing of this offering, all shares of our outstanding preferred stock will be automatically converted into shares of common stock. We have entered into an agreement pursuant to which these and other preferred stockholders will have registration rights with respect to their shares of common stock following this offering. For a description of these registration rights, see “Description of Capital Stock.”

Since our inception, we have from time to time sold shares of our common stock pursuant to option exercises and restricted stock purchase rights at per share prices ranging from $0.003 per share to $3.00 to our directors, officers, founders and consultants, subject to repurchase rights in our favor that lapse over specified periods, usually five years. The repurchase right entitles us to repurchase unvested shares at their original purchase price on termination of a purchaser’s services with us.

Listed below are those persons who participated in the transactions described above who are our executive officers or directors or who beneficially own five percent or more of our securities.

of series C preferred stock held by ARCH V Entrepreneurs Fund, L.P. The people who have investment control of the ARCH Venture Fund V, L.P., ARCH V Entrepreneurs Fund, L.P., and the Healthcare Focus Fund, L.P. shares are Robert T. Nelsen, Steven Lazarus, Mr. Bybee, Patrick Ennis, Karen Kerr and Keith Crandell, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.


(2)	Represents: (a) 308,750 shares of series A preferred stock, 643,229 shares of series B preferred stock and 621,629 shares of series C preferred stock held by CW Ventures III, L.P., (b) 53,958 shares of series A preferred stock, 112,413 shares of series B preferred stock and 108,638 shares of series C preferred stock held by CW Ventures III — A Co-Investment Fund, L.P. and (c) 53,958 shares of series A preferred stock, 112,413 shares of series B preferred stock and 98,602 shares of series C preferred stock held by J.P. Morgan/ CW Ventures III (Nanosys), L.P. The people who have investment control of the CW Ventures III, L.P., CW Ventures III — A Co-Investment Fund, L.P. and J.P. Morgan/ CW Ventures III (Nanosys), L.P. shares are Mr. Bock, Walter Channing, Charles Hartman and Barry Weinberg, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.

(3)	Represents: (a) 399,977 shares of series A preferred stock, 833,285 shares of series B preferred stock and 795,670 shares of series C preferred stock held by Polaris Venture Partners III, L.P., (b) 10,385 shares of series A preferred stock, 21,636 shares of series B preferred stock, and 20,659 shares of series C preferred stock held by Polaris Venture Partners Entrepreneurs’ Fund III, L.P. and (c) 6,304 shares of series A preferred stock, 13,133 shares of series B preferred stock, and 12,541 shares of series C preferred stock held by Polaris Venture Partners Founders’ Fund III, L.P. The people who have investment control of the Polaris Venture Partners III, L.P., Polaris Venture Partners Entrepreneurs Fund III, L.P. and Polaris Venture Partners Founders’ Fund III, L.P. shares are Steve Arnold, John Flint, Terry McGuire and Alan Spoon, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.

(4)	Represents: (a) 333,333 shares of series A preferred stock, 694,444 shares of series B preferred stock and 663,096 shares of series C preferred stock held by Venrock Associates III, L.P., (b) 75,000 shares of series A preferred stock, 156,250 shares of series B preferred stock and 149,196 shares of series C preferred stock held by Venrock Associates, and (c) 8,333 shares of series A preferred stock, 17,361 shares of series B preferred stock and 16,577 shares of series C preferred stock held by Venrock Entrepreneurs Fund III, L.P. The people who have investment control of the Venrock Associates, Venrock Associates III, L.P. and Venrock Entrepreneurs Fund III, L.P. shares are Michael Brooks, Eric Copeland, Anthony Evnin, Linda Hanauer (Venrock Associates III, L.P. only), Dr. Roberts, Anthony Sun and Michael Tyrrell, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.

(5)	Represents: (a) 297,916 shares of common stock held by the Bock Family Trust, (b) 66,666 shares of common stock held by trusts for the benefit of Mr. Bock’s children, (c) 308,750 shares of series A preferred stock, 643,229 shares of series B preferred stock, and 621,629 shares of series C preferred stock held by CW Ventures III, L.P., (d) 53,958 shares of series A preferred stock, 112,413 shares of series B preferred stock and 108,638 shares of series C preferred stock held by CW Ventures III — A Co-Investment Fund, L.P. and (e) 53,958 shares of series A preferred stock, 112,413 shares of series B preferred stock and 98,602 shares of series C preferred stock held by J.P. Morgan/ CW Ventures III (Nanosys), L.P. Mr. Bock is a general partner of CW Ventures IV, LLC which is the general partner of CW Ventures III, L.P., CW Ventures III — A Co-Investment Fund, L.P. and J.P. Morgan/ CW Ventures III (Nanosys), L.P. The people who have investment control of the CW Ventures III, L.P., CW Ventures III — A Co-Investment Fund, L.P. and J.P. Morgan/ CW Ventures III (Nanosys), L.P. shares are Walter Channing, Charles Hartman, Mr. Bock and Barry Weinberg, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.


(6)	Represents: (a) 578,332 shares of common stock held by Mr. Chow and (b) 88,611 shares of series B preferred stock held in trust for the benefit of Mr. Chow’s children. Mr. Chow disclaims beneficial ownership with respect to the shares held in trust for the benefit of his children.


(7)	Represents: (a) 414,295 shares of series A preferred stock, 863,115 shares of series B preferred stock and 823,399 shares of series C preferred stock held by ARCH Venture Fund V, L.P. (b) 178,539 shares of series C preferred stock held by Healthcare Focus Fund, L.P., and (c) 2,371 shares of series A preferred stock, 4,939 shares of series B preferred stock, and 5,470 shares of series C preferred stock held by ARCH V Entrepreneurs Fund, L.P. Mr. Bybee is a managing director of ARCH Venture Partners V, LLC, which is the general partner of ARCH Venture Partners V, L.P. ARCH Venture Partners V, L.P. is the general partner of ARCH Venture Fund V, L.P., ARCH V Entrepreneurs Fund, L.P., and Healthcare Focus Fund, L.P. The people who have investment control of the ARCH Venture Fund V, L.P., ARCH V Entrepreneurs Fund, L.P., and the Healthcare Focus Fund, L.P. shares are Robert T. Nelsen, Steven Lazarus, Mr. Bybee, Patrick Ennis, Karen Kerr and Keith Crandell, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.


(8)	Represents: (a) 41,666 shares of common stock held by Mr. McKenna and (b) 27,778 shares of series B preferred stock and 17,921 shares of series C preferred stock held by McKenna Ventures L.P. Mr. McKenna disclaims beneficial ownership of the shares held by McKenna Ventures except to the extent of his proportionate interest.

(9)	Represents: (a) 333,333 shares of series A preferred stock, 694,444 shares of series B preferred stock and 663,096 shares of series C preferred stock held by Venrock Associates III, L.P., (b) 75,000 shares of series A preferred stock, 156,250 shares of series B preferred stock and 149,196 shares of series C preferred stock held by Venrock Associates and (c) 8,333 shares of series A preferred stock, 17,361 shares of series B preferred stock and 16,577 shares of series C preferred stock held by Venrock Entrepreneurs Fund III, L.P. Dr. Roberts is a general partner of Venrock Associates. Dr. Roberts is also a member of Venrock Management III LLC, the general partner of Venrock Associates III, L.P. and a member of VEF Management III LLC, the general partner of Venrock Entrepreneurs Fund III, L.P. The people who have investment control of the Venrock Associates, Venrock Associates III, L.P. and Venrock Entrepreneurs Fund III, L.P. shares are Michael Brooks, Eric Copeland, Anthony Evnin, Linda Hanauer (Venrock Associates III, L.P. only), Dr. Roberts, Anthony Sun and Michael Tyrrell, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest therein.

Since our inception we have issued the following options and restricted stock purchase rights to our current officers and directors under our 2001 stock plan and they have exercised options and stock purchase rights to acquire our common stock as follows:



(1)	Represents a restricted stock purchase right. Such shares purchased by Mr. Bock are subject to our repurchase right upon the termination of Mr. Bock as a service provider that lapses monthly over a five year period beginning February 10, 2004. As of June 30, 2004, 295,555 shares remained subject to our repurchase right.



(2)	Represents the early exercise in full of a non-statutory option pursuant to a restricted stock purchase agreement. Such shares purchased by Mr. Chow are subject to our repurchase right upon the termination of Mr. Chow as a service provider that lapses monthly over a five year period beginning November 12, 2001. As of June 30, 2004, 80,554 shares remained subject to our repurchase right.



(3)	Represents the early exercise in full of a non-statutory option pursuant to a restricted stock purchase agreement. Shares purchased by Mr. Chow were subject to our repurchase right upon the termination of Mr. Chow as a service provider that lapsed according to the achievement by Mr. Chow of annual milestones determined in the discretion of our board of directors. As of June 30, 2004, none of such shares remained subject to our repurchase right.



(4)	Represents a restricted stock purchase right. Such shares purchased by Mr. Chow are subject to our repurchase right upon the termination of Mr. Chow as a service provider that lapses monthly over a five year period beginning November 14, 2002. As of June 30, 2004, 115,027 shares remained subject to our repurchase right.


(5)	Represents a restricted stock purchase right. Such shares purchased by Mr. Chow are subject to our repurchase right upon the termination of Mr. Chow as a service provider that lapses monthly over a



	five year period beginning January 1, 2004. As of June 30, 2004, 155,834 shares remained subject to our repurchase right.



(6)	Represents the early exercise in full of a non-statutory option pursuant to a restricted stock purchase agreement. Such shares purchased by Dr. Parce are subject to our repurchase right upon the termination of Dr. Parce as a service provider that lapses monthly over a five year period beginning January 11, 2002. As of June 30, 2004, 5,167 shares remained subject to our repurchase right.



(7)	Represents a restricted stock purchase right. Such shares purchased by Dr. Parce are subject to our repurchase right upon the termination of Dr. Parce as a service provider that lapses monthly over a five year period beginning June 1, 2002. As of June 30, 2004, 142,602 shares remained subject to our repurchase right.



(8)	Represents incentive stock option. Such option vests as to 1/60th of the shares subject to such option each month over a five year period beginning January 1, 2004. As of June 30, 2004, 106,944 shares remained unvested.



(9)	Represents an incentive stock option that was partially exercised. Such option vested as to 20% of the shares subject to such option one year after April 29, 2002 and continued vesting as to 1/60th of the shares each month thereafter. As of June 30, 2004, 41,556 shares remained unvested.



(10)	Represents an incentive stock option that was partially exercised. Such option vests as to 1/60th of the shares subject to such option each month over a five year period beginning January 1, 2003. As of June 30, 2004, 8,361 shares remained unvested.



(11)	Represents a restricted stock purchase right. Such shares purchased by Mr. Murphy are subject to our repurchase right upon the termination of Mr. Murphy as a service provider that lapses monthly over a five year period beginning January 1, 2004. As of June 30, 2004, 4,584 shares remained subject to our repurchase right.



(12)	Represents the early exercise in full of a non-statutory option pursuant to a restricted stock purchase agreement. Such shares purchased by Ms. Vergura are subject to our repurchase right upon the termination of Ms. Vergura as a service provider that lapses monthly over a five year period beginning December 13, 2001. As of June 30, 2004, 33,333 shares remained subject to our repurchase right.



(13)	Represents a restricted stock purchase right. Such shares purchased by Ms. Vergura are subject to our repurchase right upon the termination of Ms. Vergura as a service provider that lapses monthly over a five year period beginning December 17, 2002. As of June 30, 2004, 8,167 shares remained subject to our repurchase right.



(14)	Represents a restricted stock purchase right. Such shares purchased by Ms. Vergura are subject to our repurchase right upon the termination of Ms. Vergura as a service provider that lapses monthly over a five year period beginning January 1, 2004. As of June 30, 2004, 2,292 shares remained subject to our repurchase right.



(15)	Represents the early exercise in full of a non-statutory option pursuant to a restricted stock purchase agreement. Such shares purchased by Mr. McKenna are subject to our repurchase right upon the termination of Mr. McKenna as a service provider that lapses as to 20% of such shares on each anniversary of April 2, 2002. As of June 30, 2004, 25,000 shares remained subject to our repurchase right.



(16)	Represents a restricted stock purchase right. Such shares purchased by Dr. Somekh are subject to our repurchase right upon the termination of Dr. Somekh as a service provider that lapses as to 20% of such shares on each anniversary of November 18, 2003. As of June 30, 2004, all such shares remained subject to our repurchase right.


(17)	Represents a restricted stock purchase right. Such shares purchased by Mr. Young are subject to our repurchase right upon the termination of Mr. Young as a service provider that lapses as to 20% of



	such shares on each anniversary of March 18, 2004. As of June 30, 2004, all such shares remained subject to our repurchase right.



(18)	Represents a restricted stock purchase right. Such shares purchased by Dr. Yurek are subject to our repurchase right upon the termination of Dr. Yurek as a service provider that lapses as to 20% of such shares on each anniversary of February 10, 2004. As of June 30, 2004, all such shares remained subject to our repurchase right.



(19)	Represents a restricted stock purchase right. Such shares purchased by Dr. Yurek are subject to our repurchase right upon the termination of Dr. Yurek as a service provider that lapses as to 20% of such shares on each anniversary of March 15, 2004. As of June 30, 2004, all such shares remained subject to our repurchase right.

In connection with the purchase by Dr. J. Wallace Parce of 233,333 shares of our common stock on August 12, 2002, we provided Dr. Parce with a loan, secured by such shares, under a full recourse promissory note dated August 12, 2002, in the amount of $84,000 and an interest rate of 6.0% per annum. Dr. Parce repaid us the principal and interest accrued to date under such promissory note in March 2004.

In connection with the purchase by Calvin Chow of 168,333 shares of our common stock on November 11, 2002, we provided Mr. Chow with a loan, secured by such shares, under a full recourse promissory note dated November 11, 2002, in the amount of $60,600 and an interest rate of 6.0% per annum. Mr. Chow repaid us the principal and interest accrued to date under such promissory note in March 2004.

In March 2004, we entered an agreement with CW Group, Inc., certain entity and individual affiliates of CW Group, Inc. and Mr. Bock. In accordance with the terms of this agreement, we issued 16,666 shares of common stock to each of Charles Hartman, Barry Weinberg and Walter Channing, affiliates of CW Group, Inc., and 316,666 shares of common stock to Mr. Bock. We also granted to CW Group, Inc. board observation rights that terminate upon an initial public offering of our common stock, agreed to discuss with a new entity that could be formed in connection with a potential spinout transaction of some of our current technology the possibility of such new entity granting CW Group, Inc. the ability to invest in such new entity’s initial venture capital funding, stated our intention to offer Lawrence Bock an offer of employment with us and agreed to reimburse Mr. Bock for COBRA payments in connection with Mr. Bock’s maintenance of health insurance coverage with CW Group, Inc., Mr. Bock’s former employer, and the entity of which Mr. Bock remains a general partner. CW Group, Inc., in turn, agreed to terminate its rights to designate a member of our board of directors pursuant to a voting agreement, the terms of which will terminate upon an initial public offering of our common stock, fully vest Mr. Bock in his interests in CW Group, Inc. and that CW Group, Inc., and its entities, would not have any further rights to cash or equity amounts issued or granted by us to Mr. Bock or otherwise. Mr. Bock is currently an employee and serves as the executive chairman of our board of directors. Although we agreed to discuss a potential spinout transaction of some of our technology with CW Group, we have not made any agreements with any third parties to consummate a spinout. We are currently exploring whether some product opportunities, such as the use of our nanostructures in medical devices, would be opportunities that we would like to pursue internally or externally through a spinout into a separate entity for development or other arrangement.

On August 17, 2001, Dr. Charles Lieber purchased 183,333 shares of our common stock at a price per share of $0.003. Such shares purchased by Mr. Lieber are subject to our repurchase right upon the termination of Mr. Lieber as a service provider that lapsed as to 5% of such shares on October 3, 2001, with the repurchase right lapsing as to the remaining shares monthly over a five year period beginning October 3, 2001. As of June 30, 2004, 81,280 shares remained subject to our repurchase right. Dr. Lieber is a member of our scientific advisory board, was a holder of more than 5% of our voting

On August 17, 2001, Dr. Hongkun Park purchased 150,000 shares of our common stock at a price per share of $0.003. Such shares purchased by Dr. Park are subject to our repurchase right upon the termination of Dr. Park as a service provider that lapsed as to 5% of such shares on October 3, 2001, with the repurchase right lapsing as to the remaining shares monthly over a five year period beginning October 3, 2001. As of June 30, 2004, 66,502 shares remained subject to our repurchase right. Dr. Park is a member of our scientific advisory board, and was a holder of more than 5% of our voting securities for a period of time after such purchase.

Dr. Park and Dr. Lieber are professors at Harvard University. As such, Dr. Park and Dr. Lieber may receive compensation from Harvard University in respect of inventions Dr. Park and Dr. Lieber may have assigned to such university, including certain patent rights that we licensed from Harvard University in October 2001 and January 2003. In connection with such licenses, Harvard acquired 53,333 shares of our common stock in October 2001, 6,666 shares of our common stock in February 2003 and 3,333 shares of our common stock in June 2003. In addition to the compensation Dr. Park and Dr. Lieber may receive as described above, Dr. Park and Dr. Lieber may be entitled to receive a portion of such shares of common stock or the proceeds that Harvard University may recognize upon the disposition of such shares.

On September 20, 2001, Dr. A. Paul Alivisatos purchased 128,333 shares of our common stock at a price per share of $0.003. Such shares purchased by Dr. Alivisatos are subject to our repurchase right upon the termination of Dr. Alivisatos as a service provider that lapses monthly over a five year period beginning September 4, 2001. As of June 30, 2004, 57,749 shares remained subject to our repurchase right. Dr. Alivisatos is a member of our scientific advisory board, and was a holder of more than 5% of our voting securities for a period of time after such purchase.

Dr. Alivisatos is head of the Molecular Design Institute and a Director of the Material Science Division at Lawrence Berkeley Laboratories. As such Dr. Alivisatos may receive compensation from Lawrence Berkeley Laboratories in respect of inventions Dr. Alivisatos may have assigned to such institution, including certain patent rights that we licensed from Lawrence Berkeley Laboratories in October 2002.

In March 2002, we entered into a sublease with Optobionics Corporation for certain real property located at our principal offices at 2625 Hanover Street, Palo Alto, California. Our rental payments from Optobionics under this sublease were approximately $24,000 per month. Alan Chow, M.D., is a founder and an executive officer of Optobionics, and is the brother of Calvin Y.H. Chow, our chief executive officer, and Calvin Chow is a member of the board of directors of Optobionics. The sublease terminated in April 2004.

We are authorized to issue 53,500,000 shares of common stock, $0.001 par value. Upon the closing of this offering, we will be authorized to issue 120,000,000 shares of common stock, $0.001 par value, and 10,000,000 shares of undesignated preferred stock, $0.001 par value.

As of June 30, 2004, we had 2,926,361 shares of common stock outstanding that were held of record by approximately 95 stockholders and 12,693,952 shares of preferred stock outstanding that were convertible to 12,693,952 shares of common stock and held of record by approximately 42 persons.

The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of common stock are entitled to receive ratably any dividends that may be declared from time to time by the board of directors out of funds legally available for that purpose. In the event of our liquidation, dissolution or winding up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of common stock are fully paid and nonassessable, and the shares of common stock to be issued upon the closing of this offering will be fully paid and nonassessable.

Upon the closing of this offering, our board of directors will have the authority, without action by our stockholders, to designate and issue preferred stock in one or more series. The board of directors may also designate the rights, preferences and privileges of each series of preferred stock, any or all of which may be greater than the rights of the common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock upon the rights of holders of the common stock until the board of directors determines the specific rights of the holders of the preferred stock. However, these effects might include:


	•	restricting dividends on the common stock;

	•	diluting the voting power of the common stock;

	•	impairing the liquidation rights of the common stock; and

	•	delaying or preventing a change in control of our company without further action by the stockholders.

As of June 30, 2004, we had the following warrants outstanding to purchase a total of 279,778 shares of our capital stock:


	•	25,000 shares of our series B preferred stock at an exercise price of $3.60 per share, which are fully exercisable and will terminate in March 2012.

	•	13,750 shares of our series B preferred stock at an exercise price of $3.60 per share, which are fully exercisable and will terminate in May 2012.

	•	241,028 shares of our series C preferred stock at an exercise price of $0.003 per share, which become exercisable when we receive milestone payments from the holder and which expire upon the earlier to occur of 2008 or the completion of this offering.

We have reserved shares of our preferred stock for issuance upon exercise of these warrants, as well as the common stock into which such preferred stock may be converted. After the completion of this offering, any remaining warrants may only be exercised for common stock.

Holders of Registration Rights Can Require Us to Register Shares of Our Stock for Resale

The holders of 12,693,952 shares of common stock and 279,778 shares of common stock issuable upon the exercise of warrants or their permitted transferees are entitled to rights with respect to registration of these shares under the Securities Act of 1933, as amended. These rights are provided under the terms of our agreement with the holders of registrable securities. Under these registration rights, holders of the then outstanding registrable securities may require on two occasions that we register their shares for public resale. Each such registration requires the election of the holders of registrable securities holding at least 40% of the registrable securities to register at least 40% of the registrable securities held by such group of electing holders or a lesser percentage with an expected aggregate offering price to the public of at least $5,000,000. Holders of registrable securities may require that we register their shares for public resale on Form S-3 or similar short-form registration, if we are eligible to use Form S-3 or similar short-form registration, and the value of the securities to be registered is at least $1,000,000. In addition, if we elect to register any of our shares of common stock for any public offering, the holders of registrable securities are entitled to include shares of common stock in the registration. We may reduce the number of shares proposed to be registered in view of market conditions. We will pay all expenses in connection with any registration, other than underwriting discounts and commissions. None of the holders of registrable securities may require that we include shares in this offering.

Certain provisions of Delaware law and our certificate of incorporation and bylaws could make the acquisition of our company through a tender offer, a proxy contest or other means more difficult and could make the removal of incumbent officers and directors more difficult. We expect these provisions to discourage certain types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of our company to first negotiate with our board of directors. We believe that the benefits provided by our ability to negotiate with the proponent of an unfriendly or unsolicited proposal outweigh the disadvantages of discouraging these proposals. We believe the negotiation of an unfriendly or unsolicited proposal could result in an improvement of its terms.

We are subject to Section 203 of the Delaware General Corporation Law, an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging under certain circumstances, in a “business combination” with an “interested stockholder” for a period of three years following the date the person became an interested stockholder, unless:


	•	prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

	•	upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

	•	on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.

Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An “interested stockholder” is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation’s outstanding voting securities. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section 203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.

Our amended and restated certificate of incorporation to be in effect upon the closing of this offering provides for our board of directors to be divided into three classes serving staggered terms. Approximately one-third of the board of directors will be elected each year. The provision for a classified board could prevent a party who acquires control of a majority of the outstanding voting stock from obtaining control of the board of directors until the second annual stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company and could increase the likelihood that incumbent directors will retain their positions. Our amended and restated certificate of incorporation to be in effect upon the closing of this offering provides that directors may be removed with cause by the affirmative vote of the holders of the outstanding shares of common stock.

Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. At an annual meeting, stockholders may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors. Stockholders may also consider a proposal or nomination by a person who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to our Secretary timely written notice, in proper form, of his or her intention to bring that business before the meeting. The bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting of the stockholders. However, our bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our company.

Under Delaware law, a special meeting of stockholders may be called by the board of directors or by any other person authorized to do so in the certificate of incorporation or the bylaws. Only a majority of our board of directors, the chairman of the board, our chief executive officer or president (in the absence of a chief executive officer) are authorized under our bylaws to call a special meeting of stockholders. Because our stockholders do not have the right to call a special meeting, a stockholder could not force stockholder consideration of a proposal over the opposition of the board of directors by calling a special meeting of stockholders prior to the time as a majority of the board of directors believed or the chief executive officer believed the matter should be considered or until the next annual meeting provided that the requestor met the notice requirements. The restriction on the ability of stockholders to call a special meeting means that a proposal to replace the board could be delayed until the next annual meeting.

Delaware law provides that stockholders may execute an action by written consent in lieu of a stockholder meeting. However, Delaware law also allows us to eliminate stockholder actions by written consent. Elimination of written consents of stockholders may lengthen the amount of time required to take stockholder actions since actions by written consent are not subject to the minimum notice requirement of a stockholder’s meeting. However, we believe that the elimination of stockholders’ written consents may deter hostile takeover attempts. Without the availability of stockholder’s actions by written consent, a holder controlling a majority of our capital stock would not be able to amend our bylaws or remove

directors without holding a stockholders meeting. The holder would have to obtain the consent of a majority of the board of directors, the chairman of the board or the chief executive officer to call a stockholders’ meeting and satisfy the notice periods determined by the board of directors. Our certificate of incorporation provides for the elimination of actions by written consent of stockholders upon the closing of this offering.

We have applied to have our common stock listed on the Nasdaq National Market for quotation under the symbol “NNSY.”

The transfer agent and registrar for our common stock is EquiServe Trust Company, N.A. and its address is 150 Royall Street, Canton, Massachusetts 02021 and its telephone number is 816-843-4299.

Prior to this offering, there has been no public market for our stock. Future sales of substantial amounts of our common stock in the public market following this offering or the possibility of these sales occurring could adversely affect prevailing market prices for our common stock or could impair our ability to raise capital through an offering of equity securities.

After this offering, we will have outstanding 21,870,313 shares of common stock, based upon 15,620,313 shares outstanding as of June 30, 2004, assuming no exercise of outstanding options or warrants after June 30, 2004. All of the shares sold in this offering will be freely tradable without restriction under the Securities Act except for any shares purchased by our affiliates as that term is defined in Rule 144 under the Securities Act. The remaining 15,620,313 shares of common stock held by existing stockholders are restricted shares as that term is defined in Rule 144 under the Securities Act. We issued and sold the restricted shares in private transactions in reliance upon exemptions from registration under the Securities Act. Restricted shares may be sold in the public market only if they are registered under the Securities Act or if they qualify for an exemption from registration, such as the exemptions provided under Rule 144 under the Securities Act, which is summarized below.

Our officers, directors, employees and stockholders, who collectively hold an aggregate of 15,419,625 restricted shares, and the underwriters entered into lock-up agreements in connection with this offering. These lock-up agreements provide that, with certain limited exceptions, our officers, directors, certain of our employees, and certain other stockholders have agreed not to offer, sell, contract to sell, grant any option to purchase or otherwise dispose of any of our shares for a period of 180 days after the effective date of this offering. Merrill Lynch may, in its sole discretion and at any time upon prior notice, release all or any portion of the shares subject to these lock-up agreements. We have also entered into an agreement with Merrill Lynch that, with certain exceptions, we will not offer, sell or otherwise dispose of our common stock until 180 days after the date of this prospectus.

Taking into account the lock-up agreements, the number of shares that will be available for sale in the public market under the provisions of Rules 144 and 144(k) will be as follows:

Following the expiration of the initial 180 day lockup period, shares issued upon exercise of options granted by us prior to the completion of this offering will also be available for sale in the public market pursuant to Rule 701 under the Securities Act unless those shares are held by one of our affiliates, directors or officers.

Beginning 181 days after the date of this prospectus, approximately 85,057 additional shares subject to vested options will become available for sale in the public market in reliance on Rule 701 or pursuant to a registration statement on Form S-8.

Our stockholders who acquired the shares of our common stock they hold between July 2001 and July 2004 may resell the shares pursuant to Rule 144 under the Securities Act. Unless the shareholder who acquired shares from us upon exercise of stock options prior to the filing of our registration statement on Form S-8 is currently our officer, director or affiliate, that shareholder will be able to sell all of the shares they acquired as soon as their contractual lockup period expires.

We issued warrants to purchase an aggregate of 279,778 shares of our preferred stock, which will be available for resale in the public market 180 days after the offering, assuming those warrants are

In addition, after the 180th day after this prospectus, our officers, directors and other affiliates will be eligible to sell shares of our common stock they hold under Rule 144. In general, under Rule 144 as currently in effect, a person, or persons whose shares are required to be aggregated, who has beneficially owned restricted shares for at least one year, including the holding period of any prior owner except an affiliate, would be entitled to sell within any three month period a number of shares that does not exceed the greater of:



	•	one percent of the number of shares of common stock then outstanding, which will equal approximately 218,703 shares immediately after the offering, or


	•	the average weekly trading volume of our common stock during the four calendar weeks preceding the date on which notice of the sale is filed.

Sales under Rule 144 are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. Under Rule 144(k), a person who is not deemed to have been an affiliate of our company at any time during the three months preceding a sale, and who has beneficially owned the shares proposed to be sold for at least two years including the holding period of any prior owner except an affiliate, is entitled to sell the shares without complying with the manner of sale, public information, volume limitation or notice provisions of Rule 144.

Any of our employees or consultants who purchased his or her shares pursuant to a written compensatory plan or contract is entitled to rely on the resale provisions of Rule 701, which permits nonaffiliates to sell their Rule 701 shares without having to comply with the public information, holding period, volume limitation or notice provisions of Rule 144 and permits affiliates to sell their Rule 701 shares without having to comply with the Rule 144 holding period restrictions, in each case commencing 90 days after the date of this prospectus.

We intend to file a registration statement on Form S-8 under the Securities Act to register shares of our common stock that are subject to outstanding options or reserved for issuance under our 2001 stock plan and our 2004 stock plan promptly after the date of this prospectus, thus permitting the resale of these shares by nonaffiliates in the public market without restriction under the Securities Act.

Additionally, subject to limitations in our stockholders agreement, we granted demand registration rights, rights to participate in offerings that we initiate and Form S-3 registration rights to the former holders of our preferred stock and warrants to acquire our preferred stock. See “Description of Capital Stock — Holders of Registration Rights Can Require Us to Register Shares of Our Stock for Resale.”

The following is a general discussion of material U.S. federal income and estate tax consequences of the ownership and disposition of our common stock by a beneficial owner thereof that is a non-U.S. holder.” A non-U.S. holder is a person or entity that, for U.S. federal income tax purposes, is a non-resident alien individual, a foreign corporation or a foreign estate or trust. The test for whether an individual is a resident of the U.S. for federal estate tax purposes differs from the test used for federal income tax purposes. Some individuals, therefore, may be non-U.S. holders for purposes of the federal income tax discussion below, but not for purposes of the federal estate tax discussion, and vice versa.

This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, judicial decisions and administrative regulations and interpretations in effect as of the date of this prospectus, all of which are subject to change, including changes with retroactive effect. This discussion does not address all aspects of U.S. federal income and estate taxation that may be relevant to non-U.S. holders in light of their particular circumstances, including, without limitation, non-U.S. holders who are pass-through entities or who hold their common stock through pass-through entities, and does not address any tax consequences arising under the laws of any state, local or non-U.S. jurisdiction. Prospective holders should consult their own tax advisors with respect to the federal income and estate tax consequences of holding and disposing of our common stock in light of their particular situations and any consequences to them arising under the laws of any state, local or non-U.S. jurisdiction.

Subject to the discussion below, distributions, if any, made to a non-U.S. holder of our common stock out of our current or accumulated earnings and profits generally will constitute dividends for U.S. tax purposes and will be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. To obtain a reduced rate of withholding under a treaty, a non-U.S. holder generally will be required to provide us with a properly-executed Internal Revenue Service, or IRS, Form W-8BEN certifying the non-U.S. holder’s entitlement to benefits under that treaty. IRS regulations provide special rules to determine whether, for purposes of determining the applicability of a tax treaty, dividends paid to a non-U.S. holder that is an entity should be treated as paid to the entity or to those holding an interest in that entity. To the extent such distributions exceed our current and accumulated earnings and profits for U.S. tax purposes, they will constitute a return of capital and will first reduce your basis in our common stock, but not below zero, and then will be treated as gain from the sale of stock.

There will be no withholding tax on dividends paid to a non-U.S. holder that are effectively connected with the non-U.S. holder’s conduct of a trade or business within the United States if a properly executed IRS Form W-8ECI, stating that the dividends are so connected, is provided to us. Instead, the effectively connected dividends will be subject to regular U.S. income tax, generally in the same manner as if the non-U.S. holder were a U.S. citizen or resident alien or a domestic corporation, as the case may be, unless a specific treaty exemption applies. A corporate non-U.S. holder receiving effectively connected dividends may also be subject to an additional “branch profits tax”, which is imposed, under certain circumstances, at a rate of 30%, or such lower rate as may be specified by an applicable treaty, of the corporate non-U.S. holder’s effectively connected earnings and profits, subject to certain adjustments. If you are eligible for a reduced rate of withholding tax pursuant to a tax treaty, you may obtain a refund of any excess amounts currently withheld if you file an appropriate claim for refund with the IRS.

A non-U.S. holder generally will not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless:


	•	the gain is effectively connected with a trade or business of such holder in the United States and a specific treaty exemption does not apply to eliminate the tax;


	•	if a tax treaty would otherwise apply to eliminate the tax, the gain is attributable to a permanent establishment of the non-U.S. holder in the U.S.;

	•	in the case of Non-U.S. Holders who are nonresident alien individuals and hold our common stock as a capital asset, such individuals are present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions are met;

	•	the non-U.S. holder is subject to tax pursuant to the provisions of the Code regarding the taxation of U.S. expatriates; or

	•	we are or have been a United States real property holding corporation within the meaning of Internal Revenue Code Section 897(c)(2) at any time within the shorter of the five year period preceding such disposition or such holder’s holding period.

We believe that we are not, and do not anticipate becoming, a United States real property holding corporation. Even if we are treated as a United States real property holding corporation, gain realized by a non-U.S. holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as: (a) the non-U.S. holder owned directly or indirectly, no more than five percent of our common stock at all times within the shorter of (x) the five year period preceding the disposition or (y) the holder’s holding period; and (b) our common stock is regularly traded on an established securities market. There can be no assurance that our common stock will continue to qualify as being regularly traded on an established securities market.

If you are a non-U.S. holder described in the first and second bullets above, you will be required to pay tax on the net gain derived from the sale at regular graduated U.S. federal income tax rates, and corporate non-U.S. holders described in the first and second bullets above may be subject to the branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. If you are an individual non-U.S. holder described in the third bullet above, you will be required to pay a flat 30% tax on the gain derived from the sale, which tax may be offset by U.S. source capital losses (even though you are not considered a resident of the United States).

Generally, we must report to the IRS the amount of dividends paid, the name and address of the recipient, and the amount, if any, of tax withheld. A similar report is sent to the holder. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient’s country of residence.

Backup withholding will generally not apply to payments of dividends made by us or our paying agents to a non-U.S. holder if the holder has provided its federal taxpayer identification number, if any, or the required certification that it is not a U.S. person (which is generally provided by furnishing a properly-executed IRS Form W-8BEN), unless the payor otherwise has knowledge or reason to know that the payee is a U.S. person.

Under current U.S. federal income tax law, information reporting and backup withholding will apply to the proceeds of a disposition of our common stock effected by or through a U.S. office of a broker unless the disposing holder certifies as to its non-U.S. status or otherwise establishes an exemption. Generally, U.S. information reporting and backup withholding will not apply to a payment of disposition proceeds where the transaction is effected outside the United States through a non-U.S. office of a non-U.S. broker. However, U.S. information reporting requirements, but not backup withholding, will apply to a payment of disposition proceeds where the transaction is effected outside the United States by or through an office outside the United States of a broker that fails to maintain documentary evidence that


	•	a U.S. person;

	•	a foreign person which derived 50% or more of its gross income for certain periods from the conduct of a trade or business in the United States;

	•	a “controlled foreign corporation” for U.S. federal income tax purposes; or

	•	a foreign partnership (a) at least 50% of the capital or profits interest in which is owned by U.S. persons, or (b) that is engaged in a U.S. trade or business.

Backup withholding will apply to a payment of disposition proceeds if the broker has actual knowledge that the holder is a U.S. person.

Backup withholding is not an additional tax. Rather, the tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund may be obtained, provided that the required information is furnished to the IRS.

The estates of nonresident alien individuals are subject to U.S. federal estate tax on property with a U.S. situs. Because we are a Delaware corporation, our common stock will be the U.S. situs property and therefore will be included in the taxable estate of a nonresident alien decedent. This U.S. federal estate tax liability of the estate of a nonresident alien may be affected by a tax treaty between the United States and the decedent’s country of residence.

The preceding discussion of U.S. federal tax consequences is for general information only. It is not tax advice. Each prospective holder should consult its own tax advisor regarding the particular U.S. federal, state, local and non-U.S. tax consequences of purchasing, holding and disposing of our common stock.

Merrill Lynch, Pierce, Fenner & Smith Incorporated, Lehman Brothers Inc., CIBC World Markets Corp. and Needham & Company, Inc. are acting as representatives of each of the underwriters named below. Subject to the terms and conditions set forth in a purchase agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number of shares of common stock set forth opposite its name below.

Subject to the terms and conditions set forth in the purchase agreement, the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the purchase agreement if any of these shares are purchased. If an underwriter defaults, the purchase agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the purchase agreement may be terminated.

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities.

The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, including the validity of the shares, and other conditions contained in the purchase agreement, such as the receipt by the underwriters of officer’s certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

The representatives have advised us that they propose initially to offer the shares to the public at the initial public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $ per share. The underwriters may allow, and the dealers may reallow, a discount not in excess of $ per share to other dealers. After the initial public offering, the public offering price, concession and discount may be changed.

The following table shows the initial public offering price, underwriting discount and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their overallotment option.

The total expenses of the offering, not including the underwriting discount, are estimated at $1.9 million and are payable by us.

We have granted an option to the underwriters to purchase up to 937,500 additional shares at the initial public offering price, less the underwriting discount. The underwriters may exercise this option for 30 days from the date of this prospectus solely to cover any overallotments. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the purchase agreement, to purchase a number of additional shares proportionate to that underwriter’s initial amount reflected in the above table.

We, our executive officers and directors and approximately 98% of our existing security holders have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for exercisable for, or repayable with common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Merrill Lynch. Specifically, we and these other persons have agreed not to directly or indirectly:


	•	offer, pledge, sell or contract to sell any common stock;

	•	sell any option or contract to purchase any common stock;

	•	purchase any option or contract to sell any common stock;

	•	grant any option, right or warrant for the sale of any common stock;

	•	lend or otherwise dispose of or transfer any common stock; or

	•	enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise.

We have applied to have our common stock approved for quotation on the Nasdaq National Market under the symbol “NNSY.”

Before this offering, there has been no public market for our common stock. The initial public offering price was determined through negotiations among us and the representatives. In addition to prevailing market conditions, the factors considered in determining the initial public offering price were:


	•	the valuation multiples of publicly traded companies that the representatives believe to be comparable to us;

	•	our financial information;

	•	the history of, and the prospects for, our past and present operations, and the prospects for, and timing of, our future revenues;

	•	an assessment of our management, our past and present operations, and the prospects for, and timing of, our future revenues;

	•	the present state of our development; or

	•	the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.

An active trading market for our shares of common stock may not develop. It is also possible that after the offering the shares will not trade in the public market at or above the initial public offering price. The underwriters do not expect to sell more than five percent of the shares being offered in this offering to accounts over which they exercise discretionary authority.

Until the distribution of the shares is completed, Securities and Exchange Commission rules may limit the underwriters and selling group members from bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of our common stock, such as bids or purchases to peg, fix or maintain that price.

The underwriters may purchase and sell our common stock in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering. “Covered” short sales are sales made in an amount not greater than the underwriters’ option to purchase additional shares from the issuer in the offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the overallotment option. “Naked” short sales are any sales in excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common shares in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering.

The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions.

Similar to other purchase transactions, the underwriters’ purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of the common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market.

Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor any of the representatives make any representation that the representatives will engage in these transactions. If these activities are commenced, they may be discontinued at any time. These transactions may be effected on the Nasdaq National Market, in the over-the-counter market or otherwise.

In connection with this offering, underwriters and selling group members may engage in passive market making transactions in the common stock on the Nasdaq National Market in accordance with Rule 103 of Regulation M under the Securities Exchange Act of 1934 during a period beginning with the commencement of offers or sales of common stock and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker’s bid, that bid must then be lowered when specified purchase limits are exceeded.

At our request, the underwriters have reserved for sale, at the initial public offering price, up to five percent of the total number of shares of our common stock offered hereby to be sold to certain partners, employees, officers, directors and other persons associated with us. The number of shares of common stock available for sale to the general public in the offering will be reduced to the extent these persons purchase the reserved shares. Any reserved shares which are not orally confirmed for purchase

Merrill Lynch will be facilitating internet distribution for this offering to certain of its Internet subscription customers. Merrill Lynch intends to allocate a limited number of shares for sale to its online brokerage customers. An electronic prospectus is available on the web site maintained by Merrill Lynch. Other than the prospectus in electronic format, the information on the Merrill Lynch web site is not part of this prospectus.

The validity of the common stock offered hereby will be passed upon for us by Wilson Sonsini Goodrich & Rosati, Professional Corporation and for the underwriters by Latham & Watkins LLP. Investment partnerships comprised of members and persons associated with Wilson Sonsini Goodrich & Rosati and members of Wilson Sonsini Goodrich & Rosati own shares of our common stock representing less than 1% of our outstanding shares of common stock as of June 30, 2004.

Ernst & Young LLP, an independent registered public accounting firm, has audited our financial statements at December 31, 2002 and 2003, and for the period from inception (July 12, 2001) to December 31, 2001 and for each of the two years in the period ended December 31, 2003, as set forth in their report. We have included our financial statements in the prospectus and elsewhere in the registration statement in reliance on Ernst & Young LLP’s report, given on their authority as experts in accounting and auditing.

We have filed with the Securities and Exchange Commission, or SEC, a registration statement on Form S-1 under the Securities Act with respect to the common stock offered hereby. This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules filed as part of the registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, we refer you to the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The reports and other information we file with the SEC can be read and copied at the SEC’s Public Reference Room at 450 Fifth Street, N.W., Washington D.C. 20549. Copies of these materials can be obtained at prescribed rates from the Public Reference Section of the SEC at the principal offices of the SEC, 450 Fifth Street, N.W., Washington D.C. 20549. You may obtain information regarding the operation of the public reference room by calling 1(800) SEC-0330. The SEC also maintains a web site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

Once we undertake this offering, we will become subject to the information and periodic reporting requirements of the Securities Exchange Act and, in accordance therewith, file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information are available for inspection and copying at the SEC’s public reference rooms and the web site of the SEC referred to above. Our Internet address is http://www.nanosysinc.com.

We intend to provide our stockholders with annual reports containing, among other information, financial statements audited by an independent public accounting firm and we intend to make available to our stockholders quarterly reports containing unaudited financial data for the first three quarters of each fiscal year. We also intend to furnish other reports as we may determine or as required by law.

We have audited the accompanying balance sheets of Nanosys, Inc. as of December 31, 2002 and 2003, and the related statements of operations, redeemable convertible preferred stock and stockholders’ deficit and cash flows for the period from inception (July 12, 2001) to December 31, 2001 and for each of the two years in the period ended December 31, 2003. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Nanosys, Inc. at December 31, 2002 and 2003, and the results of its operations and its cash flows for the period from inception (July 12, 2001) to December 31, 2001 and for each of the two years in the period ended December 31, 2003, in conformity with U.S. generally accepted accounting principles.

The foregoing report is in the form that will be signed upon the completion of the restatement of the capital accounts described in Note 1 to the financial statements.

STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT



		Redeemable Convertible
		Preferred Stock				Common Stock					Additional
											Paid-In
		Shares		Value		Shares			Par Value		Capital


		(In thousands, except share amounts)
Sale of common stock to founders for cash			—	$	—		63,334		$	—	$	—
Sale of restricted stock to nonemployees for cash			—		—		700,000			1		1
Exercise of stock options for restricted stock in exchange for cash			—		—		321,667			—		29
Issuance of stock for services rendered			—		—		33,333			—		—
Issuance of stock in connection with technology license agreement			—		—		53,333			—		1
Sale of Series A redeemable convertible preferred stock, net of issuance costs of $102			1,833,333		1,548		—			—		—
Net loss and comprehensive loss			—		—		—			—		—

Balance at December 31, 2001			1,833,333		1,548		1,171,667			1		31
Sale of Series B redeemable convertible preferred stock, net of issuance costs of $51			4,166,667		14,949		—			—		—
Issuance of Series B redeemable convertible preferred stock warrants in connection with a line of credit agreement			—		40		—			—		—
Issuance of Series B convertible preferred stock warrants in connection with a operating lease agreement			—		73		—			—		—
Sale of stock for cash in connection with technology license agreements			—		—		3,333			—		1
Exercise of stock options and issuance of restricted stock in exchange for cash and notes receivable			—		—		535,000			1		155
Vesting of common stock from early exercises of stock options			—		—		1,772			—		1
Compensation related to grant of stock options to non- employees			—		—		—			—		41
Net loss and comprehensive loss			—		—		—			—		—

Balance at December 31, 2002			6,000,000		16,610		1,711,772			2		229
Sale of Series C redeemable convertible preferred stock, net of issuance costs of $159			6,649,341		37,084		—			—		—
Issuance of Series C redeemable convertible preferred stock warrants in connection with a research and development agreement			—		1,370		—			—		—
Sale of stock in connection with technology license agreements for cash below fair market value			—		—		30,000			—		12
Exercise of stock options for restricted stock in exchange for cash			—		—		5,000			—		2
Vesting of common stock from early exercises of stock options			—		—		72,558			—		27
Repurchase of unvested common stock from terminated employee			—		—		(45,555	)		—		(4	)
Deferred compensation related to options and restricted stock granted to employees			—		—		—			—		1,107
Amortization of employee deferred stock compensation			—		—		—			—		—
Compensation related to options and restricted stock issued to non-employees			—		—		—			—		964
Comprehensive loss:
	Net loss		—		—		—			—		—
	Unrealized gain on available-for-sale investments		—		—		—			—		—
Comprehensive loss

Balance at December 31, 2003 (carried forward)			12,649,341		55,064		1,773,775			2		2,337

[Continued from above table, first column(s) repeated]


								Accumulated
					Deferred			Other					Total
		Notes Receivable			Stock			Comprehensive		Accumulated			Stockholders’
		from Stockholders			Compensation			Income		Deficit			Deficit


		(In thousands, except share amounts)
Sale of common stock to founders for cash		$	—		$	—		$	—	$	—		$	—
Sale of restricted stock to nonemployees for cash			—			—			—		—			2
Exercise of stock options for restricted stock in exchange for cash			—			—			—		—			29
Issuance of stock for services rendered			—			—			—		—			—
Issuance of stock in connection with technology license agreement			—			—			—		—			1
Sale of Series A redeemable convertible preferred stock, net of issuance costs of $102			—			—			—		—			—
Net loss and comprehensive loss			—			—			—		(792	)		(792	)

Balance at December 31, 2001			—			—			—		(792	)		(760	)
Sale of Series B redeemable convertible preferred stock, net of issuance costs of $51			—			—			—		—			—
Issuance of Series B redeemable convertible preferred stock warrants in connection with a line of credit agreement			—			—			—		—			—
Issuance of Series B convertible preferred stock warrants in connection with a operating lease agreement			—			—			—		—			—
Sale of stock for cash in connection with technology license agreements			—			—			—		—			1
Exercise of stock options and issuance of restricted stock in exchange for cash and notes receivable			(145	)		—			—		—			11
Vesting of common stock from early exercises of stock options			—			—			—		—			1
Compensation related to grant of stock options to non- employees			—			—			—		—			41
Net loss and comprehensive loss			—			—			—		(7,088	)		(7,088	)

Balance at December 31, 2002			(145	)		—			—		(7,880	)		(7,794	)
Sale of Series C redeemable convertible preferred stock, net of issuance costs of $159			—			—			—		—			—
Issuance of Series C redeemable convertible preferred stock warrants in connection with a research and development agreement			—			—			—		—			—
Sale of stock in connection with technology license agreements for cash below fair market value			—			—			—		—			12
Exercise of stock options for restricted stock in exchange for cash			—			—			—		—			2
Vesting of common stock from early exercises of stock options			—			—			—		—			27
Repurchase of unvested common stock from terminated employee			—			—			—		—			(4	)
Deferred compensation related to options and restricted stock granted to employees			—			(1,107	)		—		—			—
Amortization of employee deferred stock compensation			—			74			—		—			74
Compensation related to options and restricted stock issued to non-employees			—			—			—		—			964
Comprehensive loss:
	Net loss		—			—			—		(9,169	)		(9,169	)
	Unrealized gain on available-for-sale investments		—			—			6		—			6

Comprehensive loss														(9,163	)

Balance at December 31, 2003 (carried forward)			(145	)		(1,033	)		6		(17,049	)		(15,882	)



		Redeemable Convertible
		Preferred Stock				Common Stock				Additional
										Paid-In
		Shares		Value		Shares		Par Value		Capital


		(In thousands, except share amounts)
Balance at December 31, 2003 (brought forward)			12,649,341	$	55,064		1,773,775	$	2	$	2,337
Issuance of Series C redeemable convertible preferred stock warrants in connection with a research and development agreement (unaudited)			—		1,723		—		—		—
Exercise of stock options for restricted stock in exchange for cash (unaudited)			—		—		44,136		—		17
Vesting of common stock from early exercises of stock options (unaudited)			—		—		33,682		—		16
Deferred compensation related to options and restricted stock granted to employees (unaudited)			—		—		—		—		11,413
Reversal of deferred stock compensation for cancellation of restricted stock granted to employees (unaudited)			—		—		—		—		(88	)
Amortization of employee deferred stock compensation (unaudited)			—		—		—		—		—
Compensation related to options and restricted stock issued to non-employees (unaudited)			—		—		—		—		503
Payment of notes receivable (unaudited)			—		—		—		—		—
Comprehensive income (loss):
	Net loss (unaudited)		—		—		—		—		—
	Unrealized gain on available-for-sale investments (unaudited)		—		—		—		—		—
Comprehensive loss (unaudited)

Balance at March 31, 2004 (unaudited)			12,649,341	$	56,787		1,851,593	$	2	$	14,198

[Continued from above table, first column(s) repeated]


								Accumulated
					Deferred			Other					Total
		Notes Receivable			Stock			Comprehensive		Accumulated			Stockholders’
		from Stockholders			Compensation			Income		Deficit			Deficit


		(In thousands, except share amounts)
Balance at December 31, 2003 (brought forward)		$	(145	)	$	(1,033	)	$	6	$	(17,049	)	$	(15,882	)
Issuance of Series C redeemable convertible preferred stock warrants in connection with a research and development agreement (unaudited)			—			—			—		—			—
Exercise of stock options for restricted stock in exchange for cash (unaudited)			—			—			—		—			17
Vesting of common stock from early exercises of stock options (unaudited)			—			—			—		—			16
Deferred compensation related to options and restricted stock granted to employees (unaudited)			—			(11,413	)		—		—			—
Reversal of deferred stock compensation for cancellation of restricted stock granted to employees (unaudited)						88			—		—			—
Amortization of employee deferred stock compensation (unaudited)			—			477			—		—			477
Compensation related to options and restricted stock issued to non-employees (unaudited)			—			—			—		—			503
Payment of notes receivable (unaudited)			145			—			—		—			145
Comprehensive income (loss):
	Net loss (unaudited)		—			—			—		(3,886	)		(3,886	)
	Unrealized gain on available-for-sale investments (unaudited)		—			—			15		—			15

Comprehensive loss (unaudited)														(3,871	)

Balance at March 31, 2004 (unaudited)		$	—		$	(11,881	)	$	21	$	(20,935	)	$	(18,595	)

Nanosys, Inc. (the “Company”) was incorporated in Delaware on July 12, 2001 and is currently engaged in the early stages of investigative research to develop nanotechnology-enabled systems. The Company is applying this investigative research to develop products based on its core technology that incorporate proprietary, high performance inorganic nanostructures with integrated functionality for multiple industries. The Company is utilizing its technology to develop products in multiple industries such as energy, defense, electronics, life sciences and information technology. The Company has established collaborations with partners and government agencies that the Company believes could benefit significantly from the incorporation of nanotechnology-enabled products into their end user products. The Company’s product development activities and collaborations typically contemplate several phases, including an investigation phase, a development phase and a commercialization phase. The Company is currently in the investigation phase of all of its potential products, including those pursuant to collaborations with partners. As part of its business strategy, the Company intends to enter into additional collaborations to enter multiple markets and expand its core technology across additional multiple industries and applications. The Company expects that it will continue to enter into investigative stage research under new collaborations, while other potential products and related collaboration arrangements proceed to development and commercialization phases. The Company has also entered into arrangements with United States government agencies. The Company believes its strategy for pursuing government contracts and grants to focus on opportunities will enable the Company to further its core technology development. The Company intends to continue to pursue government contracts and grants that enable it to develop dual use products and technologies that may be sold in both government and commercial markets. In prior years, the Company was considered to be in the development stage for accounting purposes.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying. Actual results could differ from those estimates.

The financial statements and related notes thereto as of March 31, 2004 and for the three months ended March 31, 2003 and 2004 are unaudited and, in the opinion of management, include all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of results for such interim periods. The results of operations for the three months ended March 31, 2004 are not necessarily indicative of the results expected for the entire year.

In June 2004, the Board of Directors and stockholders approved, a 1 for 3 reverse split of its redeemable convertible preferred stock and common stock. An amended and restated certificate of incorporation will be filed prior to the closing of this offering effecting the 1 for 3 reverse stock split and setting the authorized common stock and authorized preferred stock to 120,000,000 and 10,000,000 shares, respectively. All share and per share amounts for all periods presented in the accompanying financial statements have been retroactively adjusted to give effect to the stock split.

Financial instruments that potentially subject the Company to credit risk consist of investments and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company’s investments are placed with high credit-quality financial institutions and issuers. The Company generally does not require collateral to support the financial instruments subject to credit risk.

The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not recorded material losses due to customer nonpayment.

During 2002 approximately 71% and 29% of the Company’s revenue was derived from two companies. For 2003, the Company derived 53%, 19% and 11% of its revenue from three companies. For the three months ended March 31, 2003, the Company derived 67% and 23% of its revenue from two companies. For the three months ended March 31, 2004, the Company derived 27%, 26%, 19% and 13% of its revenue from four companies. The Company’s largest customer in 2002 and 2003 was located in Japan. All other customers were located in the United States.

The Company considers all highly liquid investments with an original maturity of 90 days or less at the date of purchase to be cash equivalents. Investments in debt securities and marketable equity securities are classified as “available-for-sale”. The Company views its available-for-sale portfolio as available for use in current operations. Accordingly, the Company has classified all investments as current assets, even though the stated maturity may be more than one year beyond the current balance sheet date. Available-for-sale investments are carried at fair value based on quoted market prices, with unrealized gains and losses reported in accumulated other comprehensive income, as a separate component of stockholders’ equity (deficit).

The cost basis of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. This amortization and accretion is included in interest income (expense) and other income, net. Realized gains and losses are also included in interest income (expense) and other income, net. The cost of all securities sold is based on the specific identification method.

Financial instruments consist principally of cash, available-for-sale investments and notes payable. The carrying value of notes payable approximates its fair value, as determined from information obtained from market sources and management estimates.

The Company receives payments under research and development contracts and government grants. These payments are non-refundable but are reported as deferred revenue until they are recognizable as revenue. The Company follows the following principles in recognizing revenue:


	•	Fixed-fee research and development contracts generally provide the Company with an up-front fee and a contractually defined period of service. Fees for services the Company performs under fixed-fee research and development contracts are recognized ratably over the period the Company performs these services.

	•	Variable-fee research and development contracts generally provide the Company with fees based upon an agreed-upon rate for time incurred by full time equivalent (“FTE”) research staff. Fees for services the Company performs under variable-fee research and development contracts are recognized based upon the FTE time incurred.


	•	Government grants generally provide the Company with fixed payments and a contractually defined period of research. Payments received under grants are recognized as revenues ratably over the period the Company performs the research. The Company retains ownership and exclusive rights to all inventions made under these arrangements except for nonexclusive, nontransferable, irrevocable, paid-up licenses granted to the United States government to practice directly or indirectly the subject invention throughout the world.

Under all arrangements, revenue is not recognized unless there is persuasive evidence of an arrangement, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and the collection of the related receivable is probable. Upon the completion of each of the Company’s current research and development contracts and government grants, no further obligations exist under these arrangements. The Company retains the rights to commercialize the technology it developed under research and development contracts and government grants without any royalty obligations.

In order to meet its customer’s needs, the Company enters into revenue arrangements with multiple deliverables. For example, the arrangements with the United States government may include a combination of research and development services and limited license rights. Multiple element revenue agreements entered into on or after July 1, 2003 are evaluated under Emerging Issues Task Force No. 00-21, “Revenue Arrangements with Multiple Deliverables,” to determine whether the delivered item has value to the customer on a stand-alone basis and whether objective and reliable evidence of the fair value of the undelivered item exists. Deliverables in an arrangement that do not meet the separation criteria in Issue 00-21 must be treated as one unit of accounting for purposes of revenue recognition. Generally, the Company treats its revenue arrangements with multiple deliverables as a combined unit of accounting and recognizes revenue when it delivers the services.

In September 2003, in connection with a revenue arrangement with a customer, the Company issued warrants for the purchase of Series C redeemable convertible preferred stock. In accordance with Emerging Issues Task Force (“EITF”) Issue No. 01-9, Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor’s Products), management estimated the portion of the consideration received from the customer that related to the issuance of the warrants and the portion that related to revenue for the performance of research and development services. The warrants become exercisable by the customer as the customer makes milestone payments to the Company. Until the warrants are fully exercisable, they are subject to remeasurement at fair value. In 2003, the Company received $1.0 million in cash proceeds which were attributed entirely to the value of the warrants. Because the value of the warrant exceeded the estimated total cash proceeds under the arrangement, the Company did not recognize any revenue under the arrangement and therefore recorded $370,000 of stock-based compensation in research and development expense in 2003. As of March 31, 2004, the warrants remained unvested and were remeasured at fair value. Because the estimated fair value of the Company’s stock increased during the three months ended March 31, 2004, additional expense was recorded related to the warrants. Accordingly, the Company recorded $723,000 of stock-based compensation in research and development expense during the three months ended March 31, 2004. Additional expense may be recorded in future periods if the estimated fair value of the warrants increases further. The warrants will expire if not exercised prior to the closing of the Company’s initial public offering.

Property and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization is provided using the straight-line method over the estimated useful lives of the related assets. Property and equipment are generally depreciated over a useful life of three years, except leasehold improvements, which are amortized over the term of the lease.

Research and development costs are expensed as incurred. Research and development costs consist of salaries, employee benefits, license fees, and payments to research organizations and professional service providers.

The Company accounts for employee stock options using the intrinsic-value method in accordance with Accounting Principles Board (“APB”) Opinion No. 25, and related interpretations, and has adopted the disclosure-only provisions of Statement of Financial Accounting Standards (“SFAS”) No. 123, Accounting for Stock-Based Compensation. The pro forma net loss disclosure has been determined as if the Company had accounted for its employee stock options under the fair value method of SFAS No. 123. The resulting effect on net loss pursuant to SFAS No. 123 is not likely to be representative of the effects on net loss pursuant to SFAS No. 123 in future years, since future years are likely to include additional grants and the impact of future years’ vesting.

The Company estimates the fair value of stock options using the Black-Scholes model. The following table illustrates the weighted average assumptions for the Black-Scholes model used in determining the fair value of options granted to employees:

The following table illustrates the effect on net loss had the Company applied the fair value provisions of SFAS No. 123 to employee stock compensation (in thousands, except per share amounts):

Comprehensive income (loss) is comprised of net loss and other comprehensive income. Other comprehensive income includes unrealized gains and losses on the Company’s available-for-sale securities.

The Company accounts for long-lived assets in accordance with the provisions of SFAS No. 144, Accounting for Impairment or Disposal of Long Lived Assets. This statement requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. As of December 31, 2003, the Company has not identified any impairment of its long-lived assets.

The Company utilizes the liability method of accounting for income taxes as required by SFAS No. 109, Accounting for Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax reporting bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that the deferred tax asset will not be recovered. Currently, there is no provision for income taxes as the Company has incurred operating losses to date.

On March 31, 2004, the Financial Accounting Standards Board (the “FASB”) issued its Exposure Draft, Share-Based Payment, which is a proposed amendment to FASB Statement No. 123, Accounting for Stock-Based Compensation. Generally, the approach in the Exposure Draft is similar to the approach described in Statement 123. However, the Exposure Draft would require all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. The FASB expects to issue a final standard late in 2004 that would be effective for our 2005 fiscal year. The pro forma impact of the adoption of Statement 123 on the Company’s historical financial statements is included in the footnotes to the financial statements. The Company expects to continue to grant stock-based compensation to employees and the impact of the adoption of the new standard, when and if issued, may have a material impact on its future results of operations.

As of December 31, 2002, the Company’s cash and cash equivalents of $10,828,000 included deposits in money market investment accounts. The table below outlines the Company’s available-for-sale investments as of December 31, 2003 (in thousands):

There were no material realized gains or losses on sales of available-for-sale investments in any of the periods presented. The amortized cost and estimated fair value of available-for-sale investments in debt securities at December 31, 2003, by contractual maturity, were as follows (in thousands):

In 2002, the Company entered into an equipment line of credit, which provided for up to a maximum of $2,500,000 to finance the purchases of equipment. Borrowings under the equipment line of credit convert to notes payable that are repayable ratably over 36 months, starting in the month following the borrowing. Borrowings outstanding bear interest at a rate of 5% per annum, and are secured by the financed property and equipment of the Company. At December 31, 2003, there was $1,543,000 outstanding under the equipment line of credit, which was secured by related property and equipment. Subject to limited exceptions, the Company is restricted in its ability to pay dividends on or making distributions to its capital stock by the covenants contained in the equipment line of credit. There were no further borrowings available under the equipment line of credit as of December 31, 2003. Subject to limited exceptions, the Company may not pay dividends on or make distributions with respect to its capital stock by the covenants contained in the equipment line of credit.

In May 2002, in connection with the equipment line of credit, the Company issued warrants to purchase 13,750 shares of Series B redeemable convertible preferred stock to the lender. The warrants are immediately exercisable at an exercise price of $3.60 per share at the option of the holder and expire in

2012. The Company ascribed a fair value of $40,000 to these warrants, as determined by the Black-Scholes option pricing model, using the following assumptions: a ten-year term, volatility of 0.75, no dividend yield and a 4% risk free rate. The Company recorded the fair value of the warrants, and amortized the value into interest expense on a straight-line basis over the commitment period of the equipment line of credit. During 2002 and 2003, the Company recorded $32,000 and $8,000, respectively, of interest expense related to the amortization of these warrants.

Future minimum annual principal payments due under the equipment line of credit are as follows at December 31, 2003 (in thousands):

The Company has several patent license agreements with various institutions for the right of the Company to use certain technology incorporated in the Company’s potential products. The Company can terminate these agreements at anytime, or the agreements expire upon the expiration or abandonment of the related licensed patents. The Company is also obligated to pay specified royalty fees on sales of licensed products, as defined. In the event that the Company does not obtain waivers of any minimum royalty obligation, the following table reflects the Company’s minimum royalties to the institutions (in thousands):

In connection with the execution of a patent license agreement, the Company is obligated to pay a license milestone payment in cash. The dollar amount of the milestone payment will be 23,333 (subject to adjustment for splits, dividends and the like of the Company’s capital stock) multiplied by the initial public offering price, which will be payable at various times over twenty-six months after the closing of an initial public offering. The Company is expected to expense this license milestone when and if the milestone is achieved.


	The Company leases a facility under an operating lease that expires in December 2005. In connection with entering into the operating lease, the Company issued warrants to purchase 25,000 shares of Series B redeemable convertible preferred stock to the landlord in March 2002. The warrants are immediately exercisable at an exercise price of $3.60 per share at the option of the holder and expire in

2012. The Company ascribed a fair value of $73,000 to these warrants, as determined by the Black-Scholes option pricing model using the following assumptions: a ten-year term, volatility of 0.75, no dividend yield and a 4% risk free interest rate. The Company recorded the fair value of the warrants and is amortizing the fair value of the warrants into rent expense on a straight-line basis over the term of the operating lease. During the years ended December 31, 2002 and 2003, the Company recorded $16,000 and $19,000 related to the amortization of these warrants.

The Company entered into a sublease agreement with a related party for a portion of its current rented space. The sublease expires in April 2004.

Rent expense for the period from inception to December 31, 2001, and for 2002 and 2003, was $0, $711,000 and $1,194,000, respectively. Total sublease income was $0, $86,000 and $282,000 for the period from inception to December 31, 2001, and for 2002 and 2003, respectively. At December 31, 2003, the minimum future rental payments and sublease income, under operating lease arrangements, were as follows (in thousands):


	The Company has consulting arrangements with members of its scientific advisory board guaranteeing minimum cash payments of $178,000 per year in 2004, 2005 and 2006.

As disclosed in Note 5, the Company has entered into a sublease arrangement that expires in April 2004 with a related party. The related party is a company for which the chief executive officer of Nanosys serves on the Board of Directors. The amount of sublease income recorded under this sublease arrangement was $86,000 and $282,000 in 2002 and 2003, respectively. The amount of sublease income was $60,000 and $69,000 for the three months ended March 31, 2003 and 2004, respectively. As security for the sublease, the Company required a security deposit from the subtenant of approximately $23,000 in

cash. The security deposit is classified in accrued expenses as a current liability on the balance sheet as of December 31, 2003 and March 31, 2004.

At December 31, 2003, the Company held two full recourse stockholder notes receivable in the amount of $145,000 from two officers in consideration for the exercise of stock options for 401,667 shares of common stock. The shares issued are subject to a repurchase agreement under which the shares can be repurchased at the lower of the shares original issuance price or the fair market value of the shares at the date of repurchase. The notes accrued interest at a rate of 6% per annum and were reflected as a reduction of stockholders’ equity. The notes were repaid in full in cash in March 2004.

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, less outstanding shares subject to repurchase. Outstanding shares subject to repurchase are not included in the computation of basic net loss per share until the Company’s time-based repurchase rights have lapsed. The Company has excluded all common stock subject to repurchase by the Company, preferred stock and stock options from the calculation of historical diluted net loss per common share because all such securities are antidilutive for all periods presented. The following table sets forth the common stock equivalents outstanding as of December 31, 2003 and March 31, 2004 that may be included in diluted earnings per share in future periods:

The unaudited pro forma basic and diluted net loss per share calculations assume the conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock using the as-if-converted method as of the date of issuance.

The redeemable convertible preferred stock is redeemable upon the liquidation or winding up of the Company, a greater than 50% change of control or sale of substantially all of the assets of the Company. As the redemption event is outside the control of the Company, all shares of redeemable convertible preferred stock have been presented outside of permanent equity. Further, the Company has not adjusted the carrying values of the Series A, B, or C redeemable convertible preferred stock to the redemption value of such shares, since it is uncertain whether or when a redemption event will occur. If it becomes certain that the redeemable convertible preferred stock will become redeemable, the amount reclassified from equity will be equal to the fair value of the instrument on the date that the contingent event becomes certain.

The Board of Directors is authorized to determine the rights, preferences and terms of each series of redeemable convertible preferred stock. Collectively, Series A, B and C are referred to as “redeemable convertible preferred stock” and have similar rights and preferences as outlined below (in thousands, except share amounts):

Each series of redeemable convertible preferred stock is convertible at the stockholders’ option at any time on a one-for-one basis, subject to adjustment for antidilution. Conversion is automatic upon the closing of a firm commitment underwritten public offering of common stock registered under the Securities Act of 1933, with aggregate offering proceeds exceeding $30,000,000 and an offering price of at least $16.80 per share (appropriately adjusted for any stock splits, stock dividends, recapitalization, or similar events) or upon agreement of the majority of holders of the outstanding shares.

Holders of the Series A, B and C redeemable convertible preferred stock, in preference to the holders of common stock, are entitled to receive, when and as declared by the Board of Directors, cash dividends at the rate of $0.072, $0.288, and $0.447, respectively, on each outstanding share of redeemable convertible preferred stock. Such dividends are noncumulative. Upon conversion to common stock, the holder is entitled to receive any declared and unpaid dividends on the shares of redeemable convertible preferred stock being converted. No dividends have been declared through December 31, 2003.

In the event of a liquidation or winding up of the Company, holders of the Series A, B and C redeemable convertible preferred stock have a liquidation preference of $0.90, $3.60, and $5.601 per share, respectively, together with any declared but unpaid dividends, over holders of common shares. If the assets of the Company available for distribution are insufficient to pay each holder of the redeemable convertible preferred stock the full amount of the preference payment, then the shareholders are entitled to share ratably in the distribution. After payment of the full liquidation preference of the redeemable convertible preferred stock, the remaining assets of the Company shall be distributed among the holders of the preferred and common stock pro rata based on the number of shares of stock held. The redeemable convertible preferred stockholders’ distribution is limited to 225% of their respective initial investment.

Each share of redeemable convertible preferred stock has voting rights equal to the number of common shares into which the preferred stock is convertible at the record date.

As of December 31, 2003 the Company had issued a total of 38,750 warrants to purchase Series B redeemable convertible preferred stock at $3.60 per share, in connection with an equipment line of credit and an operating lease.

The Company has also issued 241,028 warrants for the purchase of Series C redeemable convertible preferred stock at an exercise price of $0.003 per share in connection with a research and development agreement signed in September 2003. The warrants expire in 2008, or upon the closing of an initial public offering. The warrants become exercisable by the collaborative partner as the collaborative partner makes milestone payments to the Company. In accordance with EITF 01-9, Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor’s Products), the Company has allocated the portion of the consideration received from the collaborative partner that relates to the issuance of the warrants and the portion that relates to the revenue for the performance of research and development services. Until the warrants are fully exercisable, they are subject to remeasurement at fair value. Because of the increase in the estimated fair value of the Company’s Series C redeemable convertible preferred stock subsequent to September 2003, the amount of consideration allocated to the equity component of this arrangement exceeds the cash consideration received. As a result of this condition, no revenue was recognized for research and development services performed under this collaborative arrangement and $370,000 of additional research and development expense was recorded in 2003. As of March 31, 2004, the warrants remained unvested and were remeasured at fair value. Because the estimated fair value of the Company’s stock increased during the three months ended March 31, 2004, additional expense was recorded related to the warrants. Accordingly, the Company recorded $723,000 of research and development expense related to the warrants during the three months ended March 31, 2004. Additional expense may be recorded in future periods until the warrants are fully exercisable if the fair value of the Series C redeemable convertible preferred stock increases further.

Under the 2001 Stock Plan (“the Plan”), as amended, the Company may grant restricted stock, incentive and nonqualified stock options to employees, officers, directors, advisors, scientific advisory board members and consultants of the Company. All option grants are issued at an exercise price equal to 100% of the estimated fair value of common stock, as established by the Board of Directors on the date of grant; provided, however, that an individual who owns more than 10% of the total combined voting power of all classes of outstanding stock of the Company shall be granted options with a purchase price of at least 110% of the estimated fair value of the common stock on the date of grant.

Certain options granted under the Plan may be exercisable immediately and all options vest over periods determined by the Board of Directors, generally up to 5 years, and expire no more than 10 years after the date of grant. Stock which is purchased prior to the option vesting is subject to the Company’s right of repurchase, which lapses over the vesting period. Stock option activity for the period from inception (July 12, 2001) through March 31, 2004 is as follows:

Options presented as exercised in the table above for the year ended December 31, 2003 and the three months ended March 31, 2004 include the vesting of restricted common stock associated with the early exercise of stock options in previous periods.

The following table summarizes information concerning options outstanding as of December 31, 2003:

The weighted-average fair value of options granted for the period from inception to December 31, 2001 and during 2002 and 2003 was $0.06, $0.18, and $5.61 per share, respectively. The weighted-average fair value of options granted for the three months ended March 31, 2004 was $13.77 per share.

No employee stock compensation expense was reflected in the Company’s reported net loss in any period prior to December 31, 2002, as all options granted had an exercise price equal to the fair value of the underlying common stock on the date of the grant. During 2003, stock options were granted with exercise prices that were at the fair value of the common stock at the date of grant as determined by the Board of Directors. Subsequent to the commencement of the initial public offering process, the Company reevaluated the fair value of its common stock and determined that certain of the stock options granted during 2003 were granted at exercise prices that were below the reassessed fair value of the common stock on the date of grant. Accordingly, deferred stock compensation of $1,107,000 was recorded during 2003 in accordance with APB Opinion No. 25. The deferred compensation will be amortized straight-line over the vesting period of the related awards, generally five years. For 2003 the Company recorded employee stock compensation expense of $74,000. During the three months ended March 31, 2004, deferred stock compensation of $11.4 million was recorded and total employee stock compensation expense of $477,000 was recorded.

Stock-based compensation arrangements for nonemployees are accounted for in accordance with SFAS No. 123, as amended by SFAS No. 148, and EITF Issue No. 96-18, Accounting for Equity Instruments that Are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services, using a fair value approach. Compensation expense associated with these arrangements is subject to periodic remeasurement over the vesting terms as earned.

During 2002 and 2003, the Company granted options and restricted stock purchase awards of 21,000 shares and 44,000 shares, respectively, to acquire shares of common stock to non-employees. Stock compensation expense of $41,000 and $964,000 was recorded for the years ended December 31, 2002, and 2003, respectively. For the three months ended March 31, 2004, the Company issued 80,000 options and restricted stock purchase awards to acquire shares of common stock to nonemployees. Stock compensation expense of $503,000 was recorded for the three months ended March 31, 2004. The deferred compensation expense represented the difference between the fair market value and the exercise price of the common stock options for shares vesting during the period.

The following table illustrates the weighted average assumptions for the Black-Scholes model used in determining the fair value of options granted to nonemployees:

The Company has issued restricted common stock to employees, consultants, officers and directors of the Company. Shares issued pursuant to a restricted stock purchase agreement are subject to repurchase by the Company solely at its option. In the event of termination of services, the Company has the right to repurchase unvested shares at the original purchase price. The restrictions generally lapse over a five year vesting period.

In accordance with EITF Issue No. 00-23, Issues Related to the Accounting for Stock Compensation under APB Opinion No. 25 and FASB Interpretation No. 44, the shares issued pursuant to the early exercise of stock options or restricted stock purchase awards are not deemed to be issued until those shares vest. Therefore, payments received by the Company for the exercise price of stock options or restricted stock purchase awards that were early-exercised after March 21, 2002 are recorded as a liability for early exercise of stock options and restricted stock purchase awards on the balance sheet, and will be transferred into common stock and additional paid-in capital as the shares vest. A summary of activity related to restricted common stock, excluding restricted shares issued after March 21, 2002, from inception to March 31, 2004 is set forth below:

At December 31, 2003, the Company held two full recourse notes receivable in the amount of $145,000 from two officers in consideration for the exercise of stock options for 401,667 shares of common stock. The shares issued are subject to a repurchase agreement under which the shares can be repurchased

at the lower of the shares original issuance price or the fair market value of the shares at the date of repurchase. The notes accrue interest at a rate of 6% per annum and are reflected as a reduction of stockholders’ equity. The notes were repaid in full in cash in March 2004.

The Company is required to reserve and keep available out of its authorized but unissued shares of common stock a number of shares sufficient to effect the conversion of all outstanding shares of redeemable convertible preferred stock, plus shares granted and available for grant under the Company’s stock option plans. The Company had reserved shares of common stock for future issuance as of December 31, 2003 and March 31, 2004 as follows:

The Company sponsors an employee benefit plan under Section 401(k) of the Internal Revenue Code. The plan allows employees to make pretax contributions of up to the maximum allowable amount set by the Internal Revenue Service. In addition, the Company may make discretionary contributions to the plan. To date, the Company has not made any contributions to the plan.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities were as follows (in thousands):

Realization of deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. Accordingly, deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $0.3 million, $2.8 million and $3.4 million during the period from inception to December 31, 2001 and 2002 and 2003, respectively.

As of December 31, 2003, the Company had net operating loss carryforwards for federal income tax purposes of approximately $13.9 million which will expire beginning in 2021 and California net operating loss carryforwards of approximately $10.1 million which will expire beginning in 2013. The Company also has federal and California research and development tax credit carryforwards of approximately $295,000 and $279,000 respectively. The federal research tax credits will begin to expire in 2021, and the California research tax credits have no expiration date.

Utilization of the Company’s net operating loss and research tax credit carryforwards may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. Such an annual limitation could result in the expiration of net operating losses and credits before utilization.

The Company has certain agreements with customers and collaborators that contain indemnification provisions. In such provisions, the Company typically agrees to indemnify the customer or collaborator against certain types of third-party claims. The Company would accrue for known indemnification issues if a loss were probable and could be reasonable estimated. The Company would also accrue for estimated incurred but unidentified issues based on historical activity. There was no accrual for or expense related to indemnification issues for any period presented.

In April 2004, the Company’s Board of Directors authorized the filing of a registration statement with the Securities and Exchange Commission in connection with the Company’s proposed initial public offering of its common stock. If the offering is completed upon the terms presently contemplated, all outstanding shares of redeemable convertible preferred stock outstanding as of March 31, 2004 will automatically convert into 12,649,341 shares of common stock immediately prior to the closing of the proposed offering. Unaudited pro forma stockholders’ equity at March 31, 2004 reflects the automatic conversion of outstanding shares of redeemable convertible preferred stock that would occur upon completion of the offering as if that conversion had happened as of the balance sheet date.

In March 2004, the Board of Directors increased the number of shares of common stock available for future grant under the 2001 Stock Plan by 1,033,333 shares. In April 2004, the Company granted employees options to acquire 88,000 shares of common stock at a weighted average exercise price of $3.00 per share. In May and June 2004, the Company granted employees options to acquire 114,000 shares of common stock at a weighted average exercise price of $4.60 per share. As a result, the Company estimates that it will recognize $2.4 million in employee deferred stock compensation that will be amortized to expense over the five-year vesting period.

In April 2004, the Company issued 44,635 shares of Series C redeemable convertible preferred stock for $5.601 per share to a member of its board of directors resulting in aggregate net cash proceeds of $250,000. The Company will record stock-based compensation of approximately $540,000, based on the difference between the issuance price and the deemed fair value on the transaction date.

In April 2004, the Board of Directors adopted the 2004 Stock Plan. The 2004 Stock Plan provides for the grant of incentive and nonstatutory stock options to employees, directors and consultants. As of April 15, 2004, a total of 1,000,000 shares of common stock were reserved for issuance pursuant to the 2004 Stock Plan. In addition, shares reserved under the 2004 Stock Plan will also include (a) shares reserved but unissued under the 2001 Stock Plan as of the effective date of the proposed initial public offering, (b) shares returned to the 2001 Stock Plan as the result of termination of options or the repurchase of shares issued under such plan, and (c) annual increases in the number of shares available for issuance on the first day of each fiscal year beginning on January 1, 2005, equal to the lesser of:


	•	5% of the outstanding shares of common stock on the first day of the Company’s fiscal year.

	•	2,000,000 shares, or

	•	an amount the Company’s board may determine.

Subsequent to March 31, 2004, the remaining cash proceeds of $2 million were received and the warrants for the purchase of Series C redeemable convertible preferred stock have become fully exercisable. As a result, the remeasurement of the warrants at fair value has ceased. The Company expects to record approximately $200,000 of research and development expense during the three months ended June 30, 2004.

Through and including , 2004 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

The following table sets forth the costs and expenses, other than the underwriting discounts, payable by the registrant in connection with the sale of the securities being registered. All amounts are estimates except the SEC registration fee, the NASD filing fee and the Nasdaq/ National Market listing fee.

As permitted by Section 145 of the Delaware General Corporation Law, the registrant’s amended and restated certificate of incorporation includes a provision that eliminates the personal liability of its directors for monetary damages for breach or alleged breach of their duty of care. In addition, as permitted by Section 145 of the Delaware General Corporation Law, the bylaws of the registrant provide that: (1) the registrant is required to indemnify its directors and executive officers and persons serving in these capacities in other business enterprises at the registrant’s request, to the fullest extent permitted by Delaware law, including in those circumstances in which indemnification would otherwise be discretionary; (2) the registrant may, in its discretion, indemnify employees and agents in those circumstances where indemnification is not required by law; (3) the registrant is required to advance expenses, as incurred, to its directors and executive officers in connection with defending a proceeding, except that it is not required to advance expenses to a person against whom the registrant brings a claim for breach of the duty of loyalty, failure to act in good faith, intentional misconduct, knowing violation of law or deriving an improper personal benefit; (4) the rights conferred in the bylaws are not exclusive, and the registrant is authorized to enter into indemnification agreements with its directors, executive officers and employees; and (5) the registrant may not retroactively amend the bylaw provisions in a way that it adverse to our directors, executive officers and employees in these matters.

The registrant’s policy is to enter into indemnification agreements with each of its directors and executive officers that provide the maximum indemnity allowed to directors and executive officers by Section 145 of the Delaware General Corporation Law and the bylaws, as well as certain additional procedural protections. In addition, the indemnification agreements provide that the registrant’s directors and executive officers will be indemnified to the fullest possible extent not prohibited by law against all expenses, including attorney’s fees, and settlement amounts paid or incurred by them in any action or proceeding, including any derivative action by or in the right of the registrant, on account of their services as directors or executive officers of the registrant or as directors or officers of any other company or enterprise when they are serving in these capacities at the request of the registrant. The registrant will not be obligated pursuant to the indemnification agreements to indemnify or advance expenses to an indemnified party with respect to proceedings or claims initiated by the indemnified party and not by way of defense, except with respect to proceedings specifically authorized by the registrant’s board of directors or brought to enforce a right to indemnification under the indemnification agreement, the registrant’s bylaws or any statute or law. Under the

agreements, the registrant is not obligated to indemnify the indemnified party (1) for any expenses incurred by the indemnified party with respect to any proceeding instituted by the indemnified party to enforce or interpret the agreement, if a court of competent jurisdiction determines that each of the material assertions made by the indemnified party in any proceeding was not made in good faith or was frivolous; (2) for any amounts paid in settlement of a proceeding unless the registrant consents to such settlement; (3) with respect to any proceeding brought by the registrant against the indemnified party for willful misconduct, unless a court determines that each of such claims was not made in good faith or was frivolous; (4) on account of any suit in which judgment is rendered against the indemnified party for an accounting of profits made from the purchase or sale by the indemnified party of securities of the registrant pursuant to the provisions of §16(b) of the Securities Exchange Act of 1934, and related laws; (5) on account of the indemnified party’s conduct which is finally adjudged to have been knowingly fraudulent or deliberately dishonest, or to constitute willful misconduct or a knowing violation of the law; (6) an account of any conduct from which the indemnified party derived an improper personal benefit; (7) on account of conduct the indemnified party believed to be contrary to the best interests of the registrant or its stockholders; (8) on account of conduct that constituted a breach of the indemnified party’s duty of loyalty to the registrant or its stockholders; or (9) if a final decision by a court having jurisdiction in the matter shall determine that such indemnification is not lawful.

The indemnification provision in the bylaws and the indemnification agreements entered into between the registrant and its directors and executive officers may be sufficiently broad to permit indemnification of the registrant’s officers and directors for liabilities arising under the Securities Act of 1933.

Reference is made to the following documents filed as exhibits to this registration statement regarding relevant indemnification provisions described above and elsewhere herein:

(1) In October 2001, the Registrant sold an aggregate of 1,833,329 shares of its series A preferred stock to investors at a price of $0.90 per share for an aggregate purchase price of $1,649,999.

(2) In January and February 2002, the Registrant sold an aggregate of 4,166,661 shares of its series B preferred stock to investors at a price of $3.60 per share for an aggregate purchase price of $15,000,004.

(3) In April and May 2003 and April 2004, the Registrant sold an aggregate of 6,693,962 shares of its series C preferred stock to investors at a price of $5.601 per share for an aggregate purchase price of $37,492,958.

The sales of the above securities were deemed to be exempt from registration in reliance on Section 4(2) of the Securities Act or Regulation D promulgated thereunder as transactions by an issuer not involving any public offering. All recipients were either accredited or sophisticated investors, as those terms are defined in the Securities Act and the regulations promulgated thereunder. The recipients of securities in each such transaction represented their intention to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the share certificates and other instruments issued in such transactions. All recipients either received adequate information about the Registrant or had access, through employment or other relationships, to such information.

Since inception in July 2001, the Registrant issued an aggregate of 2,039,724 shares of the Registrant’s common stock to employees, consultants and directors pursuant to the exercise of stock options and stock purchase rights under the Registrant’s 2001 Amended Stock Plan, for aggregate consideration of $833,337.

The sales of the above securities were deemed to be exempt from registration in reliance on Rule 701 promulgated under Section 3(b) under the Securities Act as transactions pursuant to a compensatory benefit plan or a written contract relating to compensation.

(1) In August and September 2001, the Registrant sold an aggregate of 763,307 shares of common stock at a price of $0.003 per share to certain founders, employees and members of the Registrant’s Scientific Advisory Board for an aggregate purchase price of $2,290.

(2) In October 2001, the Registrant sold an aggregate of 53,333 shares of common stock at a price of $0.003 per share to The President and Fellows of Harvard College in connection with the license of certain patent rights for an aggregate purchase price of $160.

(3) In October 2001, the Registrant issued an aggregate of 33,333 shares of common stock to an individual in connection with a settlement agreement and mutual release with an aggregate value of $100.

(4) In April 2002, the Registrant sold an aggregate of 3,333 shares of common stock at a price of $0.36 per share to Shellwater & Co. (as nominee of the Regents of the University of California) in connection with the license of certain patent rights for an aggregate purchase price of $1,200.

(5) In January 2003, the Registrant sold an aggregate of 6,666 shares of common stock at a price of $0.36 per share to The President and Fellows of Harvard College in connection with the license of certain patent rights for an aggregate purchase price of $2,400.

(6) In April 2003, the Registrant sold an aggregate of 3,333 shares of common stock at a price of $0.45 per share to an individual and WS Investment Company, LLC for an aggregate purchase price of $1,500.

(7) In April 2003, the Registrant sold an aggregate of 16,666 shares of common stock at a price of $0.36 per share to the Massachusetts Institute of Technology in connection with the license of certain patent rights for an aggregate purchase price of $6,000.

(8) In June 2003, the Registrant sold an aggregate of 3,333 shares of common stock at a price of $0.57 per share to The President and Fellows of Harvard College in connection with the license of certain patent rights for an aggregate purchase price of $1,900.

(9) In December 2003, the Registrant sold an aggregate of 3,333 shares of common stock at a price of $0.57 per share to the Trustees of Columbia University in the City of New York in connection with the license of certain patent rights for an aggregate purchase price of $1,900.

The sales of the above securities were deemed to be exempt from registration in reliance on Section 4(2) of the Securities Act as transactions by an issuer not involving any public offering. All recipients were either accredited or sophisticated investors, as those terms are defined in the Securities Act and the regulations promulgated thereunder. The recipients of securities in each such transaction represented their intention to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the share certificates and other instruments issued in such transactions. All recipients either received adequate information about the Registrant or had access, through employment or other relationships, to such information.

a. Exhibits. The following exhibits are included herein or incorporated herein by reference:


(1)	Pursuant to a request for confidential treatment, portions of the Exhibit have been redacted from the publicly filed document and have been furnished separately to the SEC as required by Rule 406 under the Securities Act.

Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes to provides to the underwriter at the closing specified in the underwriting agreements, certificates in such denominations and registered in such names, as required by the underwriter to permit prompt delivery to each purchaser.


	(1) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

	(2) For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this amendment number 6 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, State of California on July 15, 2004.

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, THIS AMENDMENT TO THE REGISTRATION STATEMENT HAS BEEN SIGNED BY THE FOLLOWING PERSONS IN THE CAPACITIES AND ON THE DATES INDICATED:


(1)	Pursuant to a request for confidential treatment, portions of the Exhibit have been redacted from the publicly filed document and have been furnished separately to the SEC as required by Rule 406 under the Securities Act.


	Per Share	Total

Public offering price	$	$
Underwriting discount	$	$
Proceeds, before expenses, to Nanosys, Inc.	$	$



Common stock offered by Nanosys		6,250,000 shares



Shares to be outstanding after this offering		21,870,313 shares


Use of proceeds		To fund the development of our core technology and potential nanotechnology-enabled products, as well as general corporate purposes, including working capital, capital expenditures and potential acquisitions of complementary businesses, products and technologies.

Risk Factors		See “Risk Factors” and other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in shares of our common stock.

Proposed Nasdaq National Market symbol		NNSY



										Three Months Ended
	Period from Inception			Years Ended December 31,						March 31,
	(July 12, 2001) to
	December 31, 2001			2002			2003			2003			2004


	(In thousands)

										(Unaudited)
Statement of Operations Data:
Revenue	$	—		$	283		$	3,039		$	597		$	1,171
Operating expenses*		799			7,497			12,502			2,597			5,162

Loss from operations		(799	)		(7,214	)		(9,463	)		(2,000	)		(3,991	)
Net loss	$	(792	)	$	(7,088	)	$	(9,169	)	$	(2,000	)	$	(3,886	)

* Includes stock-based compensation of	$	—		$	41		$	1,408		$	116		$	1,703



	March 31, 2004

						Pro Forma
	Actual			Pro Forma		As Adjusted


	(Unaudited)

	(In thousands)
Balance Sheet Data:
Cash, cash equivalents and available-for-sale investments	$	37,657		$	37,657	$	128,757
Working capital		35,872			35,872		126,972
Total assets		43,195			43,195		134,295
Long-term liabilities		1,102			1,102		1,102
Redeemable convertible preferred stock		56,787			—		—
Total stockholders’ equity (deficit)		(18,595	)		38,192		129,292


Number of shares/% of total
outstanding shares after the offering		Date of availability for resale into public market

	6,250,000/ 29%	Prior to 180 days after the date of this prospectus due to an agreement these stockholders have with us or the underwriters.
	14,441,783/ 66%	181 days after the date of this prospectus to the date that is 365 days after the date of this prospectus.
	1,178,530/ 5%	366 days after the date of this prospectus or later due to the lapse of various rights of repurchase.


Delaware (State or other jurisdiction of incorporation or organization)		3674 (Primary Standard Industrial Classification Code Number)		13-4182327 (I.R.S. Employer Identification Number)


Michael J. O’Donnell, Esq. Mark L. Reinstra, Esq. Julia Reigel, Esq. Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, CA 94304 (650) 493-9300		Patrick A. Pohlen, Esq. Mark V. Roeder, Esq. Edward F. Vermeer, Esq. Latham & Watkins LLP 135 Commonwealth Drive Menlo Park, CA 94025 (650) 328-4600


	Page

Prospectus Summary		1
Risk Factors		6
Special Note Regarding Forward-Looking Statements		21
Use of Proceeds		22
Dividend Policy		22
Capitalization		23
Dilution		25
Selected Financial Data		27
Management’s Discussion and Analysis of Financial Condition and Results of Operations		29
Business		38
Management		54
Executive Compensation		58
Principal Stockholders		65
Our Relationship and Arrangements with our Stockholders, our Officers and our Directors		68
Description of Capital Stock		75
Shares Eligible for Future Sale		79
Material United States Federal Tax Consequences for Non-United States Holders		81
Underwriting		84
Legal Matters		87
Experts		87
Where You Can Find Additional Information		87
Financial Statements		F-1
EXHIBIT 1.1
EXHIBIT 5.1
EXHIBIT 23.1


Assumed initial public offering price per share					$	16.00
	Historical net tangible book value per share as of March 31, 2004	$	(10.04	)
	Increase per share attributable to pro forma adjustments		12.67

	Pro forma net tangible book value per share as of March 31, 2004	$	2.63
	Increase per share attributable to new investors		3.60

Pro forma net tangible book value per share after this offering						6.23

Dilution per share to new investors					$	9.77



		Shares Purchased					Total Consideration
												Average Price
		Number		Percent			Amount		Percent			Per Share

Existing stockholders			15,570,011		71	%	$	54,742,000		35	%	$	3.52
New investors			6,250,000		29			100,000,000		65		$	16.00

	Total		21,820,011		100	%		154,742,000		100	%


				Period from
				Inception									Three Months Ended
				(July 12, 2001) to			Years Ended December 31,						March 31,
				December 31,
				2001			2002			2003			2003			2004


				(In thousands, except share and per share amounts)
Statement of Operations Data:
Revenue
	Commercial collaborations			$	—		$	200		$	1,997		$	477		$	992
	Government grants				—			83			457			58			179
	Government contracts				—			—			585			62			—

		Total revenue			—			283			3,039			597			1,171

Operating expenses:
	Research and development(1)				237			5,153			9,930			1,954			3,880
	Selling, general and administrative(1)				562			2,344			2,572			643			1,282

		Total operating expenses			799			7,497			12,502			2,597			5,162

Loss from operations					(799	)		(7,214	)		(9,463	)		(2,000	)		(3,991	)
Interest income (expense) and other income, net					7			126			294			—			105

Net loss				$	(792	)	$	(7,088	)	$	(9,169	)	$	(2,000	)	$	(3,886	)

Basic and diluted net loss per share				$	(11.62	)	$	(26.82	)	$	(14.17	)	$	(4.22	)	$	(4.03	)

Weighted average shares used to compute basic and diluted net loss per share					68,151			264,236			647,114			473,786			965,068
Pro forma basic and diluted net loss per share(2)										$	(0.81	)				$	(0.29	)

Weighted average shares used to compute pro forma basic and diluted net loss per share(2)											11,359,397						13,614,409

(1) Includes stock-based compensation of the following:
			Research and development	$	—		$	41		$	1,375		$	113		$	1,354
			Selling, general and administrative		—			—			33			3			349

			Total stock-based compensation	$	—		$	41		$	1,408		$	116		$	1,703



	As of

	December 31,			December 31,			December 31,			March 31,
	2001			2002			2003			2004


	(In thousands)
Balance Sheet Data:
Cash, cash equivalents and available-for-sale investments	$	1,065		$	10,828		$	38,883		$	37,657
Working capital		676			7,335			36,679			35,872
Total assets		1,194			13,532			43,040			43,195
Long-term liabilities		—			1,115			858			1,102
Redeemable convertible preferred stock		1,548			16,610			55,064			56,787
Total stockholders’ deficit		(760	)		(7,794	)		(15,882	)		(18,595	)


Year ending December 31,

2004	$	2.6
2005		3.0
2006		3.0
2007		3.0
2008		2.9
2009		0.4


				Less than		1 to 3
		Total		1 Year		Years

Operating lease commitments*		$	1,640	$	806	$	834
Notes payable under equipment line of credit			1,543		837		706
Contractual commitments to scientific advisors			533		178		355

	Total	$	3,716	$	1,821	$	1,895


	Future
	Minimum
Year ending December 31,	Royalties

2004	$	95
2005		140
2006		293
2007		436
2008		464
2009		605
2010		685
Each year thereafter		735


Merrill Lynch & Co.	Lehman Brothers


CIBC World Markets	Needham & Company, Inc.


	*Stock-Based Compensation*


	*Recognition of Revenue*


	*Grants from and Contracts with United States Government Agencies*


	*Agreement with Defense Advanced Research Projects Agency, or DARPA*


Name	Position	Term

A. Paul Alivisatos, Ph.D.	Professor of Chemistry, University of California Berkeley Head of Molecular Design Institute, Lawrence Berkeley Laboratories	9/04/01 — 9/04/06(1)
Uri Banin, Ph.D.	Associate Professor of Institute of Chemistry and Co- Director, Institute for Nanoscience and Nanotechnology at Hebrew University of Jerusalem	9/30/03 — 9/30/04(2)
Moungi Bawendi, Ph.D.	Professor of Chemistry, Massachusetts Institute of Technology	11/08/01 — 11/08/06(1)
Louis Brus, Ph.D.	Professor of Chemistry, Columbia University	12/10/03 — 12/10/04(2)
Philippe Guyot-Sionnest, Ph.D.	Professor of Chemistry and Physics, University of Chicago	1/06/04 — 1/06/05(2)
James R. Heath, Ph.D.	Professor of Chemistry, California Institute of Technology Scientific Director, California Nanosystems Institute	9/10/03 — 9/10/04(2)
Charles M. Lieber, Ph.D.	Professor of Chemistry, Harvard University	7/30/01 — 7/30/06(1)
Paul L. McEuen, Ph.D.	Professor of Physics, Cornell University Principal Investigator, Lawrence Berkeley Laboratories	7/23/03 — 7/23/05(2)
Hongkun Park, Ph.D.	Professor of Chemistry, Harvard University	7/30/01 — 7/30/06(1)
Peidong Yang, Ph.D.	Assistant Professor of Chemistry, University of California, Berkeley	7/14/04 — 7/14/05(2)


				Director
				or
				Executive
				Officer
Name	Age		Position	Since

Lawrence A. Bock		44	Executive Chairman of the Board		2001
Calvin Y. H. Chow(3)		49	Chief Executive Officer and Director		2001
J. Wallace Parce, Ph.D.		54	Chief Technical Officer and Vice President of Research		2002
Matthew Murphy, Esq.		39	Vice President, Intellectual Property		2002
Karen L. Vergura		46	Vice President, Finance		2001
Clinton W. Bybee(2)(4)		41	Director		2001
Regis P. McKenna(2)(4)		64	Director		2002
Bryan E. Roberts, Ph.D.(1)		37	Director		2003
Sasson Somekh, Ph.D.(2)		58	Director		2003
John A. Young(1)		72	Director		2004
Gregory J. Yurek, Ph.D.(1)(4)		57	Director		2004


	*Compensation Committee Interlocks and Insider Participation*



											Long-Term
											Compensation Awards
				Annual
				Compensation							Restricted		Securities
								Other Annual			Stock		Underlying
Name and Principal Position		Year		Salary		Bonus		Compensation			Award(s)		Options(1)

Calvin Y.H. Chow			2003	$	299,717		—	$	3,539	(2)		—		—
	Chief Executive Officer
Lawrence A. Bock(3)			2003		—		—		—			—		—
	Executive Chairman of the Board and former Chief Executive Officer and President
J. Wallace Parce, Ph.D.			2003		287,020		—		3,181	(2)		—		—
	Chief Technical Officer and Vice President of Research
Matthew Murphy			2003		217,077		—		2,593	(2)		—		11,666
	Vice President, Intellectual Property
Karen L. Vergura			2003		157,944		—		68,858	(4)		—		—
	Vice President, Finance


(1)	The stock options listed in the table represent options to purchase our common stock. See “— Executive Compensation — Option Grants in 2003” for additional information regarding options to purchase our stock granted during 2003.

(2)	Consisted of payment for group term life insurance premiums.

(3)	Mr. Bock was our chief executive officer and president from July 2001 to October 2003. He was not an employee of our company and we did not pay him any compensation for his services to us.

(4)	Consisted of payment for group term life insurance premiums of $1,859 and $66,999 for payment of relocation expenses.



										Potential
			% of Total							Realizable
			Options							Value at
			Granted to							Assumed
			Employees							Annual Rates
	Number of		and							of Stock Price
	Securities		Executive							Appreciation for
	Underlying		Officers in			Exercise or				Option Term
	Options		Fiscal			Base Price		Expiration
Name	Granted		Year			Per Share		Date		5%		10%

Calvin Y.H. Chow		—		—			—		—		—		—
Lawrence A. Bock		—		—			—		—		—		—
J. Wallace Parce		—		—			—		—		—		—
Matthew Murphy		11,666		20	%	$	0.45		1/09/13	$	298,793	$	478,888
Karen L. Vergura		—		—			—		—		—		—



					Number of Securities
					Underlying
					Unexercised				Value of Unexercised
	Number of				Options at				in-the-Money Options
	Shares		Value		December 31, 2003				at December 31, 2003(1)
	Acquired on		Received
Name	Exercise		($)		Exercisable		Unexercisable		Exercisable		Unexercisable

Calvin Y.H. Chow		—		—		—		—		—		—
Lawrence A. Bock		—		—		—		—		—		—
J. Wallace Parce		—		—		—		—		—		—
Matthew Murphy		—		—		26,582		58,417	$	415,550	$	912,784
Karen L. Vergura		—		—		—		—		—		—


(1)	Based on the assumed public offering price of $16.00 per share, minus the exercise price, multiplied by the number of shares issued or issuable upon the exercise of the options.



		Before Offering					After Offering

Name and Address of Beneficial Owner		Number		Percentage			Number		Percentage

5% Stockholders
Entities affiliated with ARCH Venture Partners(1)			2,292,128		14.7	%		2,292,128		10.5	%
	8725 West Higgins Road, Suite 290
	Chicago, IL 60631
Entities affiliated with CW Group(2)			2,113,590		13.5			2,113,590		9.7
	1041 Third Avenue, 2nd Floor
	New York, NY 10021
Entities affiliated with Polaris Venture Partners(3)			2,113,590		13.5			2,113,590		9.7
	1000 Winter Street, Suite 3350
	Waltham, MA 02451
Entities affiliated with Venrock Associates(4)			2,113,590		13.5			2,113,590		9.7
	30 Rockefeller Plaza, #5508
	New York, NY 10112
Executive Officers and Directors
Lawrence A. Bock(5)			2,478,172		15.9			2,478,172		11.3
Calvin Y. H. Chow(6)			578,332		3.7			578,332		2.6
J. Wallace Parce, Ph.D.(7)			256,944		1.6			256,944		1.2
Matthew Murphy(8)			42,916		*			42,916		*
Karen L. Vergura(9)			95,831		*			95,831		*
Clinton W. Bybee(10)			2,292,128		14.7			2,292,128		10.5
	8725 West Higgins Road, Suite 290
	Chicago, IL 60631
Regis P. McKenna(11)			87,365		*			87,365		*
Bryan E. Roberts, Ph.D.(12)			2,113,590		13.5			2,113,590		9.7
	30 Rockefeller Plaza, #5508
	New York, NY 10112
Sasson Somekh, Ph.D.(13)			77,968		*			77,968		*
John A. Young			—		*			—		*
Gregory J. Yurek, Ph.D.(14)			33,332		*			33,332		*
All directors and executive officers as a group (11 persons)(15)			8,056,578		51.5			8,056,578		36.8



	Common Stock				Convertible Preferred Stock

			Aggregate								Aggregate
Name of Purchaser	Shares (#)		Consideration ($)		Series A (#)		Series B (#)		Series C (#)		Consideration ($)

5% Stockholders
Entities affiliated with ARCH Venture Partners(1)		—		—		416,666		868,054		1,007,408	$	9,142,504
Entities affiliated with CW Group(2)		—		—		416,666		868,055		828,869		8,142,503
Entities affiliated with Polaris Venture Partners(3)		—		—		416,666		868,054		828,870		8,142,503
Entities affiliated with Venrock Associates(4)		—		—		416,666		868,055		828,869		8,142,503
Executive Officers and Directors
Lawrence A. Bock(5)		364,582	$	180,644		416,666		868,055		828,869		8,142,503
Calvin Y. H. Chow(6)		578,332		179,100		—		88,611		—		319,000
J. Wallace Parce, Ph.D.		243,333		84,900		—		—		—		—
Matthew Murphy		37,443		14,810		—		—		—		—
Karen L. Vergura		85,831		11,640		—		10,000		—		36,000
Clinton W. Bybee(7)		—		—		416,666		868,054		1,007,408		9,142,504
Regis P. McKenna(8)		41,666		15,000		—		27,778		17,921		200,380
Bryan E. Roberts, Ph.D.(9)		—		—		416,666		868,055		828,869		8,142,503
Sasson Somekh, Ph.D.		33,333		19,000		—		—		44,635		250,001
John A. Young		33,333		40,000		—		—		—		—
Gregory J. Yurek, Ph.D.		33,332		19,000		—		—		—		—


	Number
Underwriter	of Shares

Merrill Lynch, Pierce, Fenner & Smith Incorporated
Lehman Brothers Inc.
CIBC World Markets Corp.
Needham & Company, Inc.

Total		6,250,000


Report of Ernst & Young LLP, Independent Registered Public Accounting Firm			F-2
Balance Sheets			F-3
Statements of Operations			F-4
Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit			F-5
Statements of Cash Flows			F-7
Notes to Financial Statements			F-8



						Years Ended						Three months ended
			Period from Inception			December 31,						March 31,
			(July 12, 2001) to
			December 31, 2001			2002			2003			2003			2004

												(Unaudited)			(Unaudited)

			(In thousands)
Cash flows from operating activities
Net loss			$	(792	)	$	(7,088	)	$	(9,169	)	$	(2,000	)	$	(3,886	)
Adjustments to reconcile net loss to net cash used in operating activities:
	Depreciation and amortization			5			537			1,323			256			374
	Stock-based compensation expense			—			41			1,408			116			1,703
	Changes in assets and liabilities:
		Accounts receivable		—			(77	)		(495	)		69			176
		Prepaid expenses and other assets		(17	)		(386	)		206			(58	)		(491	)
		Deferred revenue		—			1,912			(1,400	)		(478	)		450
		Accounts payable and other liabilities		406			736			539			236			433

Net cash used in operating activities				(398	)		(4,325	)		(7,588	)		(1,859	)		(1,241	)
Cash flows from investing activities
	Purchases of available-for-sale investments			—			—			(35,370	)		—			(10,890	)
	Maturities of available-for-sale investments			—			—			2,200			—			11,015
	Purchases of property and equipment			(117	)		(2,536	)		(2,487	)		(528	)		(440	)

Net cash used in investing activities				(117	)		(2,536	)		(35,657	)		(528	)		(315	)
Cash flows from financing activities
	Proceeds from equipment line of credit, net of issuance costs			—			1,774			727			722			—
	Payments on equipment line of credit			—			(195	)		(763	)		(158	)		(205	)
	Proceeds from sales of redeemable convertible preferred stock, net of issuance costs			1,548			14,949			37,084			—			—
	Proceeds attributed to redeemable convertible preferred stock warrant			—			—			1,000			—			—
	Proceeds from sales of common stock and exercise of stock options			32			12			14			37			32
	Proceeds from the early exercise of stock options and restricted stock			—			84			66			—			468
	Proceeds from repayment of notes receivable			—			—			—			—			145
	Payment to repurchase restricted common stock			—			—			(4	)		—			—

Net cash provided by financing activities				1,580			16,624			38,124			601			440

Net increase (decrease) in cash and cash equivalents				1,065			9,763			(5,121	)		(1,786	)		(1,116	)
Cash and cash equivalents at beginning of period				—			1,065			10,828			10,828			5,707

Cash and cash equivalents at end of period			$	1,065		$	10,828		$	5,707		$	9,042		$	4,591

Supplemental disclosure of cash flow information Cash paid for interest			$	—		$	23		$	90		$	20		$	18


			Gross		Gross
			Unrealized		Unrealized			Estimated
	Amortized Cost		Gains		Losses			Fair Value

United States government and agency securities	$	10,526	$	10	$	(1	)	$	10,535
Auction rate securities issued by states of the United States		14,550		—		—			14,550
Money market funds		1,913		—		—			1,913
Corporate debt investments		8,094		3		(6	)		8,091

Total available-for-sale investments	$	35,083	$	13	$	(7	)	$	35,089

Classified as cash and cash equivalents									(1,913	)

Classified as available-for-sale investments								$	33,176


		Operating Lease		Sublease
Year Ending December 31,		Payments		Income

2004		$	806	$	96
2005			834		—

	Total	$	1,640	$	96



	Period from Inception									Three Months Ended
	(July 12, 2001)			Year Ended December 31,						March 31,
	to
	December 31, 2001			2002			2003			2003			2004

										(Unaudited)			(Unaudited)

	(In thousands, except share and per share amounts)
Historical
Numerator:
Net loss	$	(792	)	$	(7,088	)	$	(9,169	)	$	(2,000	)	$	(3,886	)

Denominator:
Weighted-average common shares outstanding		649,907			1,418,963			1,749,195			1,716,899			1,824,972
Less: Weighted-average unvested common shares subject to repurchase		(581,756	)		(1,154,727	)		(1,102,081	)		(1,243,113	)		(859,904	)

Denominator for basic and diluted net loss per share		68,151			264,236			647,114			473,786			965,068

Basic and diluted net loss per share	$	(11.62	)	$	(26.82	)	$	(14.17	)	$	(4.22	)	$	(4.03	)

Pro forma
Net loss							$	(9,169	)				$	(3,886	)

Pro forma basic and diluted net loss per share							$	(0.81	)				$	(0.29	)

Denominator for pro forma basic and diluted net loss per share:
Shares used above								647,114						965,068
Pro forma adjustments to reflect assumed weighted-average effect of conversion of preferred stock								10,712,283						12,649,341

Shares used to compute pro forma basic and diluted net loss per share								11,359,397						13,614,409



		December 31, 2002

								Aggregate
				Shares Issued and				Liquidation
		Shares Authorized		Outstanding		Carrying Amount		Preference

Series A			1,833,333		1,833,333	$	1,548	$	1,650
Series B			4,333,334		4,166,667		14,949		15,000

	Total		6,166,667		6,000,000	$	16,497	$	16,650



		December 31, 2003 and March 31, 2004

								Aggregate
				Shares Issued and				Liquidation
		Shares Authorized		Outstanding		Carrying Amount		Preference

Series A			1,833,333		1,833,333	$	1,548	$	1,650
Series B			4,333,334		4,166,667		14,949		15,000
Series C			7,250,000		6,649,341		37,084		37,243

	Total		13,416,667		12,649,341	$	53,581	$	53,893